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INTRODUCTION
This dissertation describes 1) formulation of a novel dosage form, a gastric
retention device for drugs that have "absorption window" and application of the
device in healthy human subjects, 2) pharmacokinetic/pharmacodynamic
relationship of nicotine for better smoking cessation rates, and 3) the importance of
pharmacokinetics of enantiomer drugs in assessing bioequivalency study.
Chapter 1 of the dissertation presents formulation of a gastric retention
device in terms of factors that have an influence on characteristics of the device and
formulation of sustained release hydrochlorothiazide beads. The gastric retention
device containing the drug beads was employed in in vitro dissolution study, and
the dissolution profile was applied to predict in vivo dissolution profile and in vivo
plasma concentration vs. time profile prior to a bioavailability study.
Chapter 2 describes pharmacokinetic/pharmacodynamics of
hydrochlorothiazide formulated into sustained release beads incorporated in a
gastric retention device. Urinary data was obtained from
bioavailability/bioequivalency study and analyzed to evaluate bioavailability of
hydrochiorothiazide and consequences of slow drug input on the pharmacological2
effect. With in vivo urinary excretion rate vs. time data and in vitro dissolution
data, in vivo/in vitro correlation was established.
Chapter 3 reviewed pharmacokinetic/pharmacodynamic relationship of
nicotine that could establish a dosing regiment to improve smoking cessation. The
current nicotine replacement therapies were evaluated in terms of efficiency of the
treatments by studying the relationship among plasma nicotine concentration, rate
of nicotine input and pharmacological effect such as heart rate or craving.
Chapter 4 is a simulation study to verify the current regulatory policy on
assessing bioequivalent study of enantiomeric drugs by determining the probability
of false positives using NONMEM (Version 5.0) and SAS (Version 6.12). Factors
that can affect pharmacokinetics of enantiomers and the outcome of bioequivalency
study were taken into account, and the factors were dissolution rates, within- and
between-subject variability, dose and sample size.CHAPTER 1
FORMULATION OF A GASTRIC RETENTION DEVICE AND
SUSTAINED RELEASE HYDROCHLOROTHIAZIDE BEADS
Hyojong Kwon and James W. Ayres, Ph.D.4
ABSTRACT
A gastric retention device (GRD) was developed to achieve higher
bioavailability of drugs that have an "absorption window" in the upper intestine.
Hydrochiorothiazide was used as a model drug. Xanthan gum and locust bean gum
were main excipients in the GRD formulation. Ratio and amount of excipients had
a significant influence on rigidity of the GRD, which is very important for gastric
retention. Among a variety of shapes and sizes, a rectangular shape with a
dimension of 7* 1 5* 1 cm was chosen among those tested to be the best in terms of
enduring "house keeping waves" on an empty stomach. A foam solution composed
of Carbopol® 934 and sodium lauryl sulphate was added to a gum solution of
xanthan gum and locust bean gum, and addition of the foam solution to produce a
modified GRD (GRD2) enhanced characteristics of the original GRD (GRD1). The
modifiedGRD2exhibited increased flexibility, rigidity and rate of hydration
compared to the GRD1. Gellation process and dehydration conditions played a key
role in determining characteristic of GRD. Drug as matrix pellets or spray-coated
beads were incorporated into GRD1 and GRD2 to attain a desired sustained release
drug profile. The drug-loaded beads were coated with Surelease® and Opadry® to
obtain a desirable drug release pattern. GRD including drug beads layered with 3%
weight gain of coating containing 67% Surelease® and 33% Opadry® produced a
desirable drug release profile and was employed in a bioavailability/bioequivalence
study. Prior to the bioavailability/bioequivalency study, a dissolution profile was5
used to predict in vivo absorption profile by convolution. Pharmacokinetic models
were generated using observed plasma concentration data from a reference and
compared to a model provided in the literature. The best-fit model was selected to
assess convolution to simulate plasma concentration profiles.INTRODUCTION
Oral route of drug administration has been predominant, and various oral
drug delivery systems have been developed. Controlled release or sustained release
(SR) dosage forms are widely used in the pharmaceutical field due to a range of
advantages including improved patient compliance and prolonged drug effects with
decreased side effects
(1)These dosage forms are preferable to an intravenous (IV)
infusion to provide continuous drug input followed by maintaining constant plasma
concentrations of drug over a certain period of time
1)To develop a sustained
release dosage form that provides good bioavailability, drug release patternsas well
as physiological factors such as gastrointestinal (GI) transit need to be considered.
Some drugs have an "absorption window," which means these drugs have
limited absorption sites and little or no absorption occurs once they pass the
absorption sites
(2)Bioavailability of these drugs may be increased by employing a
dosage form that can stay above or at the absorption site and release drug slowly
for a desirable period. There have been attempts to prolong gastric residence time
(GRT) of drug delivery, such as a floating dosage form, hydrophilic matrix tablet,
HBS (hydrodynamically balanced system) capsules and tablets, and microballoon
and these dosage forms were designed to increase gastric residence time and to
overcome the extreme difficulty of retaining solid dosage formulations in an empty
stomach for a prolonged period of timeGastric residence time of solid dosage
forms is highly variable due to phase III interdigestive migrating motor complex7
(IMMC), strong contractions that sweep away indigestible debris andcontents of
an empty stomach
(2)In order to keep the dosage formulation in the stomach
during fasting and to obtain prolonged drug release,a gastric retention device
(GRD) must be big enough and rigid enough to endure IMMC. The aim of this
study was to develop a dosage form, a GRD that satisfies the following
characteristics: 1) a size of the GRD that is small enough to swallow, and then
expands in the stomach to a size sufficient to be retained in the stomach; 2) high
flexibility during preparation; 3) fast hydration; 4) appropriate rigidity following
hydration; and 5) self-disintegration after a desirable period.
MODEL DRUG
Drugs that are mainly absorbed at the upper part of the small intestinecan
be best delivered to their absorption sites using a device that hasa prolonged
residence in the stomach. A GRD can also increase bioavailability ofa drug that
may act locally in the stomach and that is absorbed or soluble mainly in the
stomach (at low PH) or that is absorbed rapidly in the GI tract(3)Drugs with
limited absorption sites, what is called an "absorption windows, "attain higher
bioavailability by increasing gastric residence time as well as duration of
absorption. This is because slow delivery of drug at the absorption sitescan avoid
saturation of active transport enzymes
(2)Saturation of transport enzymes at the
absorption sites may occur if there is fast and immediate release ofa drug, which['I
results in decreased drug absorption, because the drug molecules are moved
through the GI tract and passed the absorption sites before the enzymes can
transport all of the drug through the gut membrane
(2)Thus, a GRD is an excellent
application for drugs that have an "absorption window" in the upper intestine, such
cephalexin, chiorothiazide, nifedipine, furosemide and hydrochlorothiazide(414)
I
also an appropriate formulation when it is desirable to obtain sustained release fora
drug that is not absorbed from the colon, such as ranitidine or metoprolol (713)
Hydrochiorothiazide was selected as a drug candidate for this research.
Hydrochiorothiazide
Hydrochiorothiazide (6-Chloro-3 ,4-dihydro-2H- 1 ,2,4-benzothiadiazine-7-
sulfonamide 1,1-dioxide, C7H8C1N304S2) is a thiazide diuretic commonly
prescribed for treatment of hypertension, congestive heart failure, and edema (14)
The drug is practically insoluble in water and soluble in ethanol and methanol, and
has pKaof 7.2and9.2
(14)An initial doseof 50-100mg followedby 25-50mg
daily dose for edema is usually prescribed, and the dose for hypertension can be
adjusted from 25 to 200 mg daily
(14, 15)The half-lives of the a-distribution phase
and 13-elimination phase range from 1 to 2 his and 5 to 14 his, respectively, in
healthy individuals
(16)Hydrochiorothiazide is mainly eliminated unchanged via
the kidneys, and thus an amount of the drug absorbed should be close to that
recovered in the urine. Mean absorption of 12.5 to 75 mg of the drug from the GItract varies in the range of 40% to 60% from the GI tract after oral administration,
and the average urinary recovery in 72 hours post-administration is from 60% to
80% of the amount absorbed in healthy subjects and hypertensive patients
(16)
Ninety to 94% of the drug was recovered in the urine after IV administration
(16)A
double-peak phenomenon was reported, yet this phenomenon has not been clearly
explained. In one study, this double-peak was postulated by an interaction between
the red blood cells and hydrochlorothiazide after equilibrium between the drug in
plasma and blood cells
(16)Absorption of hydrochiorothiazide mainly takes place
in the duodenum and the first part ofjejunum, and in the stomach to a small extent
(16)A hypothesis of existence of active drug transport mechanism was supported
by the finding of a higher bioavailability of the drug associated with slower gastric
emptying in the presence of food
(17, 18)Bioavailability was lower from a SR
formulation such as pellets compared to an JR tablet, because the SR formulation
passed the drug absorption sites before the dosage form completed the drug release
(19)These studies support the absorption window theory for hydrochiorothiazide
(16-19)and therefore a higher bioavailability of the drug in a GRD can be expected if
there is a prolonged gastric residence time and saturation of transport-mediated
enzymes is avoided.10
GASTRIC RETENTION DEVICE (GRD)
Novel dosage forms such as hydrodynamically balanced system (HBS) and
intragastric floating delivery devices that have prolonged gastric residence time
have been introduced
20 22)These novel delivery systems have been promotedas
potential devices to be retained in the GI tract and to control drug release.
However, no device has shown to be retained in an empty stomach during the
"housekeeping wave contractions".
In this research, a novel drug delivery system, a GRD has been investigated
for controlled release of drug and a prolonged gastric retention period. A
synergistic interaction between xanthan gum (XG) and galactomannans suchas
locust bean gum (LG) occurs during formation of the GRD
(23)LG has lower ratio
of galactose to mannose than other galactomannans and has fewer side chains,so
that the configuration of LG makes an excellent fit with the XG molecules
(23)The
interaction called "lock-and-key effect" from the mixture of these twogums forms
weak secondary valence bonds that produce thermoreversibility of the gum mixture
by breaking of these bonds under heat, which results in enhanced viscosity anda
remarkable gel structure following cooling
(24-26)Different ratios of XG to LG
were studied, and other excipients were added to achieve desired properties for the
device.11
SUSTAINED RELEASE BEADS FORMULATION
A spray-coated bead formulation was developed andincorporated in the
GRD to achieve a desirable SR dissolution profile. A studyby Hussain, et al, was
followed to determine a satisfactory condition for the coatingprocess
(27)This
study provides information about factors that influence film-coatingand evaluates
the impact of various nozzle orifice diameters, coatingtemperatures, and airflow
(27)The influence of formulation factors suchas drug particle size and additives,
and processing techniques like compressionpressure on dissolution rates of
hydrochiorothiazide tablet has been studied, and all these issues turnedout to be
important
(28)In previous studies, dosage forms were formulatedto achieve SR or
CR of hydrochiorothiazide
9, 29)Ritschel, et al, evaluated a SR tablet consisting
of hydrochlorothiazide and triamterenein vitro! in vivoin dogs. Herman, et a!,
formulated SR pellets containing hydrochiorothiazide for dissolutionand
bioavailability studies
19, 29)The SR tablet and pellets achieved slower drug
release in in vitro dissolution profiles, however bioavailabilitieswere lower
compared to an IR dosage formulation
(19, 29)
There were three issues that need to
be considered for a SR formulation in this study. First of all, theformulation must
achieve a slow release of the drug and complete the release within24 hours for
daily administration. Second, the SR formulation must be easilyincorporated into
a GRD, and achieve uniform drug release profile from the dosage form. Third, the
formulation should be reproducible, time-efficient, andeasy to scale-up in terms of12
manufacturing. Regarding these three conditions, a spray-coating techniquewas
chosen to formulate SR beads for hydrochiorothiazide. In this study, different
coating thickness was evaluated to achieve a desirable sustained drug release
dissolution profile.
Convolution of the dissolution-time profile can be used to simulatea time
course of predicted plasma concentration profile of drug, and this simulated drug
profile was employed preceding a bioavailability/bioequivalency (BA/BE) study
for JR formulation and GRD.13
MATERIALS AND METHODS
MODEL DRUG
Hydrochlorothiazide was chosen as a model drug. There is currentlyno
commercial SR formulation available for this drug, and a SR dosage form withan
equivalent bioavailability to an JR formulation would be a useful product to
improve patient compliance, and a good challenge in dosage formulation. A
powder form of hydrochlorothiazide (Sigma Chemicals, St. Louis, MO) anda
conventional tablet (50 and 100 mg Hydrochiorothiazide USP, Lederle
Laboratories Division American Cyanamid Company, Pearl River, NY)were
purchased.
GASTRIC RETENTION DEVICE (GRD)
Xanthan gum (XG) is supplied by Kelco (Xantral® 75, Kelco, San Diego,
CA). XG and Locust bean gum (LG) (Sigma Chemicals, St. Louis, MO) are the
main ingredients for producingGRD1and GRD2. Excipients added to improve
properties of the gum mixture include Polyethylene glycol (PEG) 400 (Sigma
Chemicals, St. Louis, MO), Sodium lauryl sulphate (SLS) (Matheson Coleman &
Bell, Cincinnati OH), Carbopol® 934 (BFGoodrich Co., Cleveland, OH) and
Tetrahydroxypropyl ethylenediamine (Neutrol TE) (BASF Co., Mount Olive, NJ).14
Table 1.1 summarizes the amount and kinds of expients forGRD1and GRD2 PEG
400 is used for both GRD1 and GRD2 as a plasticizer that prevents distortion of the
structure of a dried GRD (film) and that aids folding or rolling the film. SLS,
Carbopol® 934 and Neutrol TE are added for only GRD2. SLS increases flexibility
of the film and hydration rate. SLS solution becomes viscous by adding
Carbopol® 934, and the mixture of SLS and Carbopol® 934 produces an "open"
textured foam solution. Neutrol TE is an alkaline excipient used to adjust pH of
Carbopol® 934 solution. Other alkaline neutralizers can be used. A dehydrated
GRD containing drug is inserted into a hard gelatin capsule (Capsugel®, Warner-
Lambert Co., Morris Plains, NJ).
Table 1.1. Amount and sort of excipients for GRD.
XG
(g)
LG
(g)
PEG
(ml)
SLS
(g)
CP
(g)
Sr (g)OP
(g)
NTE
(ml)
DIW
(ml)
GRD10.75 0.5 5 - 8 1 100
GRD20.750.75 5 0.1250.075 8 1 0.5 1O0
[XG: Xanthan gum, LG: Locust bean gum, PEG: Polyethylene glycol 400, SLS: Sodium lauryl
sulphate, CP: Carbopol® 934, Sr: Surelease®, OP: Opadry®, NTE: Neutrol TE, DIW: De-ionized
waterl
The main ingredients include XG, LG and PEG400. Other excipients and
various conditions for preparation were investigated.The method of preparation
is as follows.15
1. Original gastric retention device(GRD1)
1-1.The original GRD (GRD1) was prepared by dissolving 0.75g of XG
followed by dissolving 0.5 g LG in 100 ml de-ionized water (DIW).
Figures 1.1-a and 1.1b show the gum solution before heating.
1-2.Heat the gum solution to a temperature between 80 and 85°C where
the solution was liquefied. At this temperature, 5 ml PEG 400was
immediately added, and stirred for approximately 10 seconds.
1-3.Pour (1-2) into each mold, and fill it about a half, and then add drug
powder, pellets or beads. Fill up the rest of the mold with (1-2), and
then mix quickly for drug powder, pellets or beads to be
homogeneously distributed before cooling and gelling occurs.
1-4.Let the gel set at a room temperature for about 2 to 4 hours.
1-5.Put (1-4) into a refrigerator overnight.
1-6.Take each gel out of the container, and place the gel on waxedor
plastic sheeting.
1-7.Dry (1-6) in a laboratory vacuum oven at 53 °C for 4.5 to 5 hours.
Different conditions for drying process and various shapes were
studied to obtain a film that is flexible and rigid to be easily rolled
and fitted into a capsule (Examples of shapes are displayed in
Figures 1.2-a and 1.2b, and 1 .2c).20
Warm 25 ml of de-ionized water to 60-70 °C, and dissolve
0.125g of SLS, and then suspend 0.075g of Carbopol®, while
stirring with a magnetic stirrer.
Let stir rapidly for approximately 3 hours.
After 3 hours, adjust pH with Neutrol TE (0.05% V/V) to 7 to
7.5 (Change of pH paper: khaki to dark green color), and then
cool a beaker of the foam solution in an ice-water bath to set the
foam (Figure 1.4).
2-4.Heat the gum solution from step (2-2) above, meanwhile stir the
foam solution from step (2-3) above with a magnetic stirrer at the
highest speed.
2-5.The gum solution was heated to a temperature of 80 to 85°C, and 5
ml of PEG 400 was immediately added. This solution was stirred
for about 10 sec.
2-6.Remove the magnetic stirrer from the gum solution, and pour the
foam into (2-5), and mix them together with a spatula.
2-7.Pour (2-6) into a mold (rectangular shape with 75* I 5* 1 cm), and
fill it about a half. Then, add drug beads, and fill up the rest of the
mold with (2-6). Mix quickly for homogeneous distribution of drug
beads.
2-8.Let (2-7) set at the room temperature for about 2 to 4 hours.
2-9.Put (2-8) into a refrigerator overnight.23
HYDROCHLOROTHIAZIDE PELLET FORMULATION
Polyethylene Oxide (Polyox® N-80, Dow chemical Co., Midland, MO),
aqueous ethylcellulose dispersion (Surelease®, ColorCon Co., West point, PA),
microcrystalline cellulose (Avicel® PH-l0l, FMC Co., Philadelphia, PA) were
used for compressed pellet formulation. Hydrochiorothiazide pellets were prepared
by mixing the drug, Surelease®, Avicel® PH- 101, Polyox® N-80 and de-ionized
water. Other excipients like hydroxypropyl methylcellulose (HPMC) and
Carbopol® 934P were incorporated to formulate a SR dosage form. However, these
ingredients made the wet mass become too sticky and required a large quantity.
Therefore, Surelease® was chosen as a matrix type binder and sustained release
promoting material, and Avicel® PH-10l and Polyox® N-80 were used as a binder
and a filler, respectively. Ingredients for the formulation of pellets are described in
Table 1.2. The wet slurry was then sieved through a 40-mesh sieve by hand to
obtain granules, and these granules were dried at a room temperature for
approximately 6 hours. The dried granules were compressed with a die and a
punch to make pellets (3 mm in length and 0.5 mm in diameter) before
incorporating in the GRD1.24
Table 1.2. Formulation of hydrochiorothiazide pellets.
Ingredients Quantity (gram)
Hydrochiorothiazide 1
Avicel® PH 101 3
Surelease® 0.744 (3mL)
Polyox® (N-80) 1
HYDROCHLOROTHIAZIDE BEAD FORMULATION
Preparation of hydrochiorothiazide beads
Hydrochlorothiazide was also formulated into a SR bead. Table 1.3
summarizes the amount and the weight percentage of ingredients for drug-layered
beads. Hydroxypropyl cellulose (HPC) (3 g) (Krucel®, Dow Chemicals, Midland,
MI) and polyvinyl pyrrolidine (PVP) (9 g) (Povidone® K-30, Sigma Chemicals, St.
Louis, MO), both used as binders, were suspended in 100 ml of de-ionized water
using a magnetic stirrer. A powder form of hydrochiorothiazide (40 g) was
dispersed in the solution of binders, and this suspension was left at a room
temperature overnight, so polymers could be fully expanded and homogeneously
combined with the drug. White nonpareil sugar beads (40 g) (Paular Corp.,
Princeton Junction, NJ, USA) retained in a 20-mesh screen were pre-warmed in the
fluid-bed coating chamber at 50-55°C for approximately 20 minutes. The
fluidized-bed process using the bottom-spray method with a Wurster air-suspension25
colunm was utilized for the SR beads formulation. The coating equipment was
composed of a bench-bottom spray coating chamber including a 7-inch Wurster
colunm (STREA-1, Aeromatic Inc., Columbia, MD, USA) mounted on a fluid-bed
dryer (Lab-Line/P.R.L. Hi-Speed Fluid-Bed Dryer, Lab-Line Instruments Inc.,
Melrose Park, IL, USA). The suspension was pumped to the atomizer by a
peristaltic pump (Watson-Marlow 502S, Watson-Marlow Limited, Cornwall, UK).
The suspension was sprayed to coat the sugar beads to produce the most favorable
coalescence of sprayed materials at a rate of 3 mllminute using a 1.0-mm nozzle
opening (Aeromatic Inc., Columbia, MD, USA) and a nozzle air pressure of
approximately 10-15 psi with continuous fluidizing-air supply. The drug-loaded
beads were dried in the chamber using fluidizing air for at least 20 minutes at 55-
60°C to achieve uniformly coated surface of dried drug on beads after all the
suspension was applied. The beads were dried at room temperature overnight after
being removed from the chamber.
Table 1.3. The amount and the percentage of ingredients to formulate drug-layered
beads.
Ingredients Weight (g) Weight%
Sugar (20-mesh) 40 45
Hydrochlorothiazide 40 45
HPC (Krucel®) 3 3
PVP (Povidone® K-30) 6 7
De-ionized water 100 -26
Assay for content uniformity of drug-loaded beads
To ensure uniformity and content of drug loaded on the beads, assay of
drug-coated beads was performed using a spectrophotometer (Model 34, Beckman
Instruments, Inc., Fullerton, CA, USA) at 272 nm and appropriate standard curve.
One hundred mg of hydrochiorothiazide-loaded beads was dissolved in 1000 ml of
simulated gastric fluid in a volumetric flask. The assay was carried out at least
three times for samples from a batch. The standard curve is provided in Figure 1.7.
1.8
1.6
1.4
1.2
1-
0594x + 0.03 89
0.8
0.6-
R2=0.9982 0.4
0.2
0- I I
0 5 10 15 20 25 30
Concentration (ug/mL)
Figure 1.7. Standard curve of hydrochlorothiazide 50 mg loaded on the beads.
[UV abs: Absorbance from spectrophotometer]27
Coating of drug beads
Aqueous ethylcellulose dispersion coating material, Surelease® was used as
a sustained release agent. A water-soluble film-coating material, Opadry®
(Colorcon, West Point, PA, USA) was mixed with Surelease® at the ratio of 1:2 to
achieve a desirable rate of drug release. Surelease® alone (for (1) and (2) in Table
1.4) or a mixture of Surelease® and Opadry® (for (3) in Table 1.4) were suspended
in 10 ml de-ionized water, respectively. Ingredients and the amount of ingredients
for SR-coating are shown in Table 1.4.
Table 1.4. Formulation of sustained release coating layered beads.
Ingredients Weight (g) Weight%(%HCTZ)
Hydrochlorothiazide 100 (1) 89.3* (44.6**) (2) 98*
-layered beads (49**) (3) 97.1* (48.5**)
(1)Surelease® 48.39 10.7
(12% weight gain) (12g solidcontent)*)
(2)Surelease® 8.06 (2g solidcontent)(l*) 2
(2% weight_gain)
(3)Surelease®&8.06 (2g solid content)'" 2.9
Opadry® &1 (Opadry®)
(3% weight_gain)
De-ionized water 10
[HCTZ: Hydrochiorothiazide, *: Weight % of hydrochiorothiazide-layered beads, **: Weight % of
hydrochlorothiazide only.]28
Weight gain of 3% was chosen as the formulation to be incorporated into a
GRD based on the results shown in Figure 1.11 and 1.12. The suspension was
sprayed to coat the drug-layered beads at a rate of 4.5 mllminute using a 0.8-mm
nozzle opening, and a nozzle air pressure of approximately 10-15 psi with
continuous fluidizing-air supply. The SR coating-layered beads were dried in the
chamber using fluidizing air for about 20 minutes at 55-60°C after all coating was
applied.
DISSOLUTION STUDY
Dissolution studies were performed in 900 ml simulated enzyme-free
gastric fluids as indicated in the USP XXII paddle method at 37°C with 50 rpm for
24 hours. Samples were collected at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 20,
and 24 hours with replacement of equal volume of sample, and then assayed using
a UV detector at 272 nm.
SIMULATION OF PREDICTED PLASMA HYDROCHLOROTHIAZIDE
CONCENTRATION-TIME PROFILE
Reported plasma concentration vs. time data were attained after
administration of a conventional tablet, Hydrodiunl© hydrochlorothiazide 50 mg
tablet (Lot B80686, Merck Sharpe and Dohme (MSD), West Point, PA 19486) in
fasting condition by Barbhaiva, et al
(31)The reported data from reference (31)29
(MSD data) were fitted to establish a pharmacokinetic model consistent with the
data. Methods used herein to obtain the best that included using computer
software, WinNonlin, and a hand-stripping method
(33)The models were then
employed to simulate plasma concentrations which were compared to the original
reported plasma concentration data (MSD data
(31)).A pharmacokinetic model
provided in reference (31) was also applied to simulate plasma concentration data,
and these simulated data were compared to the reported MSD data
31)From the
comparison, one model that had the best-fit for the original data was chosen for
convolution to predict in vivo plasma concentration profiles of the IR and the GRD1
containing drug beads prior to conducting a preliminary BA/BE study.30
RESULTS AND DISCUSION
HYDRATION STUDY AND DETERMINING AN ACCEPTABLE GRD
Hydration studies withGRD1and GRD2 were carried out to obtain fast
initial hydration and a desirable integrity. Degree of hydration of a dried film was
measured with various shapes and sizes of GRD1, and a rectangular shape of GRD2.
After drying, GRD in a capsule was hydrated in 900 ml simulated gastric fluids at
37°C with 50 rpm of paddle rotation. In the hydration studies, drugs were not
incorporated into the GRD, because the main purpose of this hydration study was
to determine the optimal size and shape of GRD, not the rate of drug release.
Shapes and sizes of GRD1 are shown in Table 1.5 and Figure 1.8. A square shape
made the film more difficult to fit into a capsule compared to the rectangular shape,
because the square shape made the rolled film too thick to be inserted into a desired
capsule. The rectangular shaped GRD was used as a basic shape, since the
rectangular shape was determined to be the best for gastric retention from the
previous studies by Kapsi
(30)and Ahmed
32)31
Table 1.5. Various dimensions ofGRD1(1-Vill) andGRD2.
Dimension Length (1)
(cm)
Width (w)
(cm)
Height (h)
(cm)
Holes or cut-off (cm)
(See diagram below) GRD1
I 4.5 4 1.5 None
II 7.5 1.5 1 None
III 4.5 4 1.5 Holes (0.05&0.1)
IV 7.5 1.5 1 Holes (1.3)
V 8 3 1.7 Square (1.5*2*1.3)
VI 8 3 1.7 Rectangular (6*2*1.3)
VII 8 3 1.7 Rectangular (6*3*1.3)
VIII 3 3 1.7 Cylinder (0.25*1.7)
GRD2 7.5 1.5 1 None
hi'0
i. Original square shape
FilE
iii.Square shape with small holes
ii. Original rectangular shape
w
h[O00
Figure 1.8. Various shapes and sizes of GRD.
[I: Length, w: Width, h: Heightj
iv. Rectangular shape with large
holesIE[J
v. Rectangular shape
with 2 squared shape cut-offs
32
vi. Rectangular shape with
rectangular cut-off with all the edges
hI(
vii. Rectangular shape with rectangular cut-off
viii. Rectangular shape with 6 cylinder-shape cut-offs
Figure 1.8. (Continued).
[1: Length, w: Width, h: Height]33
One desired characteristic of GRD is a sponge-like structure.It means that
the GRD should be not only very elastic and flexible, but also fairly rigid and
strong. Moreover, the GRD has to be as compressible as possible to fit into the
smallest capsule without any significant destruction of structure and to be hydrated
fast, and to a large enough size in order to withstand IMMC. Different sizes of
holes were cut into the gel to obtain an open structure and to increase the surface
area. A number of capillaries with a diameter of 0.05 cm and 0.1 cm were placed
in a gel before drying as illustrated in Figure 1.8. The capillaries did not change
the thickness of the rolled film, because the numbers and sizes of the holes were
too small to substantially decrease the volume.
Moreover, these numerous holes did not make any significant improvement
in hydration rates and compressibility, because the holes were too tiny to
substantially amplify the surface area. Fewer holes with a larger diameter (1.5 cm)
in a gel were constructed before drying. Bigger holes in the gel achieved better
compressibility resulted in fitting the film into 00 or 0 size of capsules and elevated
the surface area as well as the rate of initial hydration. Instead of making holes,
cutting away some parts of a gel was conducted. Cutting parts in squares or
rectangular shape of a gel resulted in excellent compactness and fast initial
hydration, but the rigidity decreased due to excessive flexibility. The gel became
too soft and bendable after hydration. Homogeneous drug distribution was difficult
to accomplish with holes or cut-offs. Further research is needed in this area,34
because it offers promise in those cases where the gel rigidity and gum
concentrations can be increased.
Instead of changing the shape and size of GRD, different amounts of
PEG400 and various ratios of XGILG for gum solution were then evaluated to
identify some modifiable characteristics of GRD. Less than 5ml of PEG 400 made
a film following drying that was quite firm and inflexible as well as one that
hydrated very slowly, yet, rigidity increased following hydration. When the
amount of PEG 400 was more than 6 ml, the film became more soft and bendable
than appeared desirable. Therefore, 5 ml was chosen to be the optimum amount for
both plasticity and rigidity for the drying conditions used herein. Trials for
different ratios of XL/LG are shown in Table 1.6.
Table 1.6. Different amounts and ratios of gums for GRD.
Trial Ratio Amount of XG (g) Amount of LG (g)
(a) 1:1 0.5 0.5
(b) 1.5:1 0.75 0.5
(c) 1.8:1 0.9 0.5
(d) 1.5:1 0.75 0.75
[XG: Xanthan gum, LG: Locust bean gum]
A film from trial (a) was too soft and weak after hydration. In trial (b),
more XG was added in the GRD formulation (GRD1), and this GRD was fairly35
rigid from in vitro studies. However, theGRD1failed to stay in an empty stomach
in a preliminary BA/BE study. From trials (c) and (d), both GRDs were more rigid
than the ones from trial (a) and (b) after hydration. This result can be explained by
increased amount of the gums. Trial (d) gave rise to a stronger gel after hydration
and better consistency of a gum solution than trial (c). The gum solution became
highly coagulated and viscous when total amount of gums was more than 1.5g.
Adding more gums made the dehydrated film become too thick to fold or roll. This
is an area where further research with cut-offs may be useful. The 1:1 ratio of
XG/LG created the best hydration and rigidity, according to the previous study by
Kapsi
(30)The total amount was favored to be 1.5 g and therefore, 0.75 g of XG
and 0.75 g of LG were chosen to formulateGRD2.
Temperatures regarding heating a gum solution and drying a gel were
studied. As the gums are dissolved in de-ionized water, the gum solution becomes
thick and viscous due to the synergistic interaction. The solution starts being
liquefied by heat because of active molecules from broken weak secondary valence
bonds between XG and LG, and this formation is thermoreversible
9)The gum
solution was heated to 80-85 °C, and the drug was homogeneously suspended. At
temperatures below 80 °C, the solution was still quite viscous, and thus the mixture
was likely to be coagulated and the drug was not distributed homogeneously. But,
the gum solution started boiling above 85 °C, and caused the loss of
thermoreversibility as well as breaking structure of the intramolecular network36
between XG and LG
(19),resulting in a hard and brittle film. Thus, it was desirable
to heat the gums between 80 and 85 degrees during preparation process.
The dehydration process plays a key role in determination of configuration
of a film, which means that film flexibility and hydration rate can be affected by
drying temperature. Fast initial hydration is one important consideration in the
development of GRD. IMMC occurs once every 2 hours and phase III of IMMC
usually happens once every 5 to 30 minutes on an empty stomach
(1-3)but the
motility of GI tract has high intra- and inter-individual variability. Considering
average movement of phase III of IMMC, a GRD should preferably undergo
hydration and become large enough within 20 minutes to avoid traveling through
the pyloric sphincter and passing below the absorption sites.
Table 1.7. Influence of different temperatures on GRD during dehydration process.
Drying Effect of the temperature on GRD
Temperature (°C)
3 8-40 More than 8 hours for dehydration. The film became too
flat like a tissue. It took more than 30mmto hydrate
initially.
40-45 6-7 hours for dehydration. The film became flat.It took
about 20 mm to hydrate initially, however, the film
recovered only 60% of the original size in 1 hour.
50-55 5-6 hours for dehydration. The film was soft and flexible.
Initial hydration occurred within 20 mm. The film was
swollen to be more than 85% of the original size in 30
minutes.
55-60 4 hours for dehydration. The film was no longer soft and
flexible.37
Effects of the temperature in drying process are shown in Table 1.7. As
explained in Table 1.7, dehydration of a gel took more than 8 hours at a drying
temperature below 40 °C, and prolonged drying period caused slow hydration in
gastric fluid for the dried films. The gel was dried for approximately 6 to 7 hours
at around 40-50 °C, and the film was hydrated faster than the one drying at a lower
temperature, however, the volume of the GRD after hydration was approximately
60% of the original size. A drying temperature between 50-55 °C was the optimum
in the water-vacuum oven utilized in, since the film unfolded in 20 minutes (from a
gelatin capsule) and swollen back to more than 85% of the original size after the
hydration in gastric fluid. When the drying temperature was higher than 55 °C,
GRD became too stiff and flaky, even though the dehydration took less than 5
hours. While all of these conditions may produce a useful GRD under some
conditions, only one was the optimum for the particular vacuum oven and water
vacuum pressure utilized in the current study.
To enhance flexibility and hydration rate of GRD1, a foam solution was
added to a gum solution to produce ORD2. Carbopol® 934 was beneficial to
modify the SLS solution into a foamy solution with smooth consistency and
texture. Neutrol TE adjusts pH of the foam solution, which manages the viscosity
of the foam solution and eventually, the flexibility and hydration rate of GRD2.
When pH was below 7, the solution was not viscous enough, which made the film
more flexible and increased the hydration rate. However, during this process, the
GRD, became too weak and soft. The foam was smooth and stiffer at around pH 738
to 7.5, and this foam did not adversely affect the rigidity of GRD2, while the film
maintained flexibility. When pH was higher than 7.5, the foam became too stiff
and viscous, so that the film was no longer elastic.
The time for the film to be completely unfolded from a gelatin capsule in
gastric fluid is shown in Table 1.8. Percent of hydration is calculated based on
volume of a film as the following equation:
Percent hydration (%)100* (Final volume of a filmInitial volume of a film)
Initial volume of a film
Table 1.8. Percent hydration of different shaped or sized GRD in simulated gastric
fluids.
Time (mm) 10 20 30 45
GRD1 (%) (%) (%) (%)
I 40±2 60±3 75±3 100
II 45±3 75±2 90±2 100
III 40±3 62±3 77±2 100
IV 55±2 80±4 96±2 100
V 57±3 82±3 95±2 100
VI 65±3 85±3 100 100
VII 75±3 90±4 100 100
VIII 62±2 83±2 95±2 100
GRD2 46±2 78±2 92±2 100
A rectangular shape of GRD with a size of 7.5*1.5*1 cm was found to be
acceptable in terms of fast swelling and rigidity. This rectangular shaped GRD
containing drug powder, matrix, or beads and a conventional JR tablet was then39
subjected toin vitrodissolution study.In vivostudies were later carried out with
the GRD containing hydrochiorothiazide beads.
IN VITRODISSOLUTION STUDY
The drug was prepared in different forms in order to obtain a sustained drug
release profile. First, a conventional dosage form of the drug was incorporated into
the GRD1 by suspending a tablet in the gel prior to cooling. The tablet was
positioned to remain suspended in the gel using a thread. However, the dehydrated
film containing the tablet was not easily inserted into a capsule. It was very
difficult to maintain the tablet in an intact form during folding or rolling the film,
and the volume of the film with the tablet was too big to fit into a capsule.
Moreover, excipients from the tablet that dissolved partially during the cooling of
the gel resulted in a distorted GRD film.
Next, hydrochiorothiazide in the form of pellets was prepared to achieve a
desired pattern of sustained drug release; afterward, the drug was formulated into
SR beads by spray-coating. Figure 1.9 provides the dissolution profile of
hydrochlorothiazide released from conventional IR 50 mg and 100 mg tablets.
More than 95% of the drug was dissolved within 30 mm for both tablets.-
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Figure 1.9. Dissolution profiles of hydrochlorothiazide 50 and 100mg in
commercial tablets, respectively.
[HCTZ: Hydrochiorothiazide, IR: Immediate release]
Dissolution studies of new hydrochlorothiazide pellets produced herein
were carried out and compared to dissolution from the pellets or powdered drug
incorporated into GRD1 as shown in Figure 1.10. The initial rates of drug release
were similar for all three formulations, however the release of drug was completed
in 9 hours from the pellet formulation compared to approximately 20 hours from
the drug in the GRD1. Release of the drug slowed in about 2 hours, when the GRD
it was nearly fully hydrated and expanded, and sustained drug release continued
until the drug was completely released. TheGRD1containing drug pellets faced a
double delay effect, which means that drug molecules have to travel througha
barrier within the pellet matrix as well as networks in the hydrated gel to be41
released outside of the dosage form, and this resistance to travel sustains the drug
release. Ninety percent of the drug was released in 15 hours from GRD1 containing
the drug pellets, and this release pattern was considered desirable fora SR dosage
formulation.
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Figure 1.10. Dissolution profiles of hydrochlorothiazide as a pellet and the
pellets or the drug in a powder form incorporated in a GRD1, respectively.
[HCTZ: Hydrochiorothiazide, GRD: Original gastric retention device]42
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Figure 1.11 Dissolution profiles of sustained release coating-layered
hydrochlorothiazide beads.
[Sr: Surelease®, OP: Opadry®, GRD1: original gastric retention device, GRD2: modified gastric
retention device.]
A SR bead formulation produced by spray coating in a Wurster column
was also prepared. The spray coating bead formulation is considered more43
favorable than the extruded pellet, because spray-coated bead formulations are
easier to transfer from a laboratory process to an industrial process via scale-up.
Therefore, sugar beads were spray-layered with drug and then with Surelease®
and Opadry® to produce SR beads that were eventually incorporated in a GRD.
Figure 1.11 provides different dissolution profiles for beads with
different degrees of coating. As expected, dissolution rates decrease with
increasing coating-layers on drug beads. In panel (A) in Figure 1.11, coating
with Surelease® of 2% weight gain slowed the rate of drug release dramatically,
and this resulted in less than 50% of drug release in 24 hours. The difference in
drug release between the beads with 2% Surelease® coat alone and the coated
beads in theGRD1was not significantly different. Well less than 10% of drug
was released from drug loaded beads with a 12% weight gained Surelease®-
coating in 24 hours. The coating with 2% and 12% weight gain of Surelease®
produced a zero-order release from about 3 to 24 hours, yet the rates of
dissolution were too slow to complete the drug release within 24 hours. The
rate of drug release needed to be accelerated without thinning the coating layer,
because coating less than 2% weight gain of Surelease® caused difficulty in
homogeneous coating during the spray-coating process. Therefore, Opadry®
was added to increase the drug release rate from the beads with 2% weight
gained coating with Surelease®. After incorporation of Opadry®, a more
desirable release pattern could be obtained while also increasing the total
thickness of coating which is desirable in order to obtain a uniform coating.
Total 3% weight gain coating composed of 67% Surelease® and 33% of
Opadry® increased the dissolution rate compared to the thinner 2% Surelease®44
weight gain coating without Opadry®. As shown in panel (B) in Figure 1.11,
approximately 95% of drug was released in 15 hours from the beads alone, and
incorporation of the beads inGRD1and GRD2 did not make a significant
difference compared to the coated beads alone on the dissolution profile. The
dissolution profiles for hydrochiorothiazide fromGRD1and GRD2 were
considered desirable for a SR dosage formulation administered once daily.
Based on the dissolution profiles,GRD1and GRD2 containing
hydrochlorothiazide-loaded beads coated with the total 3% weight gain coating
of 67% Surelease® and 33% Opadry® was selected for evaluation in a BAJBE
study.
Dissolution profiles of hydrochiorothiazide in the GRD2 with different
hydration periods of Carbopol® 934 in foam solution and XG/LB mixture (gum
solution), respectively, during the initial gel formation process, before mixing
foam solution with gum solution, are displayed in Figure 1.12 and 1.13,
respectively.
As shown in Figure 1.12, slower rate of drug release was obtained from
dehydrated gels placed in gastric fluid as Carbopol® 934 in the foam solution
was allowed to hydrate for longer period before the initial gel formation. The
early drug release rate was too fast from the final product for the 30 mm
hydration time. Drug release from the final product (see Figure 1.12) slowed
with more than 3 hours hydration time during the initial gel formation process.100
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Figure 1.12. Dissolution profiles of hydrochiorothiazide inaGRD2
with varying the hydration period of Carbopol® 934 in foam
solution, before mixing with gum solution.
[0.5 hour, 3 hour, 6 hour and 12 hour: Hydration period of Carbopol®934.1
Fifty percent of drug release was observed at 0.5, 2, 3, and 4hours for
an initial gel formation process hydration period of 0.5 hours, 3 hours, 6 hours
and 12 hours, respectively. With 3 hours initial hydration period,90% of drug
was released from the final product in about 15 hours and the drug releasewas
completed in 24 hours. When Carbopol® 934 in the foam solutionwas
hydrated for 6 hours or more, drug release was incomplete in 24 hourswith
90% for 6 hours initial hydration and 84% for 12 hours initial hydration.
Although sustained drug release was attained, incomplete drug release isnot
desirable. Therefore, duration of 3 hours was chosen for the foam solutionto be
hydrated before it was mixed with the gum solution to form the initial gelbefore
heating.46
The influence of hydration period (before mixing gum solution with
foam solution and heating) of the mixture of XG and LG (gum solution) on the
rate of drug release was also studied. Dissolution profiles of drug release from
GRD2 with three different hydration periods of the gum solution are shown in
Figure 1.13. One was heated immediately after dissolving gums in de-ionized
water (XLG-immediate), the other was allowed to hydrate for 3 hours (XLG-
3hr), and for 6 hours (XLG-6hr) before mixing with the foam solution and
heating the gum solution after dissolving gums.
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Figure 1.13. Dissolution profiles of hydrochiorothiazide in a GRD2
with different hydration periods of a gum solution.
[XLG: Gum solution of xanthan gum and locust bean gum]
In Figure 1.13, 50% and 97% of the drug was released in 2 hours and 12
hours from XLG-immediate, respectively. Ninety percent of the drug was47
released in 15 hours for XLG-3hr and XLG-6hr. The initialrate of drug release
from XLG-immediate was relatively fast, however, therewas no substantial
difference in the dissolution profiles between XLG-3 hoursand XLG-6 hours.
Thus, about 3 hours of self-hydration periodwas applied for the formulation of
GRD2before adding the foam solution and heating thegum solution.
SIMULATION OF PREDICTED PLASMA HYDROCHLOROTHIAZIDE
CONCENTRATION-TIME PROFILE
Prior to conducting BA/BE study, expected in vivo drugconcentration in
blood vs. time profiles were predicted by convoluting in vitrodissolution data.
In order to perform convolution, a pharmacokinetic modelwas needed. Before
applying a pharmacokinetic model obtained from the literature inour
simulation, verification of the reported modelwas carried out. A
pharmacokinetic model derived from and reported for observedplasma
concentration data should simulate plasma concentration data suchthat the
simulated data and the observed data should be nearly identical.A study by
Barbhaiya RH, et al, provided plasma hydrochiorothiazideconcentration vs.
time data (MSD data) following administration of 50mg of IR
hydrochlorothiazide and a pharmacokinetic model reported to describethese
data31. The pharmacokinetic model provided in reference(31) was evaluated
prior to our simulation as shown in the following flow diagram in Figure1.14.
The obtained plasma concentration-time data from reference (31) (MSDdata)
and pharmacokinetic parameters are shown in Tables 1.9 and 1 .10
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Figure 1.14. Flow diagram for process of a pharmacokinetic model selection for
simulation of plasma hydrochlorothiazide concentration vs. time.
Table 1.9. Observed mean plasma concentration data of hydrochlorothiazide
(MSD data)
(31)
Time (hour) 0.5 1 1.52 4 6 8 1224
Concentration (ng/ml)53197261287221123845122
±SD 52108123104673920 13 6
CV% 98554736272321262749
Table 1.10. Mean bioavailability and pharmacokinetic parameter values (± SD)
from MSD data(3
Parameter Value
Cmax(ng/ml) 310±115
Tmax(h) 2.1 ±0.9
AUC (ng*h/ml) 2442±676
3 (h') 0.072±0.02
T112(h) 9.6±2.7
MRT(h) 12.4±3.2
CIR (mI/mm) 289±92
ICmaxPeak plasma concentration, Tm: Time toCmax,AUC: Area under the plasma
concentration-time curve, j3: Terminal elimination half-life, MRT: Mean residence time, CIR:
Renal clearancel
The pharmacokinetic model for MSD data was provided in reference
(31) as shown below in equation (1).
C= 967 ± 997e34T±OO6t+ 125 + 43c007502_ 1297 ± 1016e085±O33t (1)
In our study, two methods were used to generate pharmacokinetic
models using the reference data (MSD data): 1) plotting the data on semi-log
paper, a hand-stripping method
33)and 2) using the computer software,
'WinNonlin'. The pharmacokinetic model by plotting the MSD data on semi-
log paper (Hand-stripping model
(33))is provided below as an equation (2) and
shown in Figure 1.15.
C= 51 6.98e0451t + 544.86e°825t + 1 49.2e008t (2)1000
a100 0
c
10
1-
= 544.86e-O.8756x
R20.894
y = 516.98e-0.4506x
R2 = 0.9266
for A&alpha
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Figure 1.15. Application of hand-stripping method fora pharmacokinetic model
for the observed plasma concentration data from reference (31).
[:Plasma concentration data from reference (31), A: Simulated data for A and alpha,u:
Simulated data for B and beta, .: Simulated data for C and Ka]
The computer software, WinNonlin was applied to generatea
pharmacokinetic model (WinNonlin model), and this WinNonlin modelwas
used to evaluate the hand-stripping and pharmacokinetic model provided in
reference (31). A two compartment-open model withorder absorption was
found by WinNonlin to adequately describe the data as shown in Figure 1.16
and equation (3) below.
C= 461 0.966592t + 96.31 eM062t - 4707.27e678t (3)-
C
C
C0
C-)
E
0.
51
0 5 10 15 20 25
TusQr)
Figure 1.16. Pharmacokinetic fitting of the observed plasmaconcentration
(MSD data) from reference (31) using WinNonlin.
[Observed: Observed data, Predicted: Predicted fit by a pharmacokineticmodell
Figure 1.17. Plasma concentration-time profiles of hydrochlorothiazidewith the
MSD data
(31)and the predicted data.52
Predicted plasma concentrations using equation (1), (2) and (3)were
plotted and are compared to the reported plasma concentrations(MSD data) in
reference (31) in Figure 1.17. The simulated data using equation(2) and (3)
were much closer to the original MSD data than the data calculated by the
reported equation (1). Since the observed datawere fitted reasonably by means
of both equation (2) and (3), equation (3) was chosen to performconvolution of
dissolution profiles of the drug from different dosage forms,an IR and aGRD1.
The dissolution profiles of hydrochlorothiazide in the IR tablet andin theGRD1
were convolved to obtain predicted plasma concentrations usinga superposition
method
(34)
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Figure 1.18. Dissolution profile of 50 mg hydrochlorothiazide inan IR tablet
and aGRD1.
[Sr: Surelease®, OP: Opadry®]400
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Figure 1.19. Profile of predicted plasma concentration for hydrochiorothiazide
in aGRD1and in an JR by convolution and compared to the observed plasma
concentration (MSD data
(31))Table 1.11. A calculation for the predicted plasma concentration by convolution usinga superposition method
(34)
Time
(hour)
HCTZ
(mg)
0.080.250.5 1 2 3-
4 5 6 7 8 9 10 12 152024Concentration
(ng/mI)
0.0 100.0-
0.0
0.1 31.6315.7 315.7
0.3 11.9299.2118.8 418.0
0.5 1.6 276.5109.716.3 402.4
1.0 0.2237.093.813.91.6 346.3
2.0 0.0 177.269.910.31.20.0 258.6
3.0 0.0 136.053.47.80.90.00.0 198.0
4.0 0.0 107.141.96.10.70.00.00.0 155.7
5.0 0.0 86.633.74.90.50.00.00.00.0 125.7
6.0 0.0 71.827.84.00.40.00.00.00.00.0 104.1
7.0 0.0 60.823.53.40.40.00.00.00.00.00.0 88.1
8.0 0.0 52.520.22.90.30.00.00.00.00.00.00.0 759
9.0 0.0 46.117.72.50.30.00.00.00.00.00.00.00.0 66.5
10.0 0.0 40.915.72.20.20.00.00.00.00.00.00.00.00.0 59.1
12.0 0.0 33.112.71.80.20.00.00.00.00.00.00.00.00.00.0 47.8
15.0 0.0 25.19.61.30.10.00.00.00.00.00.00.00.00.00.00.0 36.2
20.0 0.0 16.56.30.90.10.00.00.00.00.00.00.00.00.00.00.00.0 23.8
24.0 0.0 11.94.50.60.10.00.00.00.00.00.00.00.00.00.00.00.00.0 17.2
[HCTZ: hydrochiorothiazide]55
An example of the spreadsheet for convolution of a commercial JR tablet
containing hydrochlorothiazide 50 mg is shown in Table 1.11.
Dissolution profiles and predicted plasma concentrationvs. time data for
GRD1 and JR tablet by convolution are displayed in Figure 1.18 and 1.19,
respectively. In Figure 1.19, peak plasma concentration (Cm) and the time for
Cmax (Tmax) were 287 nglml and 2 hours for the MSD data, and the predicted Cm
and Tmare 347.7 nglml and 0.25 hours for the JR tablet used in our study.
Predicted Cmax and Tmax for the GRD1 were lower (271.3 ng/ml) and slower (2
hours) than the IR tablet. Area under the curve from 0 hour to infinite (AUCO..If)
was calculated using the Trapezoidal rule
(33)
A predicted AUCo1f from the GRD1 (4044 ng*hlml) was higher compared
to the values from MSD data and the JR tablet (3347 and 3588 ng*blml),
respectively (see Table 1.12). The predicted bioavailability of the oral tablet data
from reference (31), the JR tablet and the GRD1 were 75%, 80% and 90%
compared to the bioavailability of the IV administration
(16)respectively.
Table 1.12. Summary of simulated pharmacokinetic parameters from different
formulations.
Formulation MSD data
'
(IR tablet)
IR tablet
purchased by the
OSU lab
GRD1
containing the
drug beads
PK parameters
Cmax (ng/ml) 287 347.7 271.3
Tmax (hr) 2 0.25 2
AUCo-1f (ng*hIml) 3347 3588 404456
Pharmacokinetic parameters for hydrochiorothiazide from an oral IR tablet
data (MSD data) from reference (31), the IR tablet, and,GRD1administration are
summarized in Table 1.12. Note that one reason the predictedCmaxfrom the IR
tablet is higher than the reported Cm for the MSD data (also IR tablet) could be
that for a rapid drug release tablet, the absorption is not dissolution limited but is
limited by absorption (as occurs with an absorption window) or GI
mixing/delivery. In this case, the convolution method will overestimate theCmax
for the JR tablet because the convolution assumes instantaneous and complete
absorption once drug is dissolved, but convolution should still give a good estimate
of the plasma concentration values from the GRD where absorption is expected to
be dissolution rate limited and not absorption rate limited.
Because hydrochiorothiazide has an absorption window at the upper
intestine, increased gastric retention time by means of the GRD played a key role in
predicting an enhanced bioavailability. As shown in Figure 1.19, the predicted
plasma concentrations from theGRD1were higher from approximately 4 hours
through 24 hours than from JR formulations, and this is because simulated drug
input from the GRD1 was continued longer than IR. This simulated plasma
concentration vs. time profile for hydrochlorothiazide supported conducting BA/BE
study with theGRD1(preliminary BA/BE study).57
CONCLUSIONS
Interaction between XG and LG provided a basic structure to formulate
GRD1and GRD2, and PEG 400 and the mixture of Carbopol® 934 and SLS
supplemented flexibility. A variety of shapes and sizes of GRD were studied with
respect to hydration rate of the dehydrated GRD; a rectangular shape with a size of
75* 1.5*1cm was chosen for further study. Different ratios of XG/LG and various
amounts of PEG400 were studied to obtain a desirable strength following
dehydration and re-hydration. Amounts of 0.75 g of XG and 0.5 g of LG for initial
preparation for the GRD1, and 0.75 g of both XG and LG for the GRD2 were used
in the formulation, respectively. This viscous gum solution was heated to between
80 and 85 °C. A foam solution composed of 0.075 g Carbopol® 934 and 0.125g
SLS at pH 7-7.5 was added into the gum solution for theGRD2to increase
hydration rate and flexibility. Hydrochiorothiazide was homogeneously suspended
in the gum solution. Each solution was poured into a mold and cooled to become a
gel before dehydration. Study of temperatures for dehydration of GRD showed that
the drying process had a considerable influence on the texture and hydration rate of
the dried GRD. The gel was dried at 50-55 °C for about 5-6 hours, and this
condition produced a flexible yet strong film.
The drug was formulated into pellets and beads to produce sustained drug
release. Both the pellets and beads were incorporated into the GRD1, and these
formulations achieved desirable sustained release profiles.58
Spray-coating was used to formulate sustained release beads for
hydrochiorothiazide. Surelease® was chosen as a sustained-release agent to coat
drug-loaded beads. With 2% coating, the rate of drug release slowed dramatically
and thus, a water-soluble polymer, Opadry® was added to enhance the dissolution
rate. The beads coated with total 3% weight gain coating consisting of 67%
Surelease® and 33% Opadry® were incorporated in theGRD1and GRD2, which
resulted in a desirable sustained drug release hydrochiorthiazide profile.
A pharmacokinetic model was generated using the observed plasma
concentration data in reference (31) by plotting data on semi-log paper (a hand-
stripping method
(33))and using the computer software, WinNonlin. These
pharmacokinetic models were compared to the model provided in the reference
(31). The best-fit model was selected to perform convolution using a superposition
method to simulate predicted plasma concentration profiles for the JR
hydrochiorothiazide tablet and hydrochlorothiazide in theGRD1prior to a
preliminary bioavailability/bioequivalency study. The predicted post-peak plasma
concentrations from theGRD1were consistently higher than that from the IR, due
to continuous and uniform drug input from the GRD1, as expected from the
prolonged drug dissolution profile.59
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CHAPTER 2
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION
OF HYDROCHLOROTHIAZIDE IN A GASTRIC RETENTION
DEVICE AND IN VIVO/IN VITRO CORRELATION
Hyojong Kwon and James W. Ayres, Ph.D.ABSTRACT
Bioavailability, pharmacokinetics, and pharmacodynamics of
hydrochiorothiazide were investigated for an immediate release (IR) formulation
and a gastric retention device (GRD) in a capsule containing 50mg of the drug. A
preliminary bioavailability/bioequivalency study was performed with 3 subjects
under fasting and fed conditions. Each subject receiveda single dose of an JR and
an original GRD(GRD1)in fasting and fed conditions, and collected urine samples
for up to 48 hours post-dosing. Each subject received theGRD1in a 000 capsule
and one subject received theGRD1in a 00 capsule additionally under fasting
condition. Bioavailability was lower from theGRD1in both a 00 capsule and a 000
capsule compared to the JR in fasting condition. However, bioavailability from the
GRD1was higher than the JR under fed condition. The GRD1 in a 00 capsule
obtained lower bioavailability than in a 000 capsule, most likely because theGRD1
in a 00 capsule was folded too tight to be unfolded within 20 minutes and thus, the
device was swept away by strong contractions in the stomach before the devicewas
unfolded and swollen back to the original size. TheGRD1did not withstand
"housekeeping contractions" on an empty stomach, which resulted in incomplete
drug release. Meanwhile, theGRD1was able to complete drug release in fed
condition by avoiding transfer into the intestine while food was present and
digested in the stomach. Even though the size (7*1.5*1 cm) of theGRD1was
bigger than the size (6.5*1.5*1 cm) proven to stay on an empty stomach from theprevious studies by Kapsi and Ahmed, the GRD was a somewhat different
formulation and was not strong or rigid enough to endure strong contractionson an
empty stomach. Therefore, theGRD1needed to be more rigid.
After modification, a more rigid GRD (GRD2) in a 000 capsulewas
compared to an JR formulation in a bioavailability/bioequivalency study with 6
subjects under fasting conditions. Each subject received a single dose of the JR
once and the GRD2 twice with at least a 1-week washout period. Bioavailability
from the GRD2 was higher than from the JR dosage form based ona cumulative
amount recovery for up to 36 hours. Mean peak excretion rate(Rm) from the
GRD2 was reduced to approximately half of that from the IR, and mean time to
peak excretion rate(Tmax) of the GRD2 was delayed compared to the JR. After
Rmax,the excretion rate of the GRD2 was continuously higher than that of the JR for
up to 48 hours. Drug absorption after administration of the GRD2 continued up to
approximately 18 hours, while the absorption stopped at about 3 to 4 hours post-
dosing of the JR. This profile indicated that the GRD2 stayed in the stomach for
about 15 to 18 hours to achieve complete and slow drug release. Urine output and
water-intake balanced for up to 48 hours, and urine production increased after
administration of hydrochlorothiazide from both the JR and the GRD2. Rate of
urine production from the JR decreased 5 hours post-dosing, while that from the
GRD2 remained higher than the JR for up to 18 hours post-dosing. The initial equal
amount of diuresis was remarkable since less of the drug was absorbed initially
from the GRD2 (2.5 .tg/ml(Rmax) at 5 hours(Tmax)) compared to the JR (4.8 j.ig/ml(Rmax) at 2.5 hours(T1)) in the fasting condition. Total amount of urine
production was higher from theGRD2compared to the IR, although the dosewas
the same. This observation can be attributed to prolonged drug input from the
GRD2followed by a feedback-increased amount of water-intake to compensate for
the prolonged diuretic effect of the drug. Bioavailability of the drug under fasting
conditions was essentially equal, but the diuretic effect from the GRD2was
increased by 27% compared to the JR. From the profiles of the relationship
between drug effect (urine production or diuresis) and drug concentration (urinary
excretion rate), clock-wise hysteresis was observed for both formulations. This
clock-wise hysteresis loop explains the development of tolerance to diuresis of
hydrochlorothiazide. In spite of the development of tolerance to
hydrochlorothiazide, slow rate of drug input activates less degree of compensatory
homeostatic reaction, resulting in higher drug efficiency and cumulative
pharmacological response (total diuresis). The maximal urine productionwas
obtained at approximately 2.5 mg/hr of urinary hydrochiorothiazide excretion rate
for both JR and GRD, and there was no significant effect on diuresis from higher
urinary drug excretion rate than 2.5 mg/hr from JR formulation due to development
of acute tolerance. Based on these results is suggested that hydrochiorothiazide in
the GRD may be more effective to lower blood pressure for a more prolonged time
period than hydrochlorothiazide in the JR dosage form. A few adverse reactions
were reported from administration of the JR due to high drug peak concentration.67
Using data from the full bioavailability/bioequivalency study,in vivo/ in
vitro correlation was established for the JR and the GRD2. Good correlations were
obtained betweenin vitrodissolution andin vivoabsorption for both JR and GRD2.
Therefore, these correlations can be used as a predictive tool in drug development
and prediction ofin vivoprofile prior to future bioavailability study. The GRD2
achieved bioequivalency along with better safety and efficiency compared to the JR
formulation, and therefore this device can achieve better patient care and
compliance.LSI
INTRODUCTION
The benzothiadiazine diuretic hydrochiorothiazide has been widely used in
treatment of hypertension, congestive heart failure and other conditions in which
sodium retention and edema occur
(1.2)Hydrochiorothiazide is commercially
available as an immediate release (IR) dosage form. The dosage of
hydrochiorothiazide is 50-100 mg initially, followed by 25-50 mg daily for adults
and 3.5 mg/kg body weight and 2.5 mg/kg body weight for infants under six
months and children, respectively, for the treatment of edema. The dose for
hypertension can be adjusted from 25 to 200 mg daily
(1)
PHARMACOKINETICS AND PHARMACODYNAMICS
The kinetics of hydrochiorothiazide are described by a 2-compartmentopen
model, with the half-lives of the a- and 13-phase ranging between 1 to 2 hrs and 5 to
14 hrs, respectively, in healthy individuals
(3)Urinary excretion rate of
hydrochlorothiazide is a mirror-image of plasma concentration, because the time
course of urinary excretion rate and plasma concentration is well correlated
(4, 5)
Renal clearance is about 300 ml/hr, which indicates the combination of glomerular
filtration and tubular secretion
'5)Hydrochiorothiazide is mainly eliminated
unchanged via the kidneys
(5),and hence the amount of the drug absorbed should be
close to that recovered in the urine. Mean drug absorption of 12.5 to 75mg of ther'sJ
drug orally administered varies from 40% to 60% in the gastrointestinal (GI) tract,
and the urinary recovery averages from 60% to 80% of the drug absorbed
(3, 5)in
one study by Shah, et a!, bioavailability of hydrochiorothiazide was around 40%
following an oral administration
(6)Ninety to 94% of the drug was recovered in
the urine after intravenous (IV) administration
(5)In a study by Beermann, et a!
(5),
peak drug concentration (Cm) averaged 70, 142, 260 and 376 ng/ml at 1.5-5 hr
from four different doses of 12.5, 25, 50 and 75 mg, respectively. Therewas a
significant difference in the total diuresis and natriuresis between placebo and the
12.5 mg dose of hydrochlorothiazide (1208 ml vs. 2009 ml and 36.9 nmolvs. 136.7
nmol, respectively) during 10 hours post-dosing
(5)However, no significant
difference in either diuresis or natriuresis was observed among 25, 50 and 75mg
doses
(6)The drug effects on diuresis and electrolytes excretion reached the
maximum after administering 12.5 mg of hydrochlorothiazide, which indicateda
lack of correlation between diuresis, natriuresis, kaliuresis, and excretion of
calcium and magnesium andCmorAUC09after higher doses of 25- 75mg
(5)
Pharmacological response of diuretics such as furosemide or hydrochiorothiazide
usually involves changes in electrolytes (i.e. sodium, chloride and potassium) and
urine production. Hydrochlorothiazide increases the urinary output of chloride,
potassium, sodium and fluid in approximately 1.5 to 6 hours post-dosing compared
to placebo
(7)There are quite a few studies done for pharmacodynamics of loop
diuretics such as furosemide with respect to development of tolerance on the drug
effect
(8-10)however, previous studies for thiazide diuretics acting at the early distal70
convoluted tubule focused on pharmacokinetics and paid little attention to the
pharmacodynamics because urine collection had not been done for adequately
prolonged periods in many studies
(h112)In this research, the time course of urine
production was studied for up to 48 hours post-administration of
hydrochlorothiazide in normal healthy subjects.
ABSORPTION OF HYDROCHLOROTI-IIAZIDE
Absorption of hydrochlorothiazide takes place in the stomach to a small
extent, and mainly in the duodenum and the first part ofjejunum
(3, 13)The
mechanism of drug absorption has not been clearly defined. An active
transportation is hypothesized to exist in the upper part of the intestine thatcan be
saturated
(4),The hypothesis is supported by the result of higher bioavailability of
hydrochiorothiazide from slower gastric emptying in the presence of food
(7, 13, 14)
Beermann, et al, studied the influence of food on drug absorption with a dose of 75
mg of the drug in healthy individuals
(13)Cm and Tm were 388±85 (ng/ml) and
2.4±0.8 (hour), and 339±77 (ng/ml) and 3.2±1.5 (hour) in fasting and fed condition,
respectively
3)The total urinary recovery of hydrochlorothiazide was 47.4±6 mg
(63.2±8%) without food and 5 5.6±4.9 mg (74.2±6.5%) with food at 48-hrs post-
dosing
(13),Volume of fluid-intake did not influence on the drug absorption after
oral administration
(13)However, food effects are less likely to be clinically
important with respect to the flat dose-response curve of hydrochiorothiazide
(5, 13)71
Lower bioavailability was observed from sustained release (SR)
formulations compared to that from a conventional JR tablet
(15, 16)In one study
conducted by Herman, et al, a complete release of 50 mg dosewas obtained in
simulated gastric fluid after 3.6 hours and 21 to 22 hours for the conventional tablet
and SR pellets, respectively
(15)The Cm of about 489 (ng/ml) at 148 minutes and
116 to 148 (ng/ml) at 140 to 207 minutes were observed for the JR tablet and the
SR pellets, respectively
5)Overall 24 hours urinary recovery was higher for the
conventional tablet (67.9%) compared to the SR pellets (26.4-36.9%)l5)A
similar result was obtained from anin vitro/in vivostudy in beagle dogs by
Ritschel, et al
(16)
In vitrodissolution of hydrochlorothiazide from a commercial
JR tablet reached 100% within 30 minutes, whereas only 54% drug release was
released from a SR tablet after 4 hours in simulated gastric fluids
6)
Bioavailability of the drug was 82% and 41% from the fast release tablet and the
slow release tablet, however Tm was not significantly different
(16)These results
support the absorption window theory for hydrochlorothiazide proposed previously
(3, 13)Therefore, improvement in bioavailability of drugs with an "absorption
window" such as hydrochlorothiazide can be expected from a prolonged gastric
retention time and slow drug release that can be achieved by means of the GRD.72
IN VIVO/IN VITRO CORRELATION (I VI VC)
In vivo-in vitro correlation (IVIVC) is established to evaluate the
relationship between a biological property and a physicochemical property of drug
molecules
(17)Pharmacokinetic parameters and in vitro dissolution profiles ofa
drug in a dosage form are commonly used for representing the biological and the
physicochemical properties, respectively
7)The essential goal of establishing
IVIVC is to achieve a consequential relationship between in vitro behavior ofa
drug and in vivo performance of the drug, which means in vitro dissolution datacan
be used as a surrogate marker for predicting in vivo behavior and bioequivalency
(17)A plasma concentration-time profile of a drug in an oral dosage form is
deconvolved to obtain an in vivo time course of an absorption profile which is then
compared to an in vitro dissolution-time profile.
The correlation can be categorized into three levels, level A, B, andc
(18)
A level A is most commonly used and follows a two-stage procedure which is
deconvolution continued by generating the relationship between the fraction of
drug absorbed and the fraction of drug dissolved
8)In order to establish the level
A IVIVC, a model should reflect the full in vivo time course from in vitro data
A Level B IVIVC is estimated based on statistical moment analysis
(18)Unlike the
level A, level B does not produce a point-to-point correlation, because the mean in
vitro dissolution time is correlated to either the mean residence time or the mean in
vivo dissolution time that is determined from various in vivo plasma data
8)A73
level C IVIVC produces a single point relationship using a dissolution parameter
and a pharmacokinetic parameter and thus, the entirein vivotime course cannot be
produced
(18)A number of rational considerations must be taken into account to
obtain an appropriate IVIVC such as the following(1923):1) the formulation should
be relatively insensitive to the variation of thein vivoenvironment, for instance, the
effect of agitation, pH, or surfactants, 2) a dissolution rate should be the rate-
limiting step in the overall absorption process, not the physical absorption of drug
such as a permeation rate, 3) IVIVC may not be an ideal surrogate for a drug that
has a fairly narrow therapeutic window. Common methods for deconvolution
include the Wagner-Nelson method and the Loo-Riegelman method for one-
compartment and two-compartment model drugs, respectively
(24)A profile ofin
vivo dissolution can be also achieved by numerical deconvolution using a computer
program such as PCDCON or Kinetica
(25)In this study, IVJVC for
hydrochlorothiazide in an JR formulation and theGRD2were established by
convolution of the dissolution-time profiles and deconvolution of the urinary
excretion rate-time profiles from the full bioavailability/bioequivalency study (level
A correlation).74
MATERIALS AND METHODS
I-Iydrochlorothiazide was used as a model drug. 1-lydrochiorothiazide 50mg
tablets, USP (Lederle Laboratories Division American Cyanamid Company, Pearl
River, NY) and a powder form of hydrochiorothiazide (TEVA pharmaceuticals-
USA, Sellersville, PA) were supplied. GRD containing 50mg hydrochlorothiazide
as spray-coated beads was produced at College of Pharmacy, Oregon State
University (OSU), Corvallis, Oregon. Ingredients and procedure of GRD
formulation and the drug bead formulation were described in the previous chapter.
BIOAVAILABILITY/BIOEQUIVALENCY STUDY (BA/BE STUDY)
Subject population
All subjects were healthy male or female adult volunteers drawn from the
OSU faculty, staff and student population. The volunteers were colleagues and
friends recruited by contacting them in person. Excluded from this study are
subjects who:
1.Are allergic to hydrochlorothiazide or any thiazide.
2.Are currently taking other medications including any diuretic or anti-
hypertensive.75
3.Are scheduled to have medical tests within the next week.
4.Are pregnant.
5.Are known to have kidney! Liver disorders.
6.Are known to have gastrointestinal disease or history of gastrointestinal disease.
7.Are smokers.
Study design
The proposal of the study was approved by Oregon State University
Institutional Review Board (IBR) for the protection of human subjects. The study
was performed from January 2001 through May 2001. All subjects signed their
written informed consents before participating in the study. All subjects were not
allowed to consume any food or fluid containing caffeine such as coffee, tea, coke
and chocolate, and alcohol during the study period. Bioavailability evaluation
involved two bioavailability/bioequivalency (BA/BE) studies, corresponding to a
preliminary BA/BE study involving 3 subjects with administration of an IR and a
GRD1under fasted and fed conditions, and to a full BA/BE study, the study with 6
subjects with administration of an JR and a GRD2. The full BA/BE study was a
partially repeated crossover design with the drug administration under fasting
conditions.,11
Preliminary bioavailability/bioeguivalency study:
Three healthy subjects (three males) were administered two treatments,an
JR tablet (Treatment A) and aGRD1in a 000 capsule (Treatment B) with a washout
period of at least one week. One subject was also administered aGRD1in a 00
capsule as well under fasting condition, after the study with the two treatments A
and B. All treatments were equivalent to 50 mg hydrochlorothiazide. Each
treatment was ingested with 12 oz (355m1) of water. All subjects were required to
fast for at least 10 hrs prior to the study. No food or beverage except for waterwas
allowed for two hours post-dosing for the fasting condition. For the fed status,
each treatment was administered immediately followed by standard breakfast
(Burger King® sausage and egg biscuit, hashbrown potatoes, and 8 oz of orange
juice).
Full bioavailability/bioequivalency study:
Six healthy subjects (4 males and 2 females) divided into two groups
ingested each treatment with at least 1-week washout period in fasting condition.
All treatments were equivalent to 50 mg hydrochiorothiazide. Group I received an
JR first and then aGRD2in a 000 capsule after 1-week of washout period, while
group 2 was administered aGRD2in a 000 capsule followed by an JR with the77
proper washout period. After the study with both JR and GRD2, subjects were
asked to repeat the study with the GRD2. Therefore, all subjects received a total of
3 doses with at least 1-week washout period between each treatment.
SAMPLING AND DRUG ASSAY METHOD
Collection of urine samples
All subjects fasted overnight before each treatment, voided their bladder,
collected a zero-time urine sample prior to dosing, and then was administered a
treatment. Subjects collected the full volume of urine output in 16 oz disposable
plastic containers at 1, 2, 3, 4, 6, 8, 10, 12, (15), 24, 36 and 48 hours post-dosing.
Fifty-ml of a urine sample was collected after the full volume of urine output was
measured accurately in order to calculate a total amount of the drug recovered. An
aliquot of a urine sample was frozen at 20 °C before analysis.
Reagents and supplies for high pressure liquid chromatography (HPLC) assay
Methanol (HPLC grade, Fisher Chemicals, NJ), acetonitrile (HPLC grade,
Fisher Chemicals, NJ), potassium monobasic phosphate (HPLC grade, Fisher
Chemicals, NJ),C18disposable 3-ml solid phase extraction (SPE) columns78
(BakerbondspeTM, JT Baker, NJ) were supplied for HPLC assay. Deionizedwater
was prepared by using the Milli-Q Reagent Water System (Millipore, Bedford,
MA).
Chromatographic conditions
The column was a micro-particulateC18reversed-phase (MicrosorbC18pore
size of 100, a particle size of 5 tm, 25 cm x 4.6 mm, Varian, Inc., Walnut Creek,
CA, USA.) preceded by aC18guard cartridge (ODS, 4x3 mm, Phenomenax, CA,
USA). A modified HPLC (High Performance Liquid Chromatography) assay of
Barbhaiya, et al
(26)was used to prepare the mobile phase and to analyze the urine
samples for drug content, however, the extraction method was replaced by a
modified solid-phase extraction method of Papadoyannis, et al
(27),due to low
efficiency of drug recovery from the method of Barbhaiya, et al. The mobile phase
was prepared by mixing de-ionized water and methanol at ratio of 95:5 and then
filtering through a 0.2 tm filter. The filtered mobile phase was running at a flow
rate of 1.5 ml/min by a delivery pump (Waters 550 Solvent Delivery System,
Waters Associates, Milford, MA), and a sample was injected using an automatic
sample injector (Waters WISP Model 712B, Waters Associates, Milford, MA).
The UV absorbance was detected at 271 nm using a spectrophotometer79
(Spectroflow757, ABI analytical Kratos division, NJ). Peak areas were recorded
and calculated by an integrator (SP4290 integrator, Spectra-physics, NY).
Standard solutions and standard curves
Hydrochlorothiazide stock solution (50 mg/mi) was prepared by dissolving
50 mg hydrochlorothiazide in mixture of methanol and water at ratio of 3:7.
Standard solutions of 200, 100, 50, 25, 10, 5, 2 and lj.iglml were prepared by serial
dilution from the stock solution. The stock solution was diluted with blank urine to
contain 1, 2, 5, 10, 25 and 200 jtg/ml of hydrochlorothiazide.
These standards (2 ml) were mixed with 1 ml of the internal standard,
hydroflumethiazide (50 jig/mi) solution in a disposable glass test tube. To these
solutions, 1 ml of blank urine was added and vortex-mixed for a few seconds prior
to extraction. Fifty .tL of the extracted sample were injected into the column. The
chromatogram was recorded, and the peak areas calculated. Retention time was
about 17 minutes and 32 minutes for hydrochlorothiazide and the internal standard,
respectively. A standard curve was constructed by plotting the peak ratios of
hydrochlorothiazide and hydroflumethiazide against the hydrochlorothiazide
concentrations in the urine. Standard curves for pure hydrochlorothiazide solution
and for hydrochiorothiazide in the urine are shown in Figures 2.1 and 2.2, and 2.3,
respectively. Sensitivity of the assay was high enough to measure 1tg/ml with a80
linear relationship between the peak ratios and hydrochiorothiazideconcentrations
in the range of I to 200 .1g/rn1 with R2 0.9937.
Figure 2.1. A typical standard curve for hydrochiorothiazide.
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Figure 2.2. A typical standard curve for hydrochiorothiazide at lower
concentrations.
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Figure 2.3. A typical standard curve for hydrochiorothiazide in the urine.82
Sample analysis: solid-phase extraction
Two-mi of the aliquot were mixed with 1 ml of the internal standard and 1
ml of water. One-mi of the mixed solution was applied to the SPEC18cartridge
previously conditioned by flushing with I ml of methanol, I ml of water and 1 ml
of 0.5 mmoi ammonium phosphate buffer. After applying a sample, the cartridge
was washed with 2 ml of water and dried by vacuuming air through it. Residues on
the cartridge were eluted by 1 ml of acetonitrile followed by 2 ml of water. Fifty-p 1
of the eluted sample were injected into the HPLC column.
PHARMACOKINETICS, PHARMACODYNAMICS AND STATISTICAL
ANALYSIS
Pharmacokinetics
A two-compartment open model was applied to describe the data in terms
of the best-fit using computer software, WinNonlin. Bioavailability of two
treatments were compared by investigating significant differences of
pharmacokinetic parameters including the total drug recovery in the urine during
the first 36 hours post-dosing (A0-36),the maximum urinary excretion rate(Rmax)
and the time to reach Rmax(Tmax).Parameters including Rand Twere
obtained from the individual urinary excretion rate-time curves, andA036andA04883
were determined from the individual cumulative amount of urinary drug recovery-
time curves. The time point for the time course of urinary excretion ratewas
recorded at a midpoint of each time interval of collecting urine samples.
Pharmacodynamics
Pharmacodynamics is defined as study of the relationship between drug
concentrations and drug effects. A sustained drug release dosage form achieves
prolonged drug concentrations within a therapeutic range as well as the drug effect
for a desirable period. Hydrochlorothiazide increases urine production due to the
diuretic effect of the drug and thus, the time course of the urine production was
chosen to represent the drug effect for the comparison between the JR formulation
and the GRD2. A profile of the rate of urine production (diuresis) vs. urinary
excretion rate was used for investigation of pharmacodynamics, and the Hill
equation (also known as the sigmoidEmaxmodel) was applied to describe the
relationship between urinary excretion rate and pharmacological effect, diuresis of
hydrochlorothiazide
(28)The Hill equation expressed below was selected in terms
of the best-fit using the computer software, WinNonlin.
EE Cs
niax + E0
C50
Eis the diuresis in ml/hr,E0is basal diuresis in mllhr,Eniaxis the maximum drug
induced diuresis in rnl/hr,C50is the urinary excretion rate of hydrochiorothiazideassociated with half maximum induced diuresis in mg/br, C is the urinary drug
excretion rate in mg/br, and S is a fitting parameter known as a slope factor
(28)
Statistics
Statistical analysis in pharmacokinetic parameters(A036and log Rmax)of
two treatments was carried out using a two-sided Student t-test, which is testing the
null hypothesisHo: JT=J.1Rat a desired level of significance, 5% (a0.05).A036
was chosen for the statistical analysis instead ofA08due to lack of a datum ofA36
48from one subject with respect to a short half-life. Difference in two treatments is
concluded from the rejection of the null hypothesis
(29)whereas equivalency of the
treatments is obtained from the failure of rejecting the null hypothesis, which
indicates there is no strong evidence of a significant difference between two
treatments.
SIMULATION OF ABSORPTION PROFILE
The cumulative amount of drug input-time curves were predicted by using a
computer program, PC-DCON. PC-DCON is a program that deconvolves drug
amount vs. time data and separates the mathematical description of drug travel
through the body into input or absorption and output or elimination functions, and85
thus makes it possible to determine how long the drug is input into the body
(25)
Little absorption occurs for a drug that has an" absorption window" in theupper
part of the intestine, once the drug passed the limited absorption sites. Thus, the
gastric residence time of drug or a dosage form releasing the drug plays a major
role to determine the amount of drug absorption. The gastric residence time fora
GRD and an JR dosage form can be determined when the cumulative amount of
drug input becomes a plateau against time, which explains when the dosage form
leaves the stomach because following that time, drug absorption ceases. In this
study, the impulse responses used were the elimination rate constants, c (0.38 br
1)
and(0.01 br) as calculated from individual urinary excretion rate-time curves
from administering an JR. Urinary excretion rate of hydrochiorothiazide from an
JR and a GRD were the input responses (R). Profiles of amount of drug absorbed-
time were generated over 48 hours for each individual, and average data were also
obtained and plotted.
IN VIVO/IN VITROCORRELATION (I VI YC)
In vitrodissolution data and urinary excretion data of an JR and aGRD2
from the full BA/BE study were used to establishin vivo/in vitrocorrelation
(I VI VC) for the JR formulation and the GRD2, respectively. Urinary excretion rate
of hydrochiorothiazide reflects plasma concentration of the drug, and therefore the
urinary excretion data were applied for deconvolution to obtain anin vivodissolution profile. When the time of maximum dissolution invitro is not
equivalent to the time of complete in vivo absorption, this results ina bi-phasic
1V1VC curve
(30)Therefore, the time of maximum in vitro dissolution hasto be
scaled to be equivalent to that of in vivo deconvolved input, whichmeans that time-
scaling must be carried out in order to correlatean in vivo dissolution profile and in
vitro dissolution profile. For example, the maximum in vitro dissolutionand in
vivo dissolution for the JR formulation were achieved in 1 hour and3 hours,
respectively. The in vitro dissolution data needed to be interpolatedto 1 hour
increments over a period of 3 hours. To correct the in vitro dissolutiondata by
time-scaling, in vitro dissolution time was multiplied bya scaling factor of
3/(maximum in vitro dissolution time)
(30)For instance,65%of the drug dissolved
at 0.1 hour(6minutes) from the in vitro dissolution profile would be plottedat 0.3
hour (0.1*3/1) by scaling time for IVIVC. The IVIVCcurve proposes 100%
achievement on x-axis for in vitro dissolution and either 100%or less than 100%
completion on y-axis for in vivo absorption over thesame time period by time-
scaling
(30)87
RESULTS AND DISCUSSION
PRELIMINARY BIOAVAILIBILITY/BIOEQUIVALENCY (BA/BE) STUDY
Since hydrochiorothiazide is not metabolized and is mainly eliminated
unchanged via the kidneys, the amount of e drug absorbed in the body is reflected
by the amount recovered in the urine
(3)The cut-off size forGRD1was chosen to
be 7*1.5*1 cm that is bigger than the largest size (6.5*1.5*1 cm) from the studies
performed previously by Kapsi and Ahmed at Oregon State University. Three male
subjects (A, B and C) participated for a pilot study with two treatments, an IR tablet
and a GRD1 in fed and fasting condition. Individual urinary excretion rate-time
curves as well as cumulative amount of drug recovery-time curves are illustrated in
Figures 2.4.a-d to 2.6.a-d for the study under fasting and fed status. In all 3
subjects under fasting condition, theGRD1failed to stay long enough to complete
drug release, which resulted in lower total drug recovery compared to the IR. The
GRD1in a 00 capsule tested in subject (C) did not successfully complete the drug
release, leading to lower bioavailability than the JR or the GRD1 in a 000 capsule.
Profiles for average urinary excretion rate-time and average cumulative amount of
drug recovery-time in fasting and fed conditions are shown in Figures 2.7.a through
-d. Individual and average cumulative amount of drug input-time curves are shown
in Figures 2.8.a through -d.E
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Figure 2.4.b. Cumulative amount recovery-time curves of hydrochiorothiazide from
subject (A) in fasting condition.8
7.5-1 a
I
6.5I1
61 I
I.
E a
5-Ill
4.51'
I I
.9 -l'
1.J
0.5
0
02
. . -
-
4 6 810121416182022242628 30 323436 38 40
Time midpoint (hours) - + IR SGRD
Figure 2.4.c. Urinary excretion rate-time curves of hydrochiorothiazide from
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Figure 2.5.d. Cumulative amount recovery-time curves of hydrochiorothiazide from
subject (B) in fed status.93
Figure 2.6.c. Urinary excretion rate-time curves of hydrochiorothiazide from
subject (C) in fed status.
50
45
40
35
30
0
25
00
I
0 -n
0246810 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44
Time (hours)-IR S (iRD
Figure 2.6.d. Cumulative amount recovery-time curves of hydrochiorothiazide
from subject (C) in fed status.U)
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Figure 2.7.a. Average urinary excretion rate-time curves of hydrochiorothiazide
from 3 subjects in fasting condition.
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Figure 2.7.b. Average cumulative amount recovery-time curves of
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Figure 2.7.c. Average urinary excretion rate-time curves of hydrochiorothiazide
from 3 subjects in fed status.
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Figure 2.7.d. Average cumulative amount recovery-time curves of
hydrochiorothiazide from 3 subjects in fed status.96
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Figure 2.8.a. Cumulative amount input-time curves of hydrochlorothiazide from
subject (A) in fasting condition.
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Figure 2.8.b. Cumulative amount input-time curves of hydrochlorothiazide from
subject (B) in fasting condition.97
30
25 0
0
0
° 20
5 .2
0r
0 246 81012141618 20 22 24 26 28 30 32 34 36 38 40 42 44
Time (hours) 0 IR GRD
Figure 2.8.c. Cumulative amount input-time curves of hydrochiorothiazide from
subject (C) in fasting condition.
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Figure 2.8.d. Average cumulative amount input-time curves of
hydrochiorothiazide from 3 subjects in fasting condition.98
Average pharmacokinetic parameters for each treatment in fasting and
fed condition are provided in the Tables 2.1 and 2.2, respectively.
Table 2.1. Mean pharmacokinetic parameters of hydrochiorothiazide afteroral
administration of 50 mg in the JR and in theGRD1in fasting condition.
Treatments
JR GRD1
Total urinary recovery (0-48h) (mg) 38.1±2.5 28.2±1.7
Maximum urinary excretion rate (mg/h) 5.9±1.7 2.8±0.8
Time for maximum urinary excretion rate (h) 3.5 2.5
Mean ± SD
Table 2.2. Mean pharmacokinetic parameters of hydrochiorothiazide after oral
administration of 50 mg in the IR or theGRD1in fed status.
Treatments
IR GRD1
Total urinary recovery (0-48h) (mg) 42.6±5.9 46.5±1.4
Maximum urinary excretion rate (mg/h) 4.5±2.4 5.5±1 .9
Time for maximum urinary excretion rate (h) 1.5 3.5
Mean ± SD
Pharmacokinetic values from GRD in a 00 capsulewere not included in
calculation of average values. Mean values Of Rniax for the JR and theGRD1
were 5.9 and 2.8 (mg/hr) in fasting condition and 4.5 and 5.5 (mg/hr) in fed
status, respectively. Average values ofA048for the IR and theGRD1in fasting
condition were 38 (76%) and 28 mg (56%), whereas the average values in fed
condition were 42.6 (85%) and 46.5 mg (93%), respectively. From the
absorption-time plots, absorption stopped at around 3 to 4 hours for the IR andat about 8 hours for theGRD1post-dosing in fasting status. Basedon these
results, it was concluded that theGRD1did not stay long enough to complete
the drug release and absorption in fasting condition, resultingin lower value of
A08from theGRD1compared the JR. Rmax for the IR was reduced under fed
conditions compared to fasting condition, because thedrug was released slowly
from the stomach while food was digested. Higher bioavailabilitywas achieved
from theGRD1in fed status due to the prolonged gastric residencetime, since
the GRD1 was retained in the stomach with food. From theresults of the
preliminary BA/BE study under fed conditions, itwas demonstrated that slow
drug release from the stomach to drug absorption sitesat upper part of the
intestine would increase bioavailability and decrease peakdrug concentration.
Even though the size of theGRD1was bigger than the size of the previous
GRDs by Kapsi and Ahmed that endured "housekeeping waves"in the stomach,
theGRD1failed to retain in the stomach for the time periodnecessary for
completion of the drug release. It was determined that the GRDshould be big
as well as strong and rigid enough to resist "housekeeping contractions"on an
empty stomach.100
FULL BIOAVAILIBILITY/BIOEQUIVALENCY (BA/BE) STUDY
With respect to results from the preliminary BA/BE study, theGRD1
needed to be modified in order to achieve superior rigidity. The process and
trials of making a modified GRD (GRD2) as well as in vitro dissolution profiles
for the GRD2 were previously described in Chapter 1. Six subjects (4 males and
2 females) participated in the full BA/BE study with the GRD2 in a 000 capsule,
and an IR tablet.
Six subjects were administered the IR and the GRD2 containing 50 mg
hydrochlorothiazide in fasting condition. The IR tablet was administered once,
meanwhile the GRD2 was dosed twice with a week of washout period. This
study design was selected to obtain reproducibility of pharmacokinetic profiles
from the GRD2 as well as to increase the power in terms of statistical analysis
for assessing bioequivalency study. The study in fed condition was not
included in the full BA/BE study based on prolonged gastric residence time of
the GRD and good bioavailability of the drug with the presence of food in the
preliminary study.
Individual urinary excretion rate-time curves and cumulative amount of
drug recovery-time curves as well as cumulative amount of drug input (or drug
absorbed)-time curves are shown in Figures 2.9.a-c through Figures 2.14.a-c.
The time course of average urinary excretion rate, average cumulative amount
of drug recovery and average cumulative amount of drug absorbed in fasting
conditions are illustrated in Figures 2.15.a-c.101
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Figure 2.9.a. Individual urinary excretion rate-timecurves of
hydrochiorothiazide from subject (1) in fasting condition.
LIR: Immediate release formulation, GRD: GRD2, GRD2:GRD2repeat]
40
0
35 -I
S
30 ,
25
20
10
C
0 2 4 6 8 10iS1416IS202224262*303234363*404244
Time (hours) - + IR--GRD GRD2
Figure 2.9.b. Individual cumulative amount recovery-time curves of
hydrochiorothiazide from subject (1) in fasting condition.
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Figure 2.9.c. Individual cumulative amount input-timecurves of
hydrochiorothiazide from subject (1) in fasting condition.
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Figure 2.10.a. Individual urinary excretion rate-timecurves of
hydrochiorothiazide from subject (2) in fasting condition.
[IR: Immediate release formulation, GRD: GRD2, GRD2:GRD2repeat]103
40
35
02468101214I6182224262830323436384o4244
Thie(lws)
IffY2- $ER
Figure 2.1 0.b. Individual cumulative amount recovery-time curves of
hydrochiorothiazide from subject (2) in fasting condition.
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Figure 2.10.c. Individual cumulative amount input-time curves of
hydrochlorothiazide from subject (2) in fasting condition.
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Figure 2.11 .a. Individual urinary excretion rate-timecurves of
hydrochlorothiazide from subject (3) in fasting condition.
[IR: Immediate release formulation, GRD: GRD2, GRD2:GRD2repeat]
45i
40
25 . - --. S 1+
:
!I
IrrIpIIrI I
0246 8101214161820222426283032343638404244
Turcniirt Øxu)- 4. j I QJ 9 .(]'fl
Figure 2.11 .b. Individual cumulative amount recovery-timecurves of
hydrochlorothiazide from subject (3) in fasting condition.
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Figure 2.11 .c. Individual cumulative amount input-time curves of
hydrochiorothiazide from subject (3) in fasting condition.
[IR: Immediate release formulation, GRD: GRD2, GRD2:GRD2repeat]
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Figure 2.12.a. Individual urinary excretion rate-time curves of
hydrochiorothiazide from subject (4) in fasting condition.
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Figure 2.12.b. Individual cumulative amount recovery-timecurves of
hydrochiorothiazide from subject (4) in fasting condition.
[IR: Immediate release formulation, GRD: GRD2, GRD2:GRD2repeat]
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Figure 2.12.c. Individual cumulative amount input-timecurves of
hydrochiorothiazide from subject (4) in fasting condition.
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Figure 2.13.c. Individual cumulative amount input-timecurves of
hydrochlorothiazide from subject (5) in fasting condition.
[IR:Immediate release formulation,GRD: GRD2, GRD2:GRD2repeat]
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Figure 2.14.a. Individual urinary excretion rate-time curves of
hydrochiorothiazide from subject (6) in fasting condition.
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Figure 2.14.b. Individual cumulative amount recovery-timecurves of
hydrochiorothiazide from subject (6) in fasting condition.
[IR: Immediate release formulation, GRD: GRD2, GRD2: GRD2 repeat]
02468101214161820222426283032343638404244
TneOi)
Figure 2.14.c. Individual cumulative amount input-timecurves of
hydrochiorothiazide from subject (6) in fasting condition.
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Figure 2.15 .a. Average urinary excretion rate-timecurves of hydrochiorothiazide
from 6 subjects in fasting condition
[IR: Immediate release formulation, GRD:GRD2]
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Figure 2.1 5.b. Average cumulative amount recovery-timecurves of
hydrochiorothiazide from 6 subjects in fasting condition.
[IR: Immediate release formulation, GRD:GRD2}
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Figure2.1 5.c.Average cumulative amount input-time curves of
hydrochiorothiazide from 6 subjects in fasting condition.
[IR: Immediate release formulation, GRD:GRD2]
Higher Rmat earlier Tm was achieved from the JR compared to the GRD2
in both individual and average urinary excretion rate-time curves. Almost zero-
order drug release was obtained from the GRD2 up to 17 hours post-dosing from
the cumulative amount of drug-time curves. The urinary excretion data were
deconvolved to predict the time for drug absorption to be stopped. From the profile
of average cumulated amount absorbed-time curves, the absorption was continued
up to approximately3.5hours and 17 hours for the IR and the GRD2 post-dosing,
respectively. This profile implied that the GRD2 was able to endure "housekeeping
contractions" and stayed long enough to complete the drug release slowly.500
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Figure 2.16. Average rate of urine production-time curves of hydrochiorothiazide
from 6 subjects in fasting condition.
[IR: Immediate release formulation, GRD:GRD2]
A profile of the average rate of urine production over time is shown in
Figure 2.16. Rates of urine production were similar between both IR and GRD2up
to 10 hours post-dosing. However, diuresis started decreasing from the IR after 10
hours, whereas the diuretic effect remained high from theGRD2up to 17 hours
based upon prolonged drug effect. The continuous drug effecton urine production
from the GRD2 was clearly observed up to approximately 17 hours from Figure
2.16. Comparisons between urine production and water-intake, and between the
ratio of urine production and water-intake are demonstrated in Figures 2.17 and
2.18. The cumulative amounts of urine output from hydrochlorothiazide in both
the IR and the GRD2 were consistent with water-intake. Thiscan be explained by113
increasing excretion of the body fluids that stimulates water-intake. The total
amount of urine production was higher from the same dose in theGRD2compared
to the IR, which would be attributed to prolonged drug input from the GRD2
followed by feedback increased amount of water-intake in order to compensate for
the increased drug effect. Bioavailabilities of the drug under fasting condition
between the JR and the GRD2 were essentially equal, but the diuretic effect from
the GRD2 was increased by 27% compared to the JR.
Average pharmacokinetic parameters for each treatment in fasting condition
are provided in the following Table 2.3. Elimination half-life (T112) of
hydrochlorothiazide was approximately 7 hours. Average values OfRmaxwere 4.8
mg/hr at 2.5 hours (Tm) and 2.5 mg/hr at 5 hours (Tmax) in fasting condition for
the JR and the GRD2, respectively. Mean values forA036were 33.3 mg (66.6%)
and 37 mg (74%), whereas the meanA048were 38.12 mg (76.2%) and 38.95 mg
(77.9%) for the JR and theGRD2in fasting condition, respectively.GRD2and JR
were bioequivalent based on the average total amount recovered in 48 hours (2.2%
difference which was well less than 20%).
Table 2.3. Mean pharmacokinetic parameters of hydrochlorothiazide from 6
subjects in fasting condition.
Treatments
IR GRD2
Total urinary recovery (0-48h) (mg) 38.1±9.6 39.0±5.2
Maximum urinary excretion rate (mg/h) 4.8±1.7 2.5±0.5
Time for maximum urinary excretion rate (h) 2.5 5114
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Figure 2.17. Time course of comparison betweenaverage urine production and
water-intake curves of hydrochiorothiazide from 6 subjects in fastingcondition.
[IR: Immediate release formulation, GRD:GRD2]
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Figure 2.18. Ratio of average urine production and water-intake-timecurves of
hydrochiorothiazide from 6 subjects in fasting condition.
[IR: Immediate release formulation, GRD: GRD2]115
Statistical analysis for bioequivalencywas carried out for A036 because the
value of A36.48 for the IR from one subjectwas not obtainable due to the short T112
(4 hours). Although mean A036 from the JR (33.3 mg)was statistically analyzed to
be significantly different (P< 0.05) relative to that fromthe GRD2 (37 mg), the two
formulations were considered to be bioequivalent becausethe difference was
approximately 11% which was less than 20%, and the ratioof the product averages
(1.03) were fallen within a FDA bioequivalency limit(80-125%)
(29)as shown
below.
0.22Ln(---7--)0.22
33.3
[ln(O.8)=-O.22, ln(1.25)=O.22}
Therefore, the difference would not be expectedto be clinically significant.
Mean values of Rm were compared statistically between the JR(4.8 mg/hr) and
the GRD2 (2.5 mg!hr), and the valueswere significantly different (P<0.05).
ANOVA tables are shown in Tables 2.4 and 2.5 for Rmax andA036, respectively.
The potentially improved bioavailability of hydrochlorothiazidefrom the GRD2,
based on higher urinary recovery, demonstrated not only that thedevice was
retained long enough to complete the drug release in the stomach, butalso the SR
dosage form was controlling the drug release to avoid the saturationat absorption
sites followed by prolonged drug effect.Table 2.4. ANOVA table for mean values ofRmaxof hydrochlorothiazide from 6
subjects in fasting condition.
Dependent Variable: In (Rmax)
Sum of
Source DF Squares
Model 6 0.20671157
Error 11 0.13031798
Corrected Total 170.33702954
116
Mean SquareF ValuePr> F
0.03445193 2.91 0.0596
0.01184709
R-SquareCoeff VarRoot MSECmax Mean
0.61333419.716070.1088440.552059
Source DF Type I SSMean SquareF ValuePr> F
subj 50.057764560.01155291 0.98 0.4741
treat 10.148947010.14894701 12.570.0046
Source DFType Ill SSMean SquareF ValuePr> F
subj 50.057764560.01155291 0.98 0.4741
treat 10.148947010.1489470112.570.0046117
Table 2.5. ANOVA table for mean values ofA036of hydrochiorothiazide from 6
subjects in fasting condition.
Dependent Variable: ln(A036)
Sum of
Source DF SquaresMean SquareF ValuePr> F
Model 6364.749260160.7915433 3.840.0258
Error 11173.933380415.8121255
Corrected Total 17538.6826405
R-SquareCoeff VarRoot MSE A035 Mean
0.67711310.975273.97644636.23096
Source DF Type I SSMean SquareF ValuePr> F
subj 5285.726612857.1453226 3.610.0353
treat 179.022647279.0226472 5.000.0471
Source DFType III SSMean SquareF ValuePr> F
subj 5285.726612857.1453226 3.610.0353
treat 179.022647279.0226472 5.000.0471118
The relationship between rate of urine production and the urinary
excretion rate of the drug exhibited a clock-wise hysteresis from boththe JR and
theGRD2as shown in Figure 2.19. Diuresis decreased after the peak excretion
rate for both formulations, and the clock-wise hysteresis indicates development
of tolerance on urine production of hydrochlorothiazide. Diureticshave been
known to elicit compensatory homeostatic mechanisms for bodyfluid and
electrolytes
(32-33)Previous studies suggested that a slow input of furosemide
triggers fewer compensatory homeostatic reactions leading to increasedtotal
pharmacological effect
(3133)In the present study, higher total urine production
was observed from theGRD2compared to the IR, and the fairly equivalent
initial diuresis between theGRD2and the IR suggests that the drug efficiency
was higher for the slower drug input rate of hydrochiorothiazide. These results
agree with finding in previous studies, which is: excretion rate of urine
following a slow input of diuretic (furosemide) produces maximumefficiency
for a prolonged time period
(3, 34)Therefore, a slow release of
hydrochlorothiazide will be beneficial clinically in terms of prolonged drug
efficiency with a range of low drug concentration in the blood fora long period
and elimination of possible adverse reactions caused by high drugpeak
concentration. Pharmacodynam ic data of hydrochlorothiazidewas fitted using
the SigmoidEmaxmodel that has been the most widely used for the relationship
between effect and stimulus that exhibits clock-wise hysteresis
(910, 35-36)using
computer software, WinNonlin as shown Figures 2.20 and 2.21. Parameters
from this pharmacodynamic modeling are shown in Table 2.6.119
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Figure 2.19. Relationship between mean rate of urine production and mean
excretion rate of hydrochlorothiazide from 6 subjects in fasting condition.
[IR: Immediate release formulation, GRD: GRD1J
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Figure 2.20. Pharmacodynamic fitting for the relationship between diuresis and
urinary excretion rate of hydrochlorothiazide in the JR.
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Figure 2.21. Pharmacodynamic fitting for the relationship between diuresisand
urinary excretion rate of hydrochiorothiazide in theGRD2.
[Observed: Observed data, Predicted: Predicted data by pharmacodynamic modeling using
WinNonlin]
Table 2.6. Pharmacodynamic parameters from the fitting with the SigmoidEmax
model.
Parameters Emax(L/hr) EC50(mg/hr) S
JR 331.5±50.7 0.58±0.23 1.8
GRD 390.6±36 1.24±12.35 0.85
[Mean ± SD]
In Figure 2.20, average diuresis reached maximum level at about 2.5
mg/hr of urinary excretion rate of hydrochlorothiazide in JR tablet, and the
curve was flattened without significant increase regardless increase in urinary
drug excretion rate. With slow input of hydrochlorothiazide from GRD in
Figure 2.21, the magnitude of increase in urine production was getting smaller
after urinary excretion rate at 2.0 mg/hr, and maximal urinary outputwas121
observed at approximately 2.5 mg/hr of urinary drug excretionrate. These
observations (maximal urine production at 2.5 mg/hr of urinary
hydrochiorothiazide excretion rate) can be explained by development of
tolerance. Because of acute tolerance to hydrochlorothiazide effecton diuresis,
increasing urinary drug excretion rate (which represents drug concentration)
higher than the excretion rate of 2.5 mg/hr does not havea significant influence
on urine production, once maximal urinary output was reached at the drug
excretion rate, 2.5 mg/hr. Therefore, it is suggested that delivery of
hydrochlorothiazide at slow input rate (urinary drug excretionrate of 2.5 mg/hr)
can achieve maximal drug effect on urine production.
ADVERSE REACTIONS
Three out of 7 subjects reported side-effects from administration of the
IR tablet between 3-8 hours post-dosing, and these adverse reactions included
severe headache, dehydration, or fatigue. Two subjects who had dehydration
and light headache continued the study, however, one subjectwas dropped from
the study because of severe headache and fatigue. This observationcan be
explained by high drug peak concentration and effects from the IR. No adverse
reactions were reported from (iRD.122
IN VIVO/IN VITRO CORRELATION
The urinary excretion rate data were utilized for deconvolutionto obtain
an in vivo dissolution (absorption) profile as shown in Figure 2.22. The in vivo
dissolution profile was correlated to the in vitro dissolution profile of
hydrochiorothiazide in the IR formulation as displayed in Figure 2.23. Thein
vivo/in vitro correlation (IVIVC) of hydrochiorothiazide inan IR formulation is
presented in Figure 2.24. The IVIVC curve is not completely linear (R2=0.92)
and approaches 100% in vitro dissolution on the x-axis while approximately
50% in vivo dissolution is achieved on the y-axis. This relationcan be used to
predict in vivo drug release profiles from in vitro dissolution profiles for
different IR formulations.
IVIVC for slow rate of drug input was achieved bymeans of the in
vivo/in vitro profiles of hydrochiorothiazide in theGRD2from the full BA/BE
study. The percent dissolution in vitro as shown in Figure 2.25was correlated
to the in vivo dissolution profile obtained by deconvolution of urinary excretion
data of hydrochlorothiazide in theGRD2displayed in Figure 2.26. Thein vivo
dissolution profile was time-scaled by multiplying time by a scaling factor of
0.57 (24/(complete in vivo dissolution time=42)) prior to interpolation to half-
hour intervals for plotting IVIVC to achieve the equal time period between
maximum dissolution and complete absorption. As shown in Figure 2.27, the
correlation between in vivo and in vitro dissolution for theGRD2is fairly linear
(R2=0.98), and this relation indicates 100% in vitro dissolution iscorrelated to
approximately 80% of the drug absorbed in vivo. This correlationcan be123
applied to predictin vivoprofiles of other modification of GRD prior to
bioavailability studies.
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Figure 2.22.In vivocumulative amount absorbed-time profile of
hydrochiorothiazide in the JR formulation.
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Figure 2.23. In vitro dissolution profile of hydrochiorothiazide in the JR
formulation.0
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Figure2.24. In vivo/in vitrocorrelation of hydrochiorothiazide for the IR
formulation.
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Figure2.25. In vitrodissolution profile of hydrochiorothiazide in the GRD2125
Figure 2.26.In vivocumulative amount absorbed-time profile of
hydrochiorothiazide in the GRD2.
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Figure 2.27.In vivo/in vitrocorrelation of hydrochlorothiazide for the GRD2.CONCLUSIONS
Bioavailability, pharmacokinctics and pharmacodynamics of
hydrochiorothiazide were investigated from the GRD and the IR. Three
subjects participated in the preliminary BA/BE study under fasting and fed
conditions. Bioavailability of hydrochlorothiazide in theGRD1was lower than
the JR under fasting conditions, while bioavailability was higher from theGRD1
than the IR in fed conditions. TheGRD1was retained in the stomach with food
and achieved higher bioavailabi!ity in fed status due to the prolonged gastric
residence time. From the preliminary BA/BE study, it was demonstrated that
slow drug release from the stomach to the absorption sites atupper part of the
intestine would increase bioavailability and decrease peak drug concentration.
Even though the size ofGRD1was bigger than the size of the previous GRDs
by Kapsi and Ahmed (with a somewhat different formulation) that endured
"housekeeping waves" in the stomach, theGRD1failed to stay in the stomach
for the time period necessary for completion of the drug release. The
preliminary BA/BE study concluded that the GRD should be big as wellas
strong and rigid enough to withstand "housekeeping wave contractions" on an
empty stomach. TheGRD1was modified to become more rigid GRD (GRD2),
and a full BA/BE study was carried out to investigate bioavailability of the
GRD2.
Pharmacokinetics, pharmacodynamics and bioavai lability of
hydrochiorothiazide in theGRD2and the IR were studied using urinary
excretion data from 6 subjects in fasting conditions.RmaxandTmaxwere127
lowered and delayed for the GRD2 compared to the IR. The drug effect from
the GRD2 was prolonged, which resulted in stimulating urine production and
feedback-induced water intake. Higher bioavailability from the GRD2was
observed compared to the JR. This is explained by the continuous drug release
above the absorption sites, which means the post-peak urinary excretionrate
remained higher from the GRD2 than the JR up to 48 hours. Even though
bioavailability of hydrochlorothiazide from the JR is reported to be about 60to
80 %, this is due to high peak drug concentration
(3)High peak concentration
might cause adverse reactions, and therefore lower peak concentration and slow
drug release would be more desirable for chronic administration. From the
absorption plot, drug absorption continued up to approximately 3.5 hours and
17 hours post-dosing for the JR and the GRD2, respectively. This indicated that
the GRD2 was large and rigid enough to withstand "housekeeping waves"on an
empty stomach and stayed in the stomach for a desirable period to achieve slow
drug release. Almost zero-order drug release was observed from the GRD2up
to 24 hours post-dosing from the profile of average cumulative amount of drug-
time curves. The rate of urine production was similar between both IR and
GRD2 up to 10 hours post-dosing. However, higher diuresis from the GRD2
was obtained up to 18 hours post-dosing based on prolonged drug effect.
Increasing excretion of body fluids stimulated water-intake. The cumulative
amount of urine output from hydrochlorothiazide in both JR and GRD2 was
mass-balanced with water-intake. The initial equal amount of diuresiswas
remarkable, since less amount of the drug was absorbed initially from theGRD2
(2.5 mg/hr (Rmax) at 5 hours (Tmax)) compared to the JR (4.8 mg/hr (Rmax) at 2.5128
hours(Tmax)) in fasting condition. Total amount of urine productionwas higher
from the same dose in the GRD2 compared to the IR, basedon continuous drug
input from the GRD2 followed by feedback increasedamount of water-intake to
compensate for the prolonged drug effect. A clock-wise hysteresisrelationship
between rate of urine production and excretion ratewas exhibited for both IR
and GRD2. Diuresis decreased after the peak excretionrate for both
formulations, which can be explained by a compensatory homeostatic
mechanism, leading to the development of toleranceto hydrochlorothiazide.
Despite development of tolerance, higher total pharmacologicaleffect and
efficiency were observed from slower drug input. This findingsuggests that
slow input of hydrochiorothiazide for a long period result inprolonged
pharmacological response and maximum drug effect without adversereactions
possibly caused by high drug peak concentration.
In vivo/in vitrocorrelation was established for both IR and SR
formulation, the GRD2.In vitrodissolution was fairly well correlated with in
vivo absorption for both formulations. Therefore, this correlationcan be used
practically in modification or development of formulations and predictionofin
vivo dissolution profile prior to conducting a future bioavailabilityor
bioequivalency study.
In this research, the GRD is concluded to be an excellent device for
drugs with limited absorption sites or for investigating drugs that might have
possible "absorption windows" in terms of prolonged gastric residence time.
Note that the GRD is also appropriate for sustained delivery of drugs whichdo129
not have a typical absorption window but which are poorly absorbed from the
lower portion of the ileum and or from the cecum.130
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CHAPTER 3
REVIEW OF NICOTINE:
PHARMACOKINETIC/PHARMACODYNAMIC
RELATIONSHIPS IN NICOTINE REPLACEMENT THERAPY
Hyojong Kwon and James W. Ayres, Ph.D135
A number of studies have been carried out to evaluate currentlyavailable
therapies for smoking cessation, and the resultswere mostly focused on smoking
cessation rates. Few studies have investigated the importance of therelationship
between nicotine concentration produced in the blood by the therapiesand
psychological, physiological or pharmacological changes (i.e.,pharmacokinetic and
pharmacodynamic relationship) that could improve current therapies inorder to
achieve better clinical outcome in smoking cessation. Fourtypes of nicotine
replacement therapy are reviewed herein for the role of pharmacokineticand
pharmacodynamic relationships in efficiency of the treatments:nicotine gum,
nicotine transdermal patch, nicotine nasalspray and nicotine inhaler. In addition,
sustained release bupropion hydrochloride (HCI) is considered forconcomitant
administration and potential influence on nicotine replacement therapy.
The overall objective of this review is 1) to evaluate thepharmacokinetics
and pharmacodynamics of nicotine with respect to the relationship betweenblood
nicotine concentrations and/or rate of nicotine input and physiologicalchanges that
may affect craving and other withdrawal symptoms, and 2) to consider potential
ways to give better results in smoking cessation by analyzing pharmacokinetics and
pharmacodynamics of nicotine. Mathematical models and both physiological
(heart rate) and psychological (craving) data are applied from four differentstudies
in order to generate new pharmacokinetic and pharmacodynamic modelingfor136
nicotine. Two methods are supported as approaches to improve smoking
abstinence for smokers who want to quit: 1) a combination ofa rapid nicotine input
every hour or 3- to 4-hours combined with a constant nicotine input during the
period of being awake; 2) a combination of 150 mg of sustained release bupropion
HC1 and a rapid nicotine input every 3- to 4-hours. Predicted blood nicotine
concentration-time profiles were simulated for the proposed approach using
previously published data for rapid input from a nicotine nasalspray, and constant
input from a nicotine patch.
A few suggestions are made for clinicians or scientists planning future
studies: 1) the key to relieve craving needs to be more clearly identified with
respect to either a high nicotine concentration or a rapid input rate, or both
concentration and input rate, 2) a relationship between the rate of input and both the
degree of craving and cardioacceleration simultaneously needs to be studied, 3)
direct comparison of a nicotine nasal spray and cigarette smoking at thesame time-
interval or a self-regulated pace needs to be carried out regarding relief of craving,
withdrawal symptoms and change in heart rate concurrently. Such studies will
improve understanding of nicotine pharmacokinetics and pharmacodynamics and
lead to better drug dosing regimens to improve smoking cessation rates.137
Currently, five kinds of treatment including nicotinegum, nicotine
transdermal patch, nicotine nasal spray (NNS), nicotine inhaler andsustained
release (SR) bupropion hydrochloride (HC1) tablets have beencommonly used to
aid treatment of quitting smoking. All of these products havebeen demonstrated to
be effective aids in smoking cessation with reference to placebo interms of either
relief of craving or withdrawal symptoms(10)Craving and withdrawal symptoms
are thought to be important clinical factors concerning smoking relapse(41-44)In
this paper, specific abstinence rates from previous clinical trialsare not reviewed
because the current objective is to find possibleways to improve current therapies
for better clinical outcome in smoking cessation basedon pharmacokinetics (PK)
and pharmacodynamics (PD) of nicotine.
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINE
Nicotine is a pyridine alkaloid and a weak base with pKai of
approximately 7.8-7.9 and apKa2of about 3 at 15 °C
(45)Because nicotine is a
weak base, the pH of a nicotine delivery system suchas a cigarette, chewing
tobacco or a nicotine gum plays a key role in the extent of absorption, andurinary
pH affects the amount of renal excretion
(46)The average amount of nicotine
absorbed into the body is approximately 1 mg from smokingone cigarette, and
therefore, a total of 25-30 mg of nicotine is bioavailable ina heavy smoker per day138
based on the fact that a heavy smoker consumes, on average, 25-30 cigarettesper
day, and this predicts approximately 30 minutes of smoking interval if smoking
was evenly distributed during 16 hours of the day(478)Elimination of nicotine is
described as a bi-exponential decline with the initial distribution phase half-life
(tii2a) of 2-20 minutes 4950 and the terminal elimination phase half-life (t112) of 1-4
hours(4850)A single one-compartment model has often been applied to nicotine
data and is fitted accurately due to the rapid distribution phase (49) Nicotine is
absorbed and distributed rapidly via the lungs and the arterial circulation to the
central nervous system(51)Nicotine arrives to the brain faster from pulmonary
administration such as smoking than intravenous injection (52) The rapid input to
the brain produces substantial stimulation of nicotine receptors followed by
activating the dopaminergic reward system, resulting in positive reinforcement
including pleasurable effects and nicotine dependence(51, 53)
TOLERANCE
Tolerance is defined as a decreasing effect with prolonged exposure to drug,
and the development of tolerance is an important factor in drug dependence. It is
important to be aware of characterization of the development of functional
tolerance to the effect of nicotine because this mechanism is correlated to the139
occurrence of craving and withdrawal symptoms, which is substantial for the
treatment of nicotine addiction.
Studies show that nicotine produces not only acute tolerance thatdevelops
within minutes and lasts for hours from a single dose, but also chronictolerance
that gradually occurs within a few days and persists for monthsor years from
multiple dosing
(5455)Most relapse occurs within days or weeks after quitting
smoking, and chronic tolerance is maintained for weeksor for years after cessation
(56-57)Therefore, chronic tolerance is not likely related to relapse
(57)
Changes in heart rate (HR), blood pressure and skin temperaturewere
studied after nicotine injection by Rosenberg, et al
(46)After the first and
sometimes the second injection, there was an increase in HR and bloodpressure
and a decrease in skin temperature, and these physiological changesover time were
similar to those from smoking a cigarette
(46)Elevated but relatively constant HR
and blood pressure from continuous nicotine injection is elucidated by the
development of acute tolerance
(46)Pleasurable effects and arousal were observed
when blood pressure and HR started increasing and skintemperature began to
decrease
(46)The effects of rapid (17.5 jg!kgImin for 1 .5mm and thenl.75
jig/kg/mm up to 30 minutes) and slow dosing rate (2.5 jig/kg/mmfor 30mm) of
nicotine on HR acceleration were compared in smokers by Porchet,et al
(55)The
peak concentrations at about 30 minutes right after the loading infusionsstopped
(55)In this study by Porchet, et a!, the peak concentration in the brainwas
calculated using the blood concentration profile, because the HR accelerationwas140
better correlated with the brain concentration4irne profiles compared to those of the
(55) venous plasma with respect to the development of tolerance .In the brain, the
early peak concentration of nicotine was observed at about 3 minutes with the rapid
dosing, whereas the peak was reached at about 30 minutes from the slow infusion.
This corresponded to the HR acceleration that reached the higher maximum at
about 3 minutes after the rapid input compared to the increase of rate at about 30
minutes after the slow infusion
(55)This observation demonstrates that the
development of acute tolerance to nicotine on HR acceleration from the slow
infusion already started before nicotine concentration reached the peak, which
resulted in lower magnitude of cardio-acceleration from the slow input rate
compared to that from the rapid input rate.
Development of acute tolerance is attributed to reinforcing nicotine self-
administration, which may influence sequential patterns of smoking behavior
(54),
and chronic tolerance to nicotine is thought to be related to mechanisms for
nicotine addiction
(57)Yet, it has not been clearly defined whether the
development of acute tolerance to the effect of nicotine influences smoking
cessation, and the mechanism of nicotine tolerance is not well understood.
Although the mechanism of development of acute tolerance to nicotine has not
been well identified, disappearance of acute tolerance may be associated with
increasing the intensity of craving. Rapid restoration of sensitivity to nicotine due
to loss of acute tolerance could lead smokers to relapse to smoking cigarettes
(41)
Chronic tolerance is related to down regulation of nervous receptors, which results141
in resistance to normal pharmacological response by drug input
(58)There have
been many studies to find the physiological or psychological sources related to
appearance of tolerance
(46, 54-55, 58-59)Russell proposed that "chronic
administration of nicotine acting as an agonist reduced the number of receptors and
increased an antagonist or blocking agent that inhibited physiological changes in
terms of depolarization, but the chronic tolerance would not affect initial stimulant
effect from small and instant-input of doses"
(58)Therefore, a person who smokes
a cigarette for the first time usually feels unpleasant and dizzy, nauseous, and/or
experiences headache
(59)These symptoms go away gradually as chronic tolerance
develops from subsequent smoking, and smokers feel pleasant and arousedevery
time they smoke.
Nicotine stimulates the sympathetic nervous system by modulating release
of neurotransmitters, such as norepinephrine, dopamine, acetyicholine, and
serotonin, and this results in changes in heart rate and blood pressure
(52, 119)
Therefore, pharmacodynamic response of nicotine is commonly quantified by
measuring cardiovascular changes,suchas heart rate or blood pressure instead of
measuring neurotransmitters. Porchet, et al, explained development of acute
tolerance to nicotine on heart rate acceleration using a hypothetical substance
acting as a noncompetitive antagonist of the effect of nicotine
(54)It was assumed
that the concentration of antagonist increased proportionally to the concentration of
nicotine (agonist) as nicotine input continued and exponentially decreased over
time as soon as the nicotine input stopped
(54)Porchet, et al, derived the half-life of142
appearance and disappearance of acute tolerance to the chronotropic effect of
nicotine as 35 minutes, and thus it would take 2-3 hours (4-5half-lives) to regain
full sensitivity to the nicotine
(54)
WITHDRAWAL AND CRAVING SYMPTOMS FROM SMOKING
ABSTINENCE
The number of smokers was estimated as 46.5 million in theUnited States
(US) by Centers for Disease Control and Prevention (CDC)
(60)About 17 million
smokers in the United States endeavor to quit smokingevery year
(61)and the
majority relapse or fail to maintain abstinence
(62)Nicotine addiction plays a key
role in this disappointing outcome because it triggers withdrawalsymptoms or
discomfort and craving or urge to smoke
(63)Nicotine withdrawal symptoms
correspond to the following: nervousness, restlessness, anxiety, irritability,mood
alteration, sleep disturbance, change in appetite, difficulty inconcentration,
drowsiness, weight gain, and minor somatic complaints(64-66)Smokers managed
to maintain abstinence without significant discomfort until plasma nicotine
concentration dropped to about 20 ng/ml, two-thirds of theaverage concentration,
30 ng/ml in a heavy smoker, and development of withdrawalsymptoms were
significant when blood nicotine concentration declined to less than one-thirdof the
usual concentration
(58)Maintaining fairly constant blood nicotine concentrations143
by nicotine replacements such as a nicotine gumor patch can relieve withdrawal
symptoms, which gives rise to enhancing abstinence rates.
Craving is different from withdrawal symptoms andaccounts for the urge or
desire to obtain the addictive substance even when withdrawalsymptoms are not
present
(63)However, a concept of craving has been debatable because the
intensity of craving is quantified mainly based on subjective self-reportedlevels of
desire to smoke. There are a few questionnaires tomeasure the intensity of
craving, for examples, 'ShiffmanlJarvik questionnaire'
(67)and 'Questions on
smoking urges by Tiffany/Drobes'
(68),and a new measurement or method to
quantify the craving was established using selected items from thesequestionnaires
(69)Each questionnaire was applied to develop different scalesto evaluate a level
of craving and thus, interpretation of the data on different scales needsto be carried
out carefully. Craving appears to be a crucial factor in regulating self-
administration or self-titration of drug and in relapse from abstinence. Cravingfor
smoking a cigarette is commonly observed during tobacco abstinence, and itis
relieved by nicotine input, such as smoking or nicotine replacement therapy,
however, smokers who are not trying to quit report feeling cravingseven though
they are allowed to smokead libitum
(59, 7072)Schuh, Ct al, suggested possible
reasons for the craving in smokers who did not try to quit smoking as the rapid
return of urge to smoke during a period of brief abstinence and likely incomplete
satisfaction from smoking a single cigarette
(72)144
Shiffman, et al, compared efficacy of 24-hour and 16-hour nicotine patches
for relief of morning craving
(73)In this study, the 21 mg/24-hour patch relieved
not only morning craving, but also craving and withdrawal symptoms throughout
the day
(73)The 24-hour patch provided significantly higher effecton temptation
frequency (50% lower than 16-hour patch), morning craving, and craving and
withdrawal symptoms during the day compared to the 16-hour patch, dueto higher
and steady nicotine concentrations from the 24-hour patch
(73)In another study by
Shiffman, et a!, a one-point increase in morning craving on a 0-10 scalewas related
with a 14% increase in relapse risk for a day, and this indicated that morning
craving was a strong predictor of relapse
(74)Tiffany, et al, measured the degree of
craving by recording craving scores as a function of prior smoking deprivation
interval and showed that the intensity of craving increased as the deprivation
interval was prolonged
(72-73)
A few studies have shown the similar effect of de-nicotinized cigaretteson
craving suppression to regular nicotine-containing cigarettes, and these
observations were credited to conditioned sensory reinforcement of smoking(74-78)
However, it is doubtful that simply sensory reinforcement from puffing a de-
nicotinized cigarette would be able to satisfy highly nicotine-dependent smokers
regarding all the pharmacological and psychological effects from nicotine.
In a study by Schuh and Stitzer, changes in craving scores on a scale of 0 to
100 were measured over time with different inter-cigarette smoking intervals, 30-,
60-, and 120-minutes intervals
(72)From this study, craving ratings were repressed145
momentarily by cigarette smoking, however, the craving started increasingwithin
minutes after stopping smoking and elevated to almost maximum levelswithin 3
hours of abstinence
(72)This could be related to nicotine blood concentrations
because the peak concentration of nicotine in blood averaged 35± 13 ng/ml and the
trough concentration was approximately 10 ng/mlor less just prior to smoking
(58),
and thus, considering the average of 1 hour as the elimination half-lifeof nicotine
in smokers, blood nicotine concentrations dropped to halfor less than half of the
maximum concentration from smoking a cigarette in 1-2 hours. Basedon blood
nicotine concentration-time profiles from previous studies
(7981),a suggestion is
now made that the blood nicotine concentration should remain higher than the
concentration observed after approximately 2 to 3 half-lives post-smokingto
reduce or prevent craving. For example, nicotine concentration shouldstay above
10 ng/ml to decrease or avoid craving, if the peak concentration is about30 ng/ml
with a nicotine half-life of 1 hour.
The rate of nicotine input also plays a key role in reliefor preventing
craving. Gomeni, et al, investigated a relationship between saliva nicotine
concentration from both rapid and slow input and craving using Tiffanyrating scale
with population PKIPD modeling
(82)The significance of the effect of the nicotine
input rate on craving was demonstrated in this PK!PD modeling by describing
inhibition of the full onset and the progression of craving intensity byan instant
nicotine input and attenuation of the craving intensityover time by a slow drug
release at a constant rate
(82)
The PKIPD modeling by Gomeni, et a!, describes146
fairly well the relationship between saliva nicotine concentrationand the intensity
of craving with different input rates, however further study withmore frequently
collected data needs to be performed to verify this conclusion interms of nicotine
mechanism of action as indicated by the authors
(82)
AIDS FOR SMOKING CESSATION
Because nicotine is highly addictive, it is noteasy for smokers to quit
smoking completely. Four types of nicotine replacement therapy(NRT), nicotine
polacrilex gum, transdermal patch, nasal spray and inhaler, plus SRbupropion
hydrochloride (HCI) (the first non-nicotine medication for smokingcessation) have
been applied as the first-line agents in the United States.
Nicotine polacrilex gum is available without prescription andcontains 2 or
4 mg of nicotine per piece. Studies show that the nicotinegum enhances
abstinence rates compared to placebo, and higher dose (4mg) improvesthe outcome
in heavy smokers
(22, 83)Moreover, chewing the gum providessensory
reinforcement that can substitute for smoking
(84)On average, about 50% of
nicotine is released from the gum by chewing for 30 minutes, and the peak nicotine
concentration in the plasma is achieved within 25-35 minutes, which is slower than
smoking a cigarette
(80, 85)The average plasma nicotine concentrationsare about 8
to 13 ng/ml from a 2 mg-gum (7-9 piece/day) and 22.5 ng/ml from a 4mg-gum (12147
piece/day), respectively
(39, 86-87)Because the rate of drug delivery by chewing
nicotine gum is not as fast as cigarette smoking, thegum should be chewed on a
fixed schedule, not in need of relief of cravingor withdrawal symptoms. Chewing
the gum irregularly may not achieve sufficient amount of nicotine inputor rapidity
of the drug delivery rate in order to relieve withdrawalsymptoms, which can result
in failure of smoking cessation. Approximately 50 percent of the nicotineis
bioavailable (1 mg and 1.5 mg for 2 and 4mg-gum, respectively)
(85)and a very
high percentage of side effects from the 2 and 4mg nicotine gum occur (23 and 27
percent of users, respectively) including burning taste, hiccups, gastricsymptoms,
nausea, temporomandibular tenderness, andlor tachycardia
(22)
To achieve constant nicotine input and better compliance, the nicotine
transdermal patch was invented. The patch deliversa fairly consistent amount of
nicotine, about 80 or 82% of the dose at a constant rate during 16or 24 hours, the
usual period of patch application
(88)The 16-hour patch produces a peak
concentration at approximately 13 nglml about 8 hour post-application, whileat
steady state, the 24-hour patch produces a peak concentration at about 16to 23
ng/ml within 4 to 9 hours of application
(89-91)Although the 24-hour patch releases
about 2 mg more than the 16-hour patch, there wasno significant difference in
overall abstinence rates
(9, 92)Corelli, et al, reported that smokers felt stronger
craving in the morning with the 16-hour patch compared to the 24-hour patch, but
the 24-hour constant nicotine input could cause sleep-disturbances
(93)Constant
plasma nicotine concentrations aid in relief of withdrawalsymptoms; however, a148
slow rate of drug input and relatively low blood nicotine concentrationscompared
to cigarette smoking did not prevent smokers from feeling craving
(94)when
wearing the patch. A couple of studies demonstrated that usinga double-24-hour
patch was preferred by smokers with respect to higheramount of nicotine input and
prevention of withdrawal symptoms compared to eithera single 16-hour or 24-hour
patch
(9596)This result implies that the dose ina single patch may not be sufficient
for heavy smokers to effectively maintain abstinence.
Nicotine nasal spray (NNS) delivers nicotine rapidly and achievespeak
drug concentration of about one half to two third of the peak concentrationfrom
cigarette smoking within 5 minutes in the artery, which is relativelycomparable to
the profiles from smoking a cigarette
(97)This rapid nicotine input can achieve
instant relief of craving, which results in higher cessation rates (26%) thanplacebo
(10%)
(98)or nicotine gum and is a little better than nicotine patch (24% vs. 20%
and 21%)
(99)In spite of the rapid nicotine delivery from NNS, there isa wide
inter-individual variability (48%) in maximum nicotine concentration and
substantially low blood nicotine concentrations in some patients, whichcan be
explained by incomplete injection of NNS into the nasal cavity, loss fromsneezing,
less frequency of use due to local irritation, and/or individual difference in nasal
absorption
(100-101)and low compliance and adverse effects suchas irritation of
nose, runny nose, eyes watering, sneezing, irritation to throat, and/or coughing,
which often results in underusing the device
(97, 99)Therefore, using only NNS
may not be reliable to aid smoking abstinence for heavy smokers
(102)149
Nicotine inhaler mimics puffing a cigaretteso that using the inhaler may
compensate for some of the stimulant reinforcement and relieve psychologicalor
behavioral craving. Even though the inhaler achieves onlyapproximately 30% of
plasma nicotine concentration from cigarette smoking, withdrawalsymptoms can
be reduced up to 50%
(103)Unlike other nicotine replacements, nicotine absorption
from the inhaler is affected by environmental temperature andprovides variability
based on inhalation volume
(103)
Moreover, absorption of nicotine from the inhaler
takes place mainly through the mucosa, which is slower thanthat from cigarette
smoking, and the average plasma nicotine concentration reaches8.1 ng!ml at about
30 minutes by puffing a single inhaler 80 timesover 20 minutes
(104)Therefore,
using the inhaler alone may not successfully keep smokers fromfeeling craving.
Each NRT achieves higher smoking cessation rates thanplacebo; however,
all of them have drawbacks such as slow nicotine absorptionrates, noncompliance,
aversive effects or insufficient relief of cravingor withdrawal symptoms, which can
fail to fully support an attempt to quit smoking. To achieve highercessation rates
and a more efficient way to help smokers quit smoking,a combination therapy was
studied. A study of combination therapy of nicotinegum and the 16-hour
transdermal patch was carried out by Kornitzer, et al, and the study showedthe
combination therapy achieved higher abstinence ratesover 52 weeks and longer
time to relapse compared to a single therapy
05)In a different study by
Fagerstrom, a combination of the 24-hour nicotine patch and nicotinegum reduced
a few withdrawal symptoms significantly
(106),which could be a major contribution150
in aiding abstinence. Baker, et al, have patented concomitanttreatment with a
nicotine patch providing sustained and slow nicotine input incombination with
nicotine nasal spray to provide rapid drug input via transmucosaladministration
(107)A proposed advantage is that the patientcan use NNS whenever desired for
self-titration to treat craving not controlled by the patch alone.Blondal, et a!, later
compared using such a combination of nicotine patch and NNS for5 months
followed by the NNS and a placebo patch for another 5 monthswith the nicotine
patch alone for 1 year
(108)This study showed that using the active combination
therapy was more effective than using the nicotine patch only, and thecombination
of NNS and a placebo patch was not as efficientas the active combination in
smoking cessation, due to low percentage of participants using NNSat the end of 1
year. A combination therapy of nicotine inhaler and a 16-hour patchwas also
demonstrated to be more effective than a single therapy in smokingcessation
(109)
A combination therapy compensates for a disadvantage associated witheach
treatment used alone: NNS that acts quickly to relieve cravingsor nicotine gum or
nicotine inhaler that provide sensory effects compared to the patch, anda constant
input from the nicotine patch helps alleviate withdrawal symptomsU06b09)
Together, the treatments increase blood nicotine concentrationsas well. Self-
administration and self-titration procedures as he is allowed using NNScan assist
more effectively to control the amount of nicotine that smokers need to maintain
their abstinence.151
In addition to nicotine replacement therapy, bupropion hydrochloride(HC1)
was introduced to aid smoking cessation in 1997
(110)The exact mechanism of
bupropion HCI is unknown, but it is presumed that the effect is relatedto an
antidepressant action that blocks neural reuptake of the neurotransmittersdopamine
and norepinephrine to reduce craving for nicotine and withdrawalsymptoms
I 12)Efficiency of bupropion HC1 on smoking cessationwas reported
(113-114)and a
combination of bupropion HCI and nicotine patchor bupropion HCI alone achieved
higher cessation rates than the patch only
(114)Because bupropion HCI was
initially used for the treatment of depression, the effects of bupropionHCI on mood
changes such as craving or withdrawal symptoms were investigated. Studies
demonstrated that bupropion HC1 had positive outcomeon reducing withdrawal
symptoms, but inconsistent results of the bupropion HC1 effecton craving were
reported, and this suggested that the main effect of bupropion HCIon smoking
cessation is not relief of craving
(hI4 116)There is a positive correlation between
doses or mean metabolite concentrations of bupropion HC1 and cessationrates as
well as side effects such as insomnia and dry mouth
(114)Johnston, et al, indicated
that unlike NRT, monitoring of bupropion HCI or metabolite concentrationswould
not improve effectiveness of bupropion HC1 because of unknown drug mechanisms
(117)Even though, a dose of 300 mg/day is commonly prescribed basedon better
efficacy than lower doses, this dose is usually accompanied by adverseevents, and
thus, a dose of 150 mg is recommended for those whocan manage their abstinence
without difficulty
14)152
ANALYSIS OF NICOTINE PHARMACOKINETICS AND
PHARMACODYNAMIC S
Nicotine replacement therapies and bupropion HC1 have beenused as major
aids in smoking cessation, and using these therapies have achievedbetter outcomes
than placebo. However, either using a single therapy aloneor a combination
therapy has not accomplished long term cessation rates higher than30% and have
failed to prevent relapse. Therefore, one needs to considera way to improve the
outcome of the current therapy in smoking abstinence rates. Most studieshave
been carried out mainly focusing on the outcomes of smokingcessation rates and
periodically indicated withdrawal symptomsor craving as obstacles to be
overcome. In this review, simulation of pharmacokinetics/pharmacodynamics
(PK/PD) of nicotine was carried out using published data in orderto identify
desirable nicotine dosing regimens that will enhance smoking cessationin terms of
relief or prevention of craving and alleviation of withdrawalsymptoms.
Several PK/PD models have been applied to describe eithertolerance on
physiological changes or craving associated with nicotine concentration.Gomeni,
et al investigated a possible relationship between saliva nicotine concentration and
fluctuation of craving using a population PK/PD model
(82)The indirect response
models for rapid input (smoking) and slow input (nicotine patch)are provided in
the following equations (1) and (2), respectively.153
max Pest dR
[i
I.0 1kR (l)(82) =
IC50 +Cp51j
OUt
dR
Pest - = R .[i+Emax C 1
EC50 + C
Pest j
(2)(82)
[Where dR/dt is the changes in the intensity of craving, k,0is the zero-order constant for production
of the response defined by the following equation,
= k(,U,ROpiac +Amplitude.cos[(ttmax ) wherek00is the first-order rate constant
for loss of the response, ROpiac represents the average placeboresponse at baseline, Amplitude is the
amplitude of the circadian variation, t is the time, tmax is the time of the peakresponse and 2it124
converts clock time in radians, and 'max is the maximal inhibition rate,IC50is the nicotine
concentration producing 50% of 'max, Cpthe estimated nicotine concentration, and Emax is the
maximal stimulation rate,EC50is the nicotine concentration producing 50% of Emax
(82)}
Two independent models, a mechanistic model, which is the indirect
response model with variation on craving of placebo based on a circadian model
with a cycle of24hours and a probabilistic model, which isa logistic model with a
binary score using a fixed reduction of 20% of the cravingscore were applied
(82)
Reduction of20%in craving was considered as a significant outcome, because
differences between average craving scores in the placebo treatment andthe
cigarette smoking treatment (mean values of 4.5 and 3.6), and betweenthe placebo
treatment and the application of the nicotine patch treatment(21mg/24 hours)
(mean values of 4.5 and 3.8) were analyzed to be significant by analysis ofvariance
(ANOVA)
(82)The assumption applied to this modeling was thata relationship
between saliva nicotine concentration and the nicotine effecton craving would be a
monotonic function
(82)In the modeling approach by Gomeni, et al, the indirect
response model with inhibition on production or the full onset of craving intensity
was favored for the cigarette smoking data and with attenuating of cravingwas154
preferred for the constant delivery of nicotine usinga patch at a pre-defined time of
a day
(82)This modeling was validated to be appropriateto describe the fluctuation
on craving as a function of saliva nicotine concentration, accordingto the goodness
of fit criteria
(82)
In the current study, the model (1) abovewas applied to simulate the effect
of nicotine on craving using average plasma concentrationvs. time data following
cigarette smoking in 11 people obtained froma study by Jarvik, et al
(69)Using the
values for all the parameters of the model provided in reference(82), craving scores
were predicted and compared to the observed scores for "Urge to smoke" in the
reference (69) as shown in Figure 3.1. Both the actual Jarvik dataand Jarvik's data
corrected for baseline score by 2.7 are presented. The Jarvikdata are corrected for
baseline score of 2.7 because the baselinescore did not go down to zero and was
observed at 2.7 right afterab libcigarette smoking.
The craving scores predicted by the Gomeni's model didnot describe the
absolute value of observed craving scores properly, whichmay be explained by
recognizing that a different scale or methodwas used for quantifying the intensity
of craving in each study. Without identifying which items of Tiffany
questionnaires were selected for the Gomeni's study, it is possible thatdifferent
questions were applied for Jarvik's study and Gomeni's study, leadingto a different
scale for measuring the craving. Note for example, that observed data points
consistently differ by a factor of about 2.7 from model predicted datapoints after155
adjusting the baseline score of the Jarvik study, but the shape of thecurves are very
similar.
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Figure 3.1. Profile of craving score vs. time.
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{(-) Predicted: Predicted craving scores calculated using a model by Gomeni, et al with the observed
plasma concentration data provided in the study by Jarvik, et al
(82, 69) Observed: Craving score
to quantify the observed intensity of craving without adjustment in the study by Jarvik,et al
(69),
Observed (base=2.7): Craving score to quantify the observed intensity of craving withadjusting the
score of 2.7 as baseline in the study by Jarvik, et al
(69)]
Although the two different indirect response models by Gomeni,et a!
described the relationship between craving and nicotine input rate fairly well in the
Gomeni's study, the average saliva nicotine concentrations from smoking (398
ng/ml) and the patch (178 ng/ml) were different, and thereforean additional
modeling study for the same nicotine concentrations with different inputrates156
needs to be required to support the further application of themodeling. Moreover,
observations measured in the modeling by Gomeni, et alwere sparse (10 measured
over 72 hours)
(82)
and thus further verification would be needed in orderto apply
this model to more detailed data as was indicated by the investigators.
Fattinger, et al, developed a semiparametric model for developmentof
tolerance to various effects (changes in heart rate (HR), bloodpressure, plasma
epinephrine, and energy expenditure) of nicotine'.The PK!PD modeling by
Fattinger, et a!, was carried out at steady-state concentration of 25 ng/mlusing a
computer-controlled intravenous infusion with two models thatconsist of an effect
compartment and a hypothetical metabolite (antagonist) compartment(118)The
first model of two models by Fattinger, et al (shown below in equation(3)) was
similar to a tolerance model by Porchet, et al, which describes developmentof
acute tolerance to heart rate elevation based on linear regression of development
and disappearance of tolerance using a parametric function
(54),except for the fact
that Fattinger, et a!, applied nicotine concentration ina hypothetical effect
compartment added to the central compartment instead of concentration in thePK
compartment
(118)
B +
aCe (t11)
e2'
(3)(l 18)
Cm50
[Where E is the predicted effect of subjectj at timet1, B, is the placebo data of each
pharmacodynamic effect with 1th baseline datum from the th subject,CeandCmare the
concentrations in the effect and metabolite compartment, respectively and obtained by the
convolution of predicted nicotine concentration in the central compartment with keoe0tandkmo& kmotrespectively,Cm50is the concentration of the hypothetical antagonist metabolite whenthe effect157
reaches 50% of the maximum effect, 12j is an interindividual random effectparameter with mean
zero and variance to be estimated(I 18)1
The second model by Fattinger, Ct al, shown in the belowequation(4)is
more flexible in terms of fitting the data using nonparametric functions, natural
cubic spline functions in the model, which would allow the shapeof effect to be
variable
(118)
F,, - B,+S2(Ce(tij))S3(C(t))e2 (4)018)
I,, IJ
[Where S2(Ce(t)) and S3(Cm(tj)) are natural cubic spline functions andrepresent concentrations in
the effect compartment and the hypothetical metabolite compartment, respectively
In the following simulation study, the models by Fattinger,et al, were not
applied to simulate predicted physiological changesor intensity of craving using
plasma concentrations, because some values for parameters suchas 'a' or 'B1' were
not provided in the reference (118), which made it difficult tocarry out verification
of the models prior to further simulation. In the study by Fattinger,et al the half-
life of tolerance was estimated to be 3.5 minutes, 21 minutes, and70 minutes for
energy expenditure, heart rate acceleration, and systolic blood pressure,
respectively
(118)The estimated half-life for heart rate acceleration, 21 minutes,
was comparable to the estimate, 35 minutes, obtained by the tolerance model of
Porchet, et al
(54)The tolerance model by Porchet, et al, describes developmentof
acute tolerance of nicotine to cardioacceleration (heart rate elevation) by applying
linear regression of the development and disappearance of tolerance usinga
parametric function
(54Nicotine input was spaced at different time intervals for
the Porchet model and to be constant to maintain steady-state concentrationfor the158
Fattinger model. However, employing these models to predict psychological
changes such as craving or withdrawal symptoms has not previously beenreported,
because the models have not been associated with the psychologicalor subjective
variables.
In this review, an attempt has been made to determine if there isa
relationship among plasma nicotine concentration, heart rate and craving by
carrying out simulations of changes in heart rate or intensity of craving basedon
plasma nicotine concentration. Nicotine concentrationwas not assumed to be
steady, and therefore the Porchet tolerance modelwas chosen to apply in the
simulation rather than the Fattinger model to apply in the simulation, becausethe
Prochet model was simpler to apply and fit experimental data reasonably well.
Porchet, et al, explained development of acute tolerance to nicotineon
positive cardioacceleration using a hypothetical substance actingas a
noncompetitive antagonist of the effect of nicotine and a linear pharmacodynamic
(4) . model .This was explained by two different first-orderprocesses of appearance
and elimination of hypothetical antagonist, which determined the rate of
development and disappearance of tolerance
(54)Porchet, et al, derived the half-life
of appearance and disappearance of functional tolerance to the chronotropic effect
of nicotine as35minutes, and thus it would take 2-3 hours(4-5half-lives) to regain
full sensitivity to the nicotine
(54)The tolerance model by Porchet, et al, cannot be
used to estimate psychological changes due to similar reasons for the model by
Fattinger, et al. That is, the data for psychological changeswere not collected and159
are not available from the study. Therefore, the tolerance models by Porchet,et al
or Fattinger, et a! did not indicate whether the development of acute tolerance
would be beneficial for smoking cessationor not.
In order to apply Porchet tolerance model in thenew current simulation
study, the model was evaluated by comparing observed heartrate provided in the
study by Gourlay, et a!
(120)and predicted heart rate using the Porchet tolerance
model described by the following equation (5) and (6).
Cant =C(r)e"''dr (5)(54)
17 - ____________________ f\(54) +(I+Cf/,))(l+C/C,)
Porchet tolerance model is composed of the above equation(5) and (6),
whereCantis concentration of noncompetitive antagonist of the effect ofnicotine,
C50is Cat 50% of the maximum effect of noncompetitive antagonist (7.7
nglml),kantis a rate constant of development of tolerance (0.02 min'),C(r) is
plasma nicotine concentration at timet,E is the effect of nicotine on
cardioacceleration (increase in heart rate), E0 is the base line (61.2 bpm),Emaxis the
maximum effect of nicotine on cardioacceleration, C is plasma nicotine
concentration, C50 is C at 50% of the maximum effect of nicotine (54)
The complete process is shown in the following flow diagram (1) inFigure 3.2 and
Table 3.1.160
Obtain published average plasma
nicotine concentration vs. time data
(120)
Equation (5) from Porchet--------------
tolerance model insert the Eguation16) from Porchet
average plasma nicotine tolerance modelcalculate E
concentration vs. time data at (heart rate) at each time point by
each time point from step 1 equation (6) with the plasma
above into equation (5) and nicotine concentration vs. time
calculateCant data and
--------- I
Cantcalculated from
equation (5) above
Observed heart rate
(HR)
(120) Predict heart rate by
Porchet tolerance model
Model verification: comparing calculated HR and observed
HR to confirm assessment of Porchet tolerance model
Figure 3.2. Flow diagram (1): model verification
(54)
[Porchet tolerance model is composed of the following equation (5) and (6), equation
(5):Ce,,, = C(r)e "'dr, whereCantis concentration of noncompetitive antagonist of the effect
of nicotine,Cant5Ois Cat 50% of the maximum effect of noncompetitive antagonist (7.7 ng/ml),
is a rate constant of development of tolerance (0.02 min1), C(r) is plasma nicotineconcentration
at time 'r, equation (6):E = E0 +
flax(C
,where E is the effect of nicotine on
(1 +Ce,,, / )(l + C /C50)
cardioacceleration (increase in heart rate),E0is the base line (61.2 bpm),Emaxis the maximum effect
of nicotine on cardioacceleration, C is plasma nicotine concentration,C50is C at 50% of the
maximum effect of nicotineTable 3.1. Application of Porchet tolerance model
(54)
to plasma nicotine concentration provided in the reference(120) for
simulation of heart rate.
Time
(Fir)
C (ng/ml)
from a
reference
(120)
Ce,,, = C(r)e' 'dr(nglml)
0
from a reference (54)
E(HR) = £
Etnax (C / C50)
(bpm) 0
(1 +
Ca,,1/ Ca,,150)
from a reference (54)
Observed HR
(bpm) from a
reference (120)
STD
0 34 4.22 89.99 85.2 3.38
0.6 18 8.87 72.17 81.2 6.38
1.2 14 9.45 69.44 78.2 6.19
1.8 12 9.19 68.37 77.2 6.23
2.1 11.1 8.74 67.99 75.79 5.51
2.4 10 8.11 67.59 74.2 4.67
3.6 8 6.75 66.79 72.2 3.82
4 7.3 6.22 66.52 71.2 3.31
4.2 7 5.95 66.38 70.7 3.05
6 5.5 4.7 65.67 67.2 1.07
[Average plasma nicotine concentration vs. time data reported ina study by Gourlay, et a!
(120)
following administration of nicotine by cigarette
smoking was obtained as shown in column (2). Porchet tolerance modelis composed of the following equation (5) and (6)as shown in the flow
diagram (1) in Figure 111.02, equation(5): Ca,,t = C(r)e(1T)drwhereCantis concentration of noncompetitive antagonist ofthe effect of nicotine,
CanoisCantat50%of the maximum effect of noncompetitive antagonist (7.7 ng/ml),k,,1is a rate constant of development of tolerance(0.02 min1),
C(t) is plasma nicotine concentration at timet,equation (6):E = E0 +
tnax(
, where E is the effect of nicotine on
(1 +Ce,,,,/Ca,,150 )(l+C/C50)
cardioacceleration (increase in heart rate),E0is the base line (61.2 bpm),Emaxis the maximum effect of nicotineon cardioacceleration, C is plasma nicotine concentration,C50is C at50%of the maximum effect of nicotine
(54),STD: Standard deviation.]162
Average plasma nicotine concentration vs. time data reportedin a study by
Gourlay, et a! following administration of nicotine by cigarettesmoking was
obtained as shown in column (2) in Table 3.1. A time pointat 0-hour indicates the
point at which subjects were allowed to smoke ad lib just priorto blood sampling.
This plasma nicotine concentration vs. time datawas applied to calculate
provided in column (3) in Table 3.1 using the above equation(5). With calculated
C, effect of nicotine on cardio acceleration (heart rate)was simulated with the
above equation (6) in column (4) in Table 3.1. Itcan be seen in column (5) in
Table 3.1 that the heart rate elevates to the peak at time 0-hourwhen plasma
nicotine concentration reaches the peak following smoking, andthe heart rate starts
decreasing as nicotine concentration decreases. Nicotine concentrationand heart
rate are both maximal at time 0 hour because the drug is absorbedso quickly
(essentially instantaneously) following smoking
p19)The process of application of
Porchet tolerance model is also displayed by the flow diagram in Figure3.2. The
predicted HR was then correlated with the observed HR provided inthe Gourlay, et
al study
20)to verify the model. There was a good correlation between the
calculated and the observed HR with R20.913 I and R20.8908 withoutthe lowest
value and with all the values, respectively, as shown in Figures 3.3and 3.4. In this
simulation, the baseline HR (Fo) was assumed to be 61.2 reportedas an average HR
in the study by Porchet, et at
(54),because the baseline HR was not provided in the
study by Gourlay, et al
(120)
This verification suggests that the Porchet tolerance
model predicts changes in HR reliably basedon plasma nicotine concentration.163
However, it is important to consider variousranges of inter-individual variability in
pharmacological effects such as cardioacceleration in PKIPDmodeling/simulation
or analysis/interpretation of the data from the simulation.
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Figure 3.3. Correlation between the calculated HR with Porchet model (54)and the
observed HR without the lowest value.
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Figure 3.4. Correlation between the calculated HR with Porchetmodel
(54)and the
observed HR with all values.
[HR: Heart rate, bpm: Beats per minute]
This type of PKIPD simulation which has previously been paidlittle
attention validates possible application of PKIPD modelingto predict promising
outcome and therefore, practicing this kind of simulationmay be beneficial for
establishing a better dosing regimen for nicotine. In additionto physiological
changes (HR), psychological effect of nicotine (changes in craving)was correlated
to plasma nicotine concentration in the current simulation study. Recall that
craving is considered as a critical factor to maintain nicotine self-administration
and to cause relapse in smokers who attempted to quit smoking
(119)
Development of acute tolerance of nicotineon HR has been studied
(82, 94,
118-119, 120)in order to elucidate whether the acute tolerance of nicotinewhich165
represents desensitization of the nervous nicotine receptors is desirable foraiding
smoking cessation. The reinforcing effect of nicotinewas more prominent in the
absence of acute tolerance during the cessation comparedto the effect of nicotine
while tolerance was still present due topresence of nicotine before the cessation
(121)Loss of acute tolerance causes regaining sensitivityto nicotine rapidly, which
possibly leads smokers to relapse to smoking cigarettes
(41, 122)On the other hand,
nicotine effect on physiological changes, suchas heart rate may not be significantly
related to nicotine reinforcement and dependence in smokers,yet subjective mood
and behavioral responses are more likely to be associated
(121, 123-124)
In a study by Schuh and Stitzer, changes in cravingscores on a scale 0 to
100 were measured over time with different inter-cigarette smokingintervals, 30-,
60-, and 120-minutes intervals
72)From this study, craving ratingswere repressed
momentarily by cigarette smoking, however, the craving startedincreasing within
minutes after stopping and elevated to almost maximum levels withinless than 3
hours of abstinence
(72)
In the current simulation study reported herein, the profile ofcraving over
time with 30-minutes interval of inter-cigarette smoking from thestudy by Schuh
and Stitzer
(72)was utilized in combination with plasma nicotine concentration from
the study by Feyerabend, et al
(48)as well as predicted HR calculated by the Porchet
model with plasma concentration data from the study by Feyerabend,et a!
(48)as
displayed in the following flow diagram (2) in Figure 3.5. Thatis, mathematical
models and both physiological and craving dataare now combined from four166
different literatures reported studies in order to generatenew PK!PD modeling for
nicotine.
Obtain plasma nicotine concentrationvs.Correlation Craving from a
time data from a reference (48) ence72
Correlation
-
C= C(r)e''drfr E= E,
E,,(CIC50)
o
I (I+C,/C,a)XI+C/C,o) I
om Porchet tolerance model from Porchet tolerance
-: insert the average model calculate E Predicted
plasma nicotine (heart rate) using the heart rate
concentration vs. time data equation with the (HR)
at each time point from step plasma nicotine
1 above into the equation concentration vs. time
FCantcalculated from
I
equation above
Figure 3.5. Flow diagram (2): establishment ofa correlation among plasma nicotine
concentration, craving and heart rate.
[Correlation: Plot the data and evaluate for correlation,Cantis concentration of noncompetitive
antagonist of the effect of nicotine, Canto isCantat 50% of the maximum effect of noncompetitive
antagonist (7.7 ng/ml),is a rate constant of development of tolerance (0.02 mm'), C(t) is
plasma nicotine concentration at timet,E is the effect of nicotine on cardioacceleration (increase in
heart rate),E0is the base line (61.2 bpm),Emaxis the maximum effect of nicotine on
cardioacceleration, C is plasma nicotine concentration,C50is C at 50% of the maximum effect of
nicotine
(54)Table 3.2. Application of Porchet tolerance model
54)
to plasma nicotine concentration provided in the reference(48).
Time
(hr)
C (ng/ml) from
reference (48)
Ca,,, = C(r)e''dr(n&'ml) from a
reference (54)
Emax(C/ C50)
E(HR) = E0
+(1 + Cant a,,(50)
(bpm) from
a reference (54)
o 7 0.87 69.44
0.5 10 4.48 69.49
1 17 10.68 70.55
1.5 20 14.57 70.28
2 22 17.26 70.11
2.5 23 18.76 69.98
3 23 19.16 69.85
3.5 21 17.69 69.56
4 22 18.65 69.64
4.5 23 19.57 69.72
5 20 17.05 69.37
5.5 24 20.48 69.81
6 27 23.06 70.07
[Porchet tolerance model is composed of the following equations,Ca,,t = C(r)e ""'dr,whereCantis concentration of noncompetitive antagonist
of the effect of nicotine,Caflt5Ois Cat 50% of the maximum effect of noncompetitive antagonist (7.7ng/ml),kantis a rate constant of development of
tolerance (0.02 mind) C(r) is plasma nicotine concentrationat timet, E = E0 + max( 50)
, where E is the effect of nicotine on
(1 +Cantí'C'0,50)(1 + CIC50)
cardioacceleration (increase in heart rate),E0is the base line (61.2 bpm),Emaxis the maximum effect of nicotineon cardioacceleration, C is plasma nicotine concentration,C50is C at 50% of the maximum effect of nicotine(54)]168
In Table 3.2, predicted heart rate was simulated using Porchettolerance
model
(54)in column (4) with Cin column (3) calculated with plasma nicotine
concentration vs. time data following cigarette smoking incolumn (1) and (2)
obtained from reference (48). The process of simulation of heartrate and
examination of possible correlation between plasma nicotineconcentration data and
craving, or between predicted heart rate and craving is depictedin the flow diagram
(2) in Figure 3.5.
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Figure 3.6. Profile of comparison between plasma nicotine concentrations(48)and
craving scores
(72),and between plasma nicotine concentrations
(48)and predicted
heart rate from a half-hourly smoking.
[Plasma nicotine concentrations were obtained from a reference (48), and cravingscores vs. time
data were reported in a reference (72). The dots(SA)are experimental data, and these data are
connected by solid lines.]169
There was no significant increase or change in heartrate (HR) after the
second nicotine input as shown in the top line in Figure 3.6 wherethe HR becomes
relatively constant after 1 hour. The minimum nicotine concentration(Cmin) was
approximately one third of the peak until 2 to4hours post-smoking
(48),and then
the nicotine concentration became less variable andmore steady with theCmjn
about 2/3 of the peak
(48)After
4thdose, the peak plasma nicotine concentrations
were fairly steady at around 48 to 53 ng/ml, and so were cravingscores in between
20 to 36
(48, 72)This correlation between plasma nicotine concentration andcraving
score indicated that accumulation of nicotine from frequent smoking would result
in more constant nicotine concentrations over time leadingto reduced craving
throughout the day. In reference to this correlation, it isnow suggested that
changes in HR may not be directly related to changes in craving.
In one study by Jarvik, et al, a relationship between blood nicotine
concentrations and cigarette craving was examined
(69)In the Jarvik, et al study,
plasma nicotine concentration was associated with" Urgeto smoke" (a rating that
indicates the intensity of craving) afterad libsmoking, and a significant negative
correlation was observed
(69)The exponential correlation (Urge to smoke=5.358e
O.02*Concentration
R2=0.9993 shown in Figure 3.7) betweenthe "Urge to smoke"
(69)
and the plasma nicotine concentration
(69)was obtained in our simulation study
using the data from the Jarvik, et al, study
(69)and employed in further simulations.2.5
170
Figure 3.7. A relationship between plasma nicotine concentration followedby
administration of nicotine by cigarette smoking and "Urge to smoke (UTS)"ratings
(72)
[.:Observed data from the study by Jarvik, et al
(72),
(-):Predicted correlation in our simulation.]
Gourlay, et a!, studied cardiovascular effects after smoking (1 puff/minute
for 10 minutes), nasal nicotine spray (NNS) (1spray of 0.5 mg per each nostril),
and intravenous nicotine infusion (2 jig/kg for 30 minutes)
(120)Employing the
data of plasma nicotine concentration from cigarette smoking and heartrate (HR)
changes in the study by Gourlay, et al
20),plasma nicotine concentrationcan now
be seen to be well exponentially correlated (R20.9778) to heartrate with the
baseline heart rate of 61.2
(54)in Figure 111.8.35
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Figure 3.8. A relationship between plasma nicotine concentrationand heart rate
(HR) followed by rapid input from cigarette smoking
(54, 120)
[.:Observed data from the study by Gourlay, et al, (-): Predicted correlationin our simulation
study
This correlation was for a plasma nicotine concentrationprofile and HR
change after a rapid nicotine input (Arterial Tm (VenousTm) at 8.2±3.3 (11.9
±1.9) minutes for smoking). If the initial nicotine input is slow(ArterialTmax
(VenousTmax)at 29±2.9 (30±3.2) minutes), the development of tolerance of
nicotine on cardiovascular effect results in clock-wise hysteresis ioop(120)as
illustrated in Figure 3.9.172
75
HR (bpm)
Figure 3.9. A clock-wise hysteresis loo on heart rate (FIR) from slow rate of
nicotine input by intravenous infusion
20)
The flow diagram (3) displays a process of establishinga correlation
between heart rate (HR) and "Urge to smoke" as shown in Figure 3.10. Heartrate
was predicted for each plasma nicotine concentration provided in the study by
Jarvik, et a!
(69)using the correlation (Heart rate9.991 1 *Ln(plasma nicotine
concentration)+5 1.362) which was newly generated herein and is shown in Figure
3.8.Obtain plasma nicotine concentrations vs. time
data from a reference (69)
Insert the concentration data above into tiot
equation to simulate heart rate: HR=9.99 11 *Ln(C)+5 1.362
Obtain predicted HR
Correlate predicted HR and
"Urge to smoke"
Obtain "Urge to smoke" vs.
time data from a reference (69)
Figure 3.10. Flow diagram (3): establishment ofa correlation between heart rate and "Urge to smoke" rating.
[14 : Comparison to establish a correlation, HR: Heart rate, C: Plasma nicotine concentration(ng/ml)]174
L______
UT
Figure 3.11. A correlation between predicted heart rate (HR) and "Urge to smoke
(UTS)"
(69)
[.:Data points with calculated HR and observed UTS data from the study by Jarvik, et al
(69),
Predicted correlation in our simulation study]
This predicted HR was correlated to "Urge to smoke" from the study by
Jarvik, et al
(69)as is now shown in Figure 3.11. A correlation between predicted
HR and "Urge to smoke" ratings in reference to plasma nicotine concentrationswas
best fit (R2=rO.9037) to an exponential function.
The flow diagram (4) in Figure 3.12 shows the route to choose a model for
simulation of heart rate by comparing results using the Porchet tolerance model and
the correlation of "Urge to smoke" and heart rate (HR13 1 .82eI42UTS obtained in
Figure 3.1 1). In Table 3.3, column (2) provides plasma nicotine concentrationsvs.
time data with multiple dosing (assuming cigarette smoking every 3-hour) that175
were predicted by superposition method
(126)in relationship to an average plasma
nicotine concentration vs. time data from a reference (69) and using an elimination
rate constant(ket)of 0.533 (hr1). With simulated plasma nicotine concentrations
vs. time data with multiple dosing in column (2),Cantwas calculated in column (3),
and theCantand plasma concentrations were applied to obtain predicted heart rate
by the Porchet tolerance model as shown in column (4) in Table 3.3. In column
(5), a correlation (UTS=5.3579eO224C) of plasma nicotine concentration and "Urge
to smoke" was applied to predict "Urge to smoke" ratings for predicted plasma
nicotine concentrations from column (2). These simulated "Urge to smoke" ratings
were inserted into a correlation (HR= 131. 82e°
1422UTS)between heart rate (HR) and
"Urge to smoke (UTS)" to predict heart rate as depicted in column (6) in Table 3.3.
Predicted heart rate (HR) data by (i) Porchet tolerance model and (ii) the
correlation, HR13 1 .82eI422TS were compared to select a model for the
remaining simulations as illustrated in the flow diagram (4) in Figure 3.12. Figure
3.13 and 3.14 now show profiles of predicted plasma nicotine concentrationsvs.
time with multiple dosing by cigarette smoking every 3-hour and a profile of
predicted "Urge to smoke" ratings vs. time data, respectively.Obtain average plasma nicotine concentrationvs. time
data (cigarette smoking) from a reference (69)
Generate predicted plasma nicotine concentrationvs. time data with
multiple dosing (input every 3-hour) using the concentration data from the
above step (1) and a model, C31e533t(69)
;;:; ;::; :;;::;i;
tHerincmnnu'ctinenrentritinn vtime dcith
from step 2 above into the equation and calculateCant
Cantcalculated from the equation above
E=E E(C/C,0)from Porchet tolerance model
(lC/C,0)(1+C/C,0)
calculate E (heart rate) using the equation with the plasma
nicotine concentration vs. time data and Cant
y ...................
UTS5.358eOO22C:insert the plasma
nicotine concentration s vs. time data
from step 2 into the equation to
obtain predicted "UTS"
Obtain predicted"UTS" vs.
HR=131.82e422UTS:insert the
predicted "UTS" vs. time data into
the equation to obtain predicted HR
Comparison:
Porchet model is
selected for
future simulation
Figure 3.12. Flow diagram (4): a model selection for simulation ofheart rate.
[C: Plasma nicotine concentration,t:time, UTS: "Urge to smoke" rating]
Predicted heart rate (HR)Table 3.3. Prediction of heart rate using the Porchet tolerance model
(54)
and a correlation between heart rate and "Urgeto
smoke" with predicted plasma nicotine concentrationsvs. time data (multiple dosing every 3-hour) calculated withan
average plasma nicotine concentrations vs. time data obtained from the reference (69).
rTime (hr)Predicted C
(ng/ml)
CantC(r)e' (t_r)d
°
(ng!ml)_(54)
Em=(C/C50) E = E0
+ (1+ C, /C,,0)(1 + C/C50)
(bpm)
(54)
UTS=5.358&
O.022C
HR=l 31 .82&
0. 1422UTS
0 30.9 3.8 88.2 2.7 89.9
1 18.2 12.3 70.4 3.6 79.4
2 8.8 7 67.3 4.4 70.5
3 37 9 83.6 2.4 94.5
4 21.4 15 70.7 3.3 82.3
6 41.7 12.6 82 2.1 97.7
8 24.7 17.7 71 3.1 85.1
10 16.4 13 69.2 3.7 77.8
12 12.2 9.8 68.2 4.1 73.8
20 5.3 4.5 65.6 4.8 67
24 3.7 3.1 64.7 4.9 65.4
{C: plasma nicotine concentration, UTS: "Urge to smoke" rating, HR: heartrate, bpm: Beats per minute, Porchet tolerance model is composedof the
following equations,C,, = }C(z)e ''dr,whereCantis concentration of noncompetitive antagonist of theeffect of nicotine,C50is Cat 50%
of the maximum effect of noncompetitive antagonist (7.7 ng/ml),kantis a rate constant of development of tolerance (0.02 mint),C(t) is plasma
nicotine concentration at time t,E = E0 + Em=(C /C50)
, where E is the effect of nicotine on cardioacceleration (increase in heart rate)
( + C,,,, / C,,,,,50)(1 + C /C50)
E0is the base line (61.2 bpm),Emaxis the maximum effect of nicotine on cardioacceleration, C isplasma nicotine concentration,C50is C at 50% of the maximum effect of nicotine
(54)j178
Figure 3.13. Profile of simulated plasma nicotine concentrations over time from
multiple dosing by cigarette smoking every 3-hour
(69)
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Figure 3.14. Profile of predicted "Urge to smoke (UTS)" ratings for the simulated
plasma nicotine concentrations over time following nicotine administration by
cigarette smoking every 3-hour.179
In Figure 3.15, heart rate was predicted with simulated plasmanicotine
concentration vs. time data following this multiple nicotine dosingby cigarette smoking
every 3-hour using the Porchet tolerance model and the correlation of heartrate (HR)
and "Urge to smoke (UTS)" (HR=131.82eMl422tJTS). The standarddeviations between
HR from the Porchet tolerance model and from the correlation of HRand "Urge to
smoke (UTS)" (HR=13 I .82el422uJTS) were less than 10,except for the data that were
out of the correlation range. The exponential correlation of HR and "Urgeto smoke
(UTS)" would not predict the right values, if the datawere not in the range of the
correlation. Therefore, the Porchet tolerance modelwas chosen to be used to predict
HR using plasma concentration data for the remaining simulations.
100-i
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Figure 3.15. Predicted heart rate (HR) from multiple nicotine dosing by cigarette
smoking using the Porchet' s tolerance model and UTS model (the correlation ofheart
rate (HR) and "Urge to smoke (UTS)", HR=13 1 .82e°1422UTS)180
A combination of rapid input rate (nicotine nasalspray (NNS) 2 mg per input
(101))every 3- or 4-hour and constant input rate (nicotine transdermal patch 15mg
delivered! 16 hours
(88))was proposed as a desirable dosing regimen for smoking
cessation for smokers who want to quit and applied to simulate plasmanicotine
concentration vs. time data. This simulated plasma nicotine concentrationvs. time data
was used to predict heart rate and "Urge to smoke" rating. An example of simulation
for a combination of rapid input every 3-hour and constant input isshown in Table 3.4.
The column (2) in Table 3.4 provides simulated plasma nicotineconcentrations
obtained by superposition method
(126)with plasma nicotine concentrationvs. time data
following administration of nicotine by a combination of rapid inputevery 3-hour and
constant input for 16 hours. With this simulated plasma nicotine concentrationdata,
Cantwas calculated in column (3) to predict heart rate using the Porchet tolerance model
as shown in column (4), and "Urge to smoke (UTS)" rating was predicted by
"UTS=5.358&°°22'"in column (5) in Table 3.4. The flowdiagram (5) in Figure 3.16
displays the process for simulation of heart rate and "Urgeto smoke" for the proposed
dosing regimen, combination of rapid input at different time-intervals,every 3- or 4-
hour and constant input for 16 hours. The dosing intervals for the rapidinput were
determined based on a half-life of tolerance disappearance (35 minutes)from the
tolerance model by Porchet, et al
54)Table 3.4. Example of simulation of plasma nicotineconcentrations vs. time data, heart rate using the Porchettolerance
model
(54)and "Urge to smoke (UTS)" ratings bya correlation, UTS5.358e22C with an average plasma nicotine
concentrations vs. time data obtained from the reference (88) and(101), assuming nicotine is delivered bya combination of
rapid input (nicotine nasal spray (2mgper input)'°') every 3-hour and constant input (nicotine patch (15mgdelivered! 16
hours)88).
Time (hr)Predicted C
(ng/ml) Cant = I C(r)e' 'dr(ng/ml)
(54) E = E0
Em(C I C50) (bpm)
(54)
(1 + ce,,, /C050)(1 + C/C50)
UTS5 .35 8e0022C
0 0 0 61.2 5.4
1 8.3 5.2 67.7 4.5
2 8.8 6.9 67.3 4.4
3 19 15.9 69.4 3.5
4 15.4 13.1 68.7 3.8
5 13.1 11.2 68.2 4
6 21.6 18.4 69.5 3.3
10 12.1 10.4 68 4.1
12 9.6 8.2 67.3 4.3
20 5 4.3 65.4 4.8
24 3 2.6 64.2 5
[C: plasma nicotine concentration, UTS: "Urge to smoke" rating, HR: heartrate, bpm: Beats per minute, Porchet tolerance model is composedof the
following equations,Ca,t= whereCantis concentration of noncompetitive antagonist of theeffect of nicotine,C,50is Cat 50%
of the maximum effect of noncompetitive antagonist (7.7 ng/ml),kantis a rate constant of development of tolerance (0.02 mind),C(r) is plasma
nicotine concentration at timet, E =+
Emax(C /C50)
,where E is the effect of nicotineon cardioacceleration (increase in heart rate) (1 +Cant/Ca,,:50)(1 + C /C50)
E0is the base line (61.2 bpm),Ernaxis the maximum effect of nicotine on cardioacceleration, Cis plasma nicotine concentration,C50is C at 50% of the maximum effect of nicotine
(54)]
-a
00-aSimulate plasma nicotine concentrationvs. time data with multiple
dosing: rapid nicotine input every 1-, 3-or 4-hour by nicotine nasal
spray (NNS) using plasma nicotine concentration vs. time data
from a reference (101) and a PK model, C=l6.4ei96t+10.2&9t(101)
Obtain plasma nicotine
concentration vs. time data with
constant input rate (patch) from
a reference (88)
Simulate plasma nicotine concentrationvs. time data for the combination
of rapid and constant input rate by superpositionmethod
F
I
plasma nicotine concentration vs.
time data into the equation to
predict "Urge to smoke" rating
Obtain predicted "Urge to
: insert the plasma nicotine concentration vs. time data
from step 2 above into the equation and calculateC
Cantcalculated from the equation above
smoke (UTS)"
E E Em,(C/C5o) from Porchet tolerance modelpredict E (heart rate) °
(1 + C, /C,,,0)(1 + C/C,0)
using the equation with the plasma nicotineconcentration vs. time data andCant
Figure 3.16. Flow diagram (5): prediction of heartrate and "Urge to smoke (UTS)" ratings witha profile of predicted plasma
nicotine concentrations from a combination ofa rapid input and a constant slow input
(54, 88, 101)183
Figure 3.17. Profile of simulated plasma nicotine concentration over time from a
combination of rapid input by nicotine nasal spray (NNS) every hour, 3 hours and 4
hours, and constant input by a patch.
Figure 3.18. Profile of predicted "Urge to smoke (UTS)" scores over time from a
combination of rapid input every hour, 3 hours and 4 hours, and constant input.184
As shown in Figure 3.17, nicotine peak concentrations of10.75, 20.16,
22.76 (ng/ml) were observed at 0.13, 3.08, 6.08 hour post-dosingfor every 3-hour
dosing and, 10.75, 21.61, 23.1 (ng/ml)were at 0.125, 4.08, 8.08 hour post-dosing
for every 4-hour dosing, respectively. In Figure 3.18, thepredicted "Urge to smoke
(UTS)" scores decreased when the nicotine concentration elevated,and vice versa.
The predicted " Urge to smoke (UTS)"were 4.3 (vs. 5.4) (20% reduction), 3.5
(35% reduction), 3.3 (39% reduction) at 0.17, 3.13, 6.17 hours forevery 3-hour
dosing, and 4.2 (22% reduction), 3.3 (39% reduction), 3.1 (43%reduction) at 0.13,
4.08, 8.08 for every 4-hour dosing, respectively, and graduallyincreased to the
"Urge to smoke (UTS)" score of 5 at 24 hoursas the predicted nicotine
concentration decreased. The predicted " Urge to smoke (UTS)"score from
cigarette smoking was in between 2.7 and 5.05
(69)The predicted "Urge to smoke
(UTS)" dropped quickly to 2.7 from 5.05as soon as nicotine was delivered by
smoking. In previous studies, it was reported thateven though smokers were
allowed to smokead lib,the "Urge to smoke (UTS)" did notgo down to zero
(69, 82),
but reached a lowest valueof 2.7.185
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Figure 3.19. Profile of simulated heart rate (FIR)over time from a combination of
rapid input every hour, 3 hours and 4 hours, and constant input.
In Figure 3.19, predicted heart rate (HR) increasedas nicotine was delivered
rapidly and remained high above 65 bpm for up to 20 hours forevery 3-hour and 4-
hour dosing, however, the degree of heart rate (HR) increase for 3- and4-hour
input interval was less from the second (69.7 and 70 bpm) and the third rapidinput
(69.5 and 69.7 bpm) compared to the first input (72.4 bpm for both input intervals).
This can be explained by continuous existence of tolerance to cardioaccelerationas
a result of the constant drug delivery in addition to the rapid input.
In Figures 3.17, 3.18 and 3.19, a dosing regimen witha combination of a
rapid nicotine input (2 mg per input) every hour over first 6 hours and theconstant
input (15 mg/i 6 hours) was simulated to study changes in "Urge to smoke(UTS)"186
and heart rate (HR) in addition to every 3- and 4-hour dosing intervals.Maximum
plasma concentration(Cmax) reached at about 28 (ng/mI) at 5-hour post-dosing,and
thisCmaxwas lower than the average value from cigarette smoking. Degree of
changes in "Urge to smoke (UTS)" and heart rate (HR)was a little higher from
every hour rapid input than 3- or 4-hour dosing interval, due to higher drug
concentration; however, the differences were not significant (2.96vs. 3.03 (1%
difference in reduction of "Urge to smoke" rating), 70vs. 69 bpm).
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Figure 3.20. Profile of simulated plasma nicotine concentrationsover time from a
combination of a higher dose (4 mg per input) of rapid inputevery hour, 3 hours
and 4 hours, and constant input (15 mg/i 6 hours).187
A higher amount of rapid input (4mgper each input) was combined with the
constant input (15mg delivered! 16 hours) for the second simulationin Figure 3.20
(the simulation process is the sameas displayed in the flow diagram (5) in Figure
3.16). Dosing intervals of the rapid inputwere the same as the first simulation at
every hour, 3 hours, and 4 hours.
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Figure 3.21. Profile of predicted "Urge to smoke (UTS)"scores over time from a
combination of a higher dose (4 mg per input) of rapid inputevery hour, 3 hours
and 4 hours, and constant input (15 mg/16 hours).188
As shown in Figures 3.20, 3.2 land 3.22, higher amount of nicotine
delivered by the rapid input increasedCm,initial changes in HR and degrees of
"Urge to smoke (UTS)" reduction. Withevery 3- and 4-hour rapid dosing, "Urge
to smoke (UTS)" scores dropped from 5.4 to 2.5 to 2.6 (54% to 52% reduction)
when theCmreached approximately 32.5 to 33.6 ng/ml, while heartrate (HR) was
about 70 to 71 without significant fluctuation. The simulatedCm(45 to 46 ng!ml)
from every hour dosing was elevated too high to predict "Urgeto smoke (UTS)"
score using the model. In spite of high Cm from the 1-hour dosing interval, heart
rate (HR) was maintained at around 70 to 72 bpm after initial peak of
approximately 88, due to the development of tolerance.
90
60t-------------r
0 246 8
3hr-interval
-
-.----------.-----
- .- ______f_______ ---n
1012141618202224
Time (hr)
1fYl---J
Figure 3.22. Profile of simulated heart rate (HR) over time froma combination of a
double dose of rapid input every hour, 3 hours and 4 hours, andconstant input.189
In the third simulation followed the simulation process depicted in the flow
diagram (5) in Figure 3.16, a combination of the rapid input (2 mg per input)every
3- and 4-hours and a higher amount of constant input (30mg deliveredll6 hours)
was examined to predict plasma nicotine concentration, "Urge to smoke (UTS)
scores and heart rate (HR) in Figures 3.23, 3.24 and 3.25. With the rapid dosing at
every 3 or 4 hours, "Urge to smoke (UTS)" scores and heart rate (HR) were in the
range of 2.4 to 3 (56% to 45% reduction from the score of 5.4) and approximately
70 to 71 bpm after the second dose for up to about 9 hours post-dosing.
Figure 3.23. Profile of simulated plasma nicotine concentration over time from a
combination of rapid input (2 mg per input) every hour, 3 hours and 4 hours, and a
higher amount of constant input (30 mg/16 hours).6
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Figure 3.24. Profile of predicted "Urge to smoke (UTS)scores over time from a
combination of rapid input (2mg per input)every 3 hours and 4 hours, and a higher
dose of constant input (30 mg!16 hours).
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Figure 3.25. Profile of simulated heart rate (HR) over time froma combination of
rapid input (2 mg per input) every hour, 3 hours and 4 hours, anda higher dose of
constant input (30 mg/I 6 hours).191
CONCLUSIONS AND DISCUSSION
Our simulation studies were carried out based on assumptions garnered
from prior literatures that there is a correlation between plasma nicotine
concentration and "Urge to smoke (UTS)" scores, and that a combination of rapid
and constant input would achieve non-steady state and non-uniform nicotine
concentrations. In this simulation study, the fact that predicted cravingwas not
directly related to nicotine effect on heart rate was confirmedas suggested in
previous studies
(121, 123-124)Reduction in craving was more correlated to the rate of
nicotine input as well as the nicotine concentration, particularly the minimum
plasma nicotine concentration,Cmin. As nicotine concentration decreased, intensity
of craving increased. Therefore, maintaining a certain nicotine concentration, about
one half or higher than one third of the peak nicotine concentration, is important in
order to keep craving from being elevated. Considering a 20% reduction in the
intensity of craving as significant or useful, the proposed dosing regimens of
combination of rapid input every 3- to 4- hours and constant input achieved
significant effects (greater than 20% reduction) on decrease of craving. A rapid
nicotine delivery is presumed to be related to arousal or feeling of pleasure, which
may result in instant relief of craving. Therefore, a constant nicotine input can
reduce the intensity of craving and help prevent withdrawal symptoms, and a rapid
nicotine delivery will act immediately to provide arousal or pleasure and to inhibit
possible craving from insufficient blood nicotine concentration as well as morning192
craving from overnight abstinence. The simulation study was carried out using
average data published in the references
(88, 101);however, there were limitations of
obtaining the full data sets. Due to lack of raw data, statistical analysiswas not
carried out. Therefore, a clinical trial is needed to make further verification for the
suggested dosing regimens.
An alternative proposal to improve smoking cessation rates is to administer
a combination of 150 mg of SR bupropion HC1 and a rapid nicotine input every 3
to 4 hours such as input by nicotine nasal spray (NNS). A 300 mg-dose of
bupropion SR is currently recommended for smoking cessation to obtain the
maximum outcome; however, the 300 mg-dose is likely to cause adverse events,
and therefore a reduced dose of 150 mg is more desirable whenever possible, and a
combination with NNS should supplement the effect from bupropion HC1. Adding
NNS to bupropion SR could relieve craving more efficiently, since the effect of
bupropion HCJ on relief of craving has been conflicting and is not considered as the
major action of bupropion HC1 on smoking cessation. In both combination
therapies proposed above, the doseofconstant inputofnicotine or either the dose
or frequency of rapid input of nicotine should be determined based on the degree of
nicotine dependence such as "Nicotine dependence score" by Fagertrom test
p25)
Here are a few suggestions that should improve the current therapy: first,
the key to relieve craving needs to be more clearly identified regarding either a high
nicotine concentration or a rapid input rate, or both the concentration and the input
rate. Gomein, et al demonstrated that there was a relationship between saliva193
nicotine concentrations and rate of input, and craving by exercising PKJPD
modeling
(82);however, the investigators suggested that further study should be
carried out to verify this conclusion due to sparsely collected data. Additionally,
different saliva nicotine concentrations were used in the study by Gomein, el alto
compare a nicotine transdermal patch and cigarette smoking, and hence a study of
PKIPD modeling at the same nicotine concentrations from different input rates
would be worth investigating. Second, relationships between rate of input from
cigarette smoking and nicotine replacement therapy and both psychological and
physiological changes such as craving scores and cardioacceleration need to be
studied simultaneously. The relationship between blood nicotine concentrations
from cigarette smoking and "Urge to smoke (UTS)" as a craving score was
investigated, and showed a positive correlation between relief of craving and
aversive rapid smoking as well as blood nicotine concentrations
(69)However, a
relationship between craving scores and heart rates from cigarette smoking,
nicotine replacement therapy or bupropion HC1 has not been studied. Third, direct
comparison of NNS and cigarette smoking at the same time-intervals needs to be
carried out regarding relief of craving, withdrawal symptoms and changes in heart
rates concurrently.194
REFERENCES
1.Abelin T, Ehrsam R, Buhier-Reichert A, Imhof PR, MullerP, Thommen A
(1989) Controlled trial of transdermal nicotine patch intobacco withdrawal,
Lancet, 1(8628): 7-10.
2. Areechon W, Punnotok J (1988) Smoking cessation throughthe use of
nicotine chewing gum: a double-blind trial in Thailand, Clin.Ther., 10:
183-186.
3.Blondal T (1989) Controlled trial of nicotine polacrilexgum with
supportive measures, Arch. Intern. Med., 149: 1818-1821.
4.Blondal T, Franzon M, Westin A (1997) A double-blindrandomized trial of
nicotine nasal spray as an aid in smoking cessation, Eur.Respir. J., 10:
1585-1590.
5.Bolliger CT, Zeliweger JP, Danielsson T, Van Biljon X, RobidouA, Westin
A, Perruchoud AP, Säwe U(2000) Smoking reduction with oralnicotine
inhalers: double blind, randomized clinical trial of efficacyand safety, BMJ,
32 1(7257): 329-333.
6.Buchkremer G, Bents H, Horstmann M, Opitz K, Tolle R(1989)
Combination of behavioral smoking cessation with transdermalnicotine
substitution, Addict. Behav., 14: 229-238.
7.Tonnesen P. Paoletti P, Gustavsson G, Russell MAH, Saracci R, GulsvikA,
Rijcken B, Säwe U (1999) Higher dosage nicotine patches increaseone-
year smoking cessation rates: Results from the European CEASE trial,
Collaborative European Anti-Smoking Evaluation. EuropeanRespiratory
Society, Eur. Respir. J., 13: 238-246.195
Campbell IA, Prescott RJ, Tj eder-Burton SM (1991)Smoking cessation in
hospital patients given repeated advice plus nicotineor placebo chewing
gum, Respir. Med., 85: 155-157.
9.Daughton DM, Heatley SA, Predergast JJ, Causey D,Knowles M, RoIfCN,
Cheney RA, Hatlelid K, Thompson AB, Rennard SI (1991)Effect of
transdermal nicotine delievery as an adjunct to low-interventionsmoking
cessation therapy. A randomized, placebo-controlled,double-blind study,
Arch. Intern. Med., 151: 749-752.
10. Daughton D, Susman J, Sitorius M, Belenky S, MillatmalT, Nowak R, Patil
K, Rennard SI (1998) Transdermal nicotine therapy and primarycare.
Importance of counseling, demographic, and participant selectionfactors on
1-year quit rates. The Nebraska Primary Practice SmokingCessation Trial
Group, Arch. Fam. Med., 7: 425-430.
11. Davidson M, Epstein M, Burt R, Schaefer C, WhitworthG, McDonald A
(1998) Efficacy and safety of an over-the-counter transdermalnicotine
patch as an aid for smoking cessation, Arch. Fam. Med., 7(6):569-74.
12. Fagerstrom KO (1984) Effects of nicotine chewinggum and follow-up
appointments in physician-based smoking cessation, Prey. Med.,13: 517-
527.
13. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS,Baker TB
(1994) Two studies of the clinical effectiveness of the nicotinepatch with
different counseling treatments, Chest, 105: 524-53 3.
14. Benowitz N, Jacob P (1993) Nicotine and cotinine elimination
pharmacokinetics in smokers and nonsmokers, clin.pharmacol.ther.,53:316-
323.
15. Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, DohertyK, Rosner B,
Vokonas PS (2000) Effects of nicotine gum dose by level ofnicotine
dependence, Nicotine Tob. Res., 2(1): 53-63.196
16. Wallstrom M, Nilsson F, Hirsch JM (2000) A randomized,double-blind,
placebo-controlled clinical evaluation ofa nicotine sublingual tablet in
smoking cessation, Addiction, 95(8): 1161-1171.
17. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeilJJ (1995) Double
blind trial of repeated treatment with transdermalnicotine for relapsed
smokers, BMJ, 311(7001): 363-366.
18. Gross J, Johnson J, Sigler L, Stitzer ML (1995) Doseeffects of nicotine
gum, Addict. Behav., 20: 371-381.
19. Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, JonesRT (1987)
Nicotine gum and behavioral treatment:a placebo controlled trial, J.
Consult. Clin. Psychol., 55: 603-605.
20. Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, HumfleetGL, Hartz
DT (1996) Mood management and nicotinegum in smoking treatment- a
therapeutic contact and placebo-controlled study, J. Consult.Clin. Psychol,
64: 1003-1009.
21. Hays JT, Croghan GA, Offord KP, Hurt RD, SchroederDR, Wolter TD,
Nides MA, Davidson M (1999) Over-the-counter Nicotinepatch therapy for
smoking cessation: Results from randomized, double-blind, placebo-
controlled and open label trials. Am. J. Public Health, 89:1701-1707.
22. Herrera N, Franco R, Herrera L, Partidas A, Rolando R,FagerstrOm KO
(1995) Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind
placebo-controlled trial within a behavior modificationsupport program,
Chest, 108: 447-451.
23. Hjalmarson AT, Frazon M, Westin A, Wikiund 0 (1994) Effect ofnicotine
nasal spray on smoking cessation. A randomized, placebo-controlled,
double-blind study, Arch. Intern. Med., 154: 2567-2572.197
24. Hjalmarson Al (1984) Effect of nicotine chewinggum in smoking
cessation. A randomized, placebo-controlled, double-blind study,JAMA,
252: 2835-2858.
25. Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML (1989)
Nicotine vs placebo gum in general medical practice, JAMA, 261: 1300-
1305.
26. Hurt RD, Dale LC, Fredrickson PA, Caidwell CC, Lee GA, OffordKP,
Lauger GG, Marusic Z, Neese LW, Lundberg TG (1994) Nicotine patch
therapy for smoking cessation combined with physician advice andnurse
follow-up. One-year outcome and percentage of nicotine replacement,
JAMA, 271: 595-600.
27. Jamrozik K, Fowler G, Vessey M, Wald N (1984) Placebo controlled trial
of nicotine chewing gum in general practice, Br. Med. J., 289: 794-797.
28. Jarvik ME, Schneider NG (1984) Degree of addiction and effectiveness of
nicotine gum therapy for smoking, Am. J. Psychiatry, 141: 790-791.
29. Jarvix MJ, Raw M, Russell MAll, Feyerabend C (1982) Randomized
controlled trial of nicotine chewing-gum, Br. Med. J., 285: 537-540.
30. Jensen EJ, Schmidt E, Pedersen B, DahI R (1991) The effect of nicotine,
silver acetate, and placebo chewing gum on the cessation of smoking. The
influence of smoking type and nicotine dependence, Tnt. J. Addict, 26:
1223-123 1.
31. Joseph AM, Antonnucio DO (1996) Lack of efficacy of transdermal
nicotine in smoking cessation, N. Engi. J. Med., 341: 1157-1158.
32. Fortmann SP, Killen JD, Telch MJ, Newman B (1988) Minimal contact
treatment for smoking cessation. A placebo controlled trial of nicotine
polacrilex and self-directed relapse prevention: initial results of the Stanford
Stop Smoking Project, JAMA, 260: 1575-1580.198
33. Lewis SF, Piasecki TM, Fiore MC, Anderson JE, BakerTB (1998)
Transdermal nicotine replacement for hospitalized patients:A randomized
clinical trial, Prey. Med., 27(2): 296-303.
34. Niaura R, Goldstein MG, Abrams DB (1994) Matching highand low-
dependence smokers to self-help treatment withor without nicotine
replacement, Prey. Med., 23: 70-77.
35. Schneider NG, Jarvik ME, Forsythe AB, Read LL, ElliottML, Schweiger A
(1983) Nicotine gum in smoking cessation:a placebo-controlled, double-
blind trial, Addict. Behav., 8: 253-261.
36. Schneider NG, Olmstead R, Mody FV, Doan K, FranzonM, Jarvik ME,
Steinberg C (1995) Efficacy of a nicotine nasalspray in smoking cessation:
a placebo-controlled, double-blind trial, Addiction, 90: 167 1-1682.
37. Schneider NG, Olmstead R, Nilsson F, Mody FV, FranzonM, Doan K
(1996) Efficacy of a nicotine inhaler in smoking cessation:a double-blind,
placebo-controlled trial, Addiction, 91(9): 1293-1306.
38. Stapleton JA, Sutherland G, Russell MAll (1998) How muchdoes relapse
after one year erode effectiveness of smoking cessationtreatments? Long
term follow up of randomized trial of nicotine nasalspray, BMJ, 3 16(7134):
830-83 1.
39. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, ForchammerH,
Stockner M (1988) Effect of nicotine chewinggum in combination with
group counseling on the cessation of smoking, N. Engi. J. Med., 318(1): 15-
18.
40. Westman EC, Levin ED, Rose JE (1993) The nicotine patch insmoking
cessation. A randomized trial with telephone counseling. Arch. Intern.
Med., 153: 1917-1923.199
41. Brandon TH, Tiffany ST, Obremski KM, Baker TB (1990) Postcessation
cigarette use: the process of relapse, addict. Behav., 15:105-114.
42. Glassman AH (1993) Cigarette smoking: implications for psychiatric
illness, Am. J. Psychiatry, 150: 546-553.
43. Killen JD, Fortmann SP, Newman B, Varady A (1991) Prospective study of
factors influencing the development of craving associated with smoking
cessation, Psychopharmacology, 105: 191-196.
44. Shiffman S. Paty JA, Gnys M, Kassel JD, Hickcox M (1996) First lapses to
smoking: within subjects analysis of real time reports, J. Consult. Clin.
Psychol., 64: 366-379.
45. Beckett A, Gorrod J, Jenner P (1972) A possible relation between pKa and
lipid solubility and the amounts excreted in urine of some tobacco alkaloids
given to man, J. Pharm. Pharmacol., 24 (2): 115-120.
46. Rosenberg J, Benowitz NL, Jacob P, Margaret-Wilson K (1980) Disposition
kinetics and effects of intravenous nicotine, Clin. Pharmacol. Ther., 28(4):
5 17-522.
47. Benowitz NL, Jacob P (1984) Daily intake of nicotine during cigarette
smoking, Clin. Pharmacol. Ther., 35: 499-504.
48. Feyerabend C, Ings RMJ, Russell MAH (1985) Nicotine pharmacokinetics
and its application to intake from smoking, Br. J. Clin. Pharmacol., 19: 239-
247.
49. Scherer G, Jarczyk L, Heller W, Biber A, Neurath G, Adlkofer F (1988)
Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette
smokers, Kim. Wochenschr., 66 (suppl XI): 5-11.200
50. Kyerematen G, Damiano M, Dvorchik B, Vesell E(1982) Smoking-induced
changes in nicotine disposition: application ofa new HPLC assay for
nicotine and its metabolites, Clin. Pharmacol. Ther.,32: 769-780.
51. Benowitz NL (1996) Pharmacology of nicotine:addiction and therapeutics,
Ann. Rev. Pharmacol. Toxicol., 36: 597-613.
52. Clarke P, Schwartz R, Paul S, Pert B, Pert A (1985)Nicotine binding in rat
brain: autoradiographic comparison of 3H-acetylcholine, 3H-nicotine,and
'251-a-bungarotoxin, J. Neurosci., 5(5):1307-1315.
53. Fowler J, Volkow N, Wang G, Pappas N, Logan J,MacGregor R, Alexoff
D, Shea C, Schlyer D, Wolf A, Warner D, Zezulkova I, CilentoR (1996)
Inhibition of monoamine oxidase B in the brains of smokers,Nature, 379:
733-736.
54. Porchet HC, Benowitz NL, Sheiner LB (1987) Pharmacodynamicmodel of
tolerance: application to nicotine, J. Pharmacol. Exp. Ther.,244(1): 231-
236.
55. Porchet HC, Benowitz NL, Sheiner LB, Copeland JR(1987) Apparent
tolerance to the acute effect of nicotine results in part fromdistribution
kinetics, J. Clin. Invest., 80: 1466-1471.
56. Hughes J, Gulliver S, Fenwick J, Valliere W, Cruser K,Pepper S, Shea P,
Solomon L, Flynn B (1992) Smoking cessationamong self-quitters, Health
Psychol., 11(5): 331-334.
57. Perkins KA, Gerlach D, Broge M, Grobe JE, Sanders M, FonteC, Vender J,
Cherry C, Wilson A (2001) Dissociation of nicotine tolerancefrom tobacco
dependence in humans, Pharmacol. Exp. Ther., 296(3): 849-56.201
58. Russell MAH (1988) Nicotine replacement: the role of blood nicotine
levels, their rate of change, and nicotine tolerance, In: Pomerleau OF,
Pomerleau SC (eds); Fagerstrom KO, Henningfield JE, Hughes JR
(associate eds) Nicotine replacement: A critical evaluation, New York, 63-
94.
59. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991)
Symptoms of tobacco withdrawal, Arch. Gen. Psychiatry, 48: 52-59.
60. centers for Disease Control and Prevention (CDC) (2001) Cigarette
smoking among adults-United States, 1999, Morb. Mortal. Wkly. Rep.,
50(40): 869-873.
61. Centers for Disease Control and Prevention (CDC) (1993) Smoking
cessation during previous year among adults-United States, 1990 and 1991,
Morb. Mortal. Wkly. Rep., 42(26): 504-507.
62. Benowitz NL (1991) Stable isotope studies of nicotine kinetics and
bioavailability, Clin. Pharmacol. Ther., 49: 270-277.
63. Zeliweger JP (2001) Anti-Smoking therapies: is harm reduction a viable
alternative to smoking cessation?, Drugs, 61: 1041-1044.
64. Flegal KM. Troiano RP, Pamuk ER, Kuczmarski RJ, Campbell SM (1995)
The influence of smoking cessation on the prevalence of overweight in the
United States, N. Engi. J. Med., 333(18): 1165-1170.
65. Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco
withdrawal, Arch. Gen. Psych., 43: 289-294.
66. West RJ, Jarvis MJ, Russel MAH, Carruthers ME, Feyerabend C (1984)
Effect of nicotine replacement on the cigarette withdrawal syndrome, Br. J.
Addict., 79: 215-219.202
67. Shiffman S. Jarvik ME (1976) Smoking withdrawalsymptoms in two
weeks of abstinence, Psypharmacol. (Ber.), 50:35-39.
68. Tiffany ST, Drobes DJ (1991) The developmentand initial validation ofa
questionnaire on smoking urges, Br. J. Addict., 86:1467-1476.
69. Jarvik ME, Madsen DC, Olmstead RE,Iwamoto-schaap PN, Elms JL,
Benowitz NL (2000) Nicotine blood levels and subjectivecraving for
cigarettes, Pharmacol. Biochem. Behav., 66(3):553-558.
70. Perkins KA, Sexton JE, DiMarco A, Fonte C (1994)Acute effects of
tobacco smoking on hunger and eating in male andfemale smokers,
Appetite, 22: 149-158.
71. Gilbert RM, Pope MA (1982) Early effects of quittingsmoking,
Psychopharmacol., 78: 121-127.
72. Schuh KJ, Stitzer ML (1995) Desire to smoke duringspaced smoking
intervals, Psychopharmacol., 120: 289-295.
73. Shiffman S, Elash C, Paton 5, Gwaltney C, Paty J,Clark D, Liu K, Marino
M (2000) Comparative efficacy of 24-hour and 16-hourtransdermal
nicotine patches for relief of morning craving, Addiction,95(8): 1185-1195.
74. Shiffman S, Engberg J, Paty J, Perz W, Gnys M,Kassel J, Hickcox M
(1997) A day at a time: predicting smoking lapse from dailyurge, J.
Abnormal Psychol., 106(1): 104-116.
75. Russell MAll, Feyerabend C, Cole PV (1976) Plasma nicotinelevels after
cigarette smoking and chewing nicotinegum, BMJ, 1(6017): 1043-1046.
76. Gross J, Lee J, Stitzer ML (1997) Nicotine-containingversus De-
nicotinized cigarettes: Effects on craving and withdrawal,Pharmacol.
Biochem. Behav., 57(1/2): 159-165.203
77. Butchky MF, Bailey D, Henningfield JE, Pickworth WB (1995) Smoking
without nicotine delivery decreases withdrawal in 12-hour abstinent
smokers, Pharmacol. Biochem. Behav., 50: 91-96.
78. Hasenfratz M, Baldinger B, Battig K (1993) Nicotineor tar titration in
cigarette smoking behavior?, Psychopharmacol., 112: 253-258.
79. Russell, MAH, Jarvis MJ, Feyerabend C, Ferno 0 (1983) Nasal nicotine
solution: a potential aid to giving up smoking?, Br. Med. J. (Clin. Res. Ed.),
286(6366): 683-684.
80. Russell MAH, Jarvis MJ, West RJ, Feyerabend C (1985) Buccal absorption
of nicotine from smokeless tobacco sachets, Lancet, 2(8468): 1370.
81. Russell MAH, Jarvis MJ, Sutherland G, Feyerabend C (1987) Nicotine
replacement in smoking cessation. Absorption of nicotine vapor from
smoke-free cigarettes, JAMA, 257(23): 3262-3265.
82. Gomeni R, Teneggi V. lavarone L, Squassante L, Bye A (2001) Population
pharmacokinetic-pharmacodynamic model of craving in an enforced
smoking cessation population: indirect response model and probabilistic
modeling, Pharm. Res., 18(4): 537-543.
83. Malcolm RE, Sillett RW, Turner JA, Ball KP (1980) The use of nicotine
chewing gum as an aid to stopping smoking, Psychopharmacology (Berl.),
70(3): 295-596.
84. Rose J, Levin E (1991), Inter-relationships between conditioned and
primary reinforcement in the maintenance of cigarette smoking, Br. J.
Addict., 86: 605-609.
85. Benowitz NL, Jacob P, Savanapridi C (1987) Determinants of nicotine
intake while chewing nicotine polacrilex gum, Clin. Pharmacol. Ther.,
4 1(4): 467-473.204
86. Raw M, Jarvis MJ, Feyerabend C, Russell MA (1980) Comparison of
nicotine chewing-gum and psychological treatments for dependent smokers,
BMJ, 281(6238): 481-482.
87. McNabb ME (1984) Chewing nicotine gum for 3 months: what happens to
plasma nicotine levels?, Can. Med. Assoc. J., 131(6): 5 89-92.
88. Johansson C, Olsson P, Gunnarsson P, Säwe U (1996), Pharmacokinetics of
a 16-hour transdermal nicotine patch, Clin. Drug. Invest., 12(4): 195-206.
89. Benowitz NL (1995) Clinical pharmacology of transdermal nicotine, Eur. J.
Pharm. Biopharm., 41: 168-174.
90. Fagerstrom KO., Sachs D (1995) Medical management of tobacco
dependence: a critical review of nicotine skin patches, Current Pulmonol.,
16: 223-238.
91. Fagerstrom KO, Sawe U, Tormesen P (1992) Therapeutic use and safety of
nicotine patches: efficacy and safety, J. Smoking-related Diseases, 3: 247-
261.
92. Palmer KJ, Buckley MM, Faulds D (1992) Transdermal Nicotine. A review
of its pharmacodynamic and pharmacokinetic properties, and therapeutic
efficacy as an aid to smoking cessation, Drugs, 44(3): 498-529.
93. Corelli RL, Hudmon KS (2002) Medications for smoking cessation, West J.
Med., 176(2): 13 1-135.
94. Benowitz N (1991), Pharmacodynamics of nicotine: Implications for
rational treatment of nicotine addiction, Br. J. Addict., 86: 495-499.205
95. Leischow SJ, Valente SN, Hill AL, Otte PS, Aickin M, Holden T, Kligman
E, Cook G (1997) Effects of nicotine dose and administration methodon
withdrawal symptoms and side effects during short-term smoking
abstinence, Exp. Clin. Psychopharmacol., 5(1): 54-64.
96. Russell MA, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G,
Sawe U, Connor P (1993) Targeting heavy smokers in general practice:
randomised controlled trial of transdermal nicotine patches, BMJ,
306(6888): 1308-1312.
97. Schneider NG (1994) Nicotine nasal spray, Health Value, 18(3): 10-14.
98. Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M,
Feyerabend C (1992) Randomised controlled trial of nasal nicotinespray in
smoking cessation, Lancet, 340(88 15): 324-329.
99. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A (1999)
Randomized comparative trial of nicotine polacrilex, a transdermal patch,
nasal spray, and an inhaler, Arch. Intern. Med., 159: 2033-2038.
100. Benowitz NL, Zevin S, Jacob P (1997) Source of variability in nicotine and
cotinine levels with use of nicotine nasal spray, transdermal nicotine, and
cigarette smoking, Br. J. Clin. Pharmacol., 43: 259-267.
101. Sutherland G, Russell MAH, Stapleton J, Feyerabend C, Ferno 0 (1992)
Nasal nicotine spray: a rapid nicotine delivery system, Psychopharmacology,
108: 512-518.
102. Benowitz NL (1993) Nicotine replacement therapy: What has been
accomplished-can we do better?, Drugs, 45(2): 157-170.
103. Lunell E, Molander L, Leischow SJ, Fagerstrom KO (1995) Effect of
nicotine vapour inhalation on the relief of tobacco withdrawal symptoms, Eur.
J. Clin. Pharmaco!., 48: 235-240.206
104. Schneider NG, Olmstead RE, Franzon MA, Lunell E (2001) The nicotine
inhaler: clinical pharmacokinetics and comparison with other nicotine
treatments, Clin. Pharmacokinet., 40(9): 66 1-684.
105. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G (1995)
Combined use of nicotine patch and gum in smoking cessation: a placebo-
controlled clinical trial, Prey. Med., 24(1): 4 1-47.
106. Fagerstrom KO (1994) Combined use of nicotine replacement products,
Health Values, 18(3): 15-20.
107. Baker R, Santus G, Vintilla-Friedman S (1998) Method and therapeutic
system for smoking cessation, U.S. Patent, 5,721,257.
108. Blondal T, Gudmundsson U, Olafsdottir I, Gustavsson G, Westin A (1999)
Nicotine nasal spray with nicotine patch for smoking cessation: randomized
trial with six year follow up, BMJ, 30: 285-288.
109. Bohadana A, Nilsson F, Rasmussen T, Martinet Y (2000) Nicotine inhaler
and nicotine patch as a combination therapy for smoking cessation: a
randomized, double-blind, placebo-controlled trial, Arch. Intern. Med., 160:
3 128-3 134.
110. Okuyemi KS, Ahiuwalia JS, Harris KJ (2000) Pharmacotherapy of smoking
cessation, Arch. Fam. Med., 9(3): 270-28 1.
111. Ferris RM, Cooper BR (1993) Mechanism of antidepressant activity of
burpopion, J. Clin. Psychiatr. Monogr., 11: 2-14.
112. Cryer P. Haymond M, Santiago J, Shah S (1976) Norepinephrine and
epinephrine release and adrenergic mediation of smoking-associated
hemodynamic and metabolic events, N. Engi. J. Med., 295: 573-577.207
113. Ferry LH, Robbins AS, Scariati PD, MastersonA, Abbey DE, Burchette RJ
(1992) Enhancement of smoking cessation using theantidepressant bupropion
hydrochloride, Circulation, 86(Abstr.): 167.
114. Hurt RD, Sachs DP, Glover ED, Offord KP,Johnston JA, Dale LC,
Khayrallah MA, Schroeder DR, Glover PN, SullivanCR, Croghan IT,
Sullivan PM (1997) A comparison of sustained-releasebupropion and
placebo for smoking cessation, N. Engi. J. Med., 337(17):1195-1202.
115. Jorenby DE, Leischow SJ, Nides MA, RennardSI, Johnston JA, Hughes
AR, Smith SS, Muramoto ML, Daughton DM, DoanK, Fiore MC, Baker
TB (1999) A controlled trial of sustained-release bupropion,a nicotine
patch, or both for smoking cessation, N. Engi. J. Med.,340(9): 685-691.
116. Shiffman S, Johnston JA, Khayrallah M, Elash CA,Gwaltney CJ, Paty JA,
Gnys M, Evoniuk G, DeVeaugh-Geiss J (2000) The effectof bupropion on
nicotine craving and withdrawal, Psychopharmacology(Ben.), 148(1): 33-
40.
117. Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP,Grasela TH,
DeVeaugh-Geiss J (2001) Relationship between drugexposure and the
efficacy and safety of bupropion sustained release forsmoking cessation,
Nicotine Tob. Res., 3(2): 13 1-140.
118. Fattinger K, Verotta D, Benowitz N (1997) Pharmacodynamicsof acute
tolerance to multiple nicotinic effects in humans, JPET, 281:1238-1246.
119. Houtsmuller EJ, Stitzer ML (1999) Manipulation of cigarettecraving
through rapid smoking: efficacy and effectson smoking behavior,
Psychopharmacology, 142: 149-157.
120. Gourlay S. Benowitz N (1997) Arteriovenous differences inplasma
concentration of nicotine and catecholmines and related cardiovascular
effects after smoking, nicotine nasal spray, and intravenousnicotine, Clin.
Pharmacol. Ther., 62(4):453-463.208
121. West R, Russell M (1988) Loss of acute nicotine tolerance and severity of
cigarette withdrawal, Psychopharmacology, 94(4): 563-565.
122. Chornock W, Stitzer M, Gross J, Leischow S (1992) Experimental model
of smoking re-exposure: effects on relapse, Psychopharmacology, 108(4):
495-500.
123. Lee B, Benowitz NL, Jacob P (1987) Influence of tobacco abstinenceon
the disposition kinetics and effects of nicotine, Clin. Pharmacol. Ther.,
41(4): 474-479.
124. Perkins K, Grobe J, Epstein L, Caggiula A, Stiller R, Jacob R (1993)
Chronic and acute tolerance to subjective effects of nicotine, Pharmacol.
Biochem. Behav., 45(2): 375-38 1.
125. Heatherton TF, Kozlowski LT, Frecker RC, Fagertrom KO (1991) The
Fagertrom test for nicotine dependence: A revision of the Fagertrom
Tolerance Questionnaire, Br. J. A ddict., 86: 1119-1127.
126. Holt K (1997) Ph.D. dissertation, College of Pharmacy, Oregon State
University.209
CHAPTER 4
BIOEQUTVALENCE OF RACEMIC DRUGS:
A SIMULATION STUDY
Hyojong Kwon, Chandrahas G. Sahajwalla, Ph.D, Mehul U. Mehta,
Ph.D, Patrick J. Marroum, Ph.D, and Jogarao V. S. Gobburu, Ph.D210
ABSTRACT
The aim of this study was to verify regulatory criteria in the current policy
for assessing bioequivalency of chiral drug products. A model with first-order
dissolution and absorption, and nonlinear stereo-specific pre-systemic and systemic
(affinity of S>R) metabolism was employed to perform simulations. Five scenarios
involving varied dissolution profiles (f2<50) were evaluated. Within- (WVar) and
between-subject variability (BVar), dose (D) and sample size (N) were taken into
account to simulate 1000 cross-over bioequivalency trials under each scenario.
Standard bioequivalency criteria were applied to determine the probability of false
positives (%-+). Monte-Carlo simulations and statistical testing were done with
NONMEM (Version 5.0, Levell.1) and SAS (Version 6.12). The %-+ of
bioequivalency studies were higher for RS and R and lower for S. The current
simulation study demonstrated the importance of considering enantiomer
pharmacokinetics while assessing bioequivalency of chiral drugs.211
INTRODUCTION
Bioequivalency (BE) of different formulations is evaluatedby measuring
the rate and extent of absorption of the active moiety ina pertinent marmer with
sufficient statistical power
4)However, rate and extent of absorptionmay not be
the only consideration for BE studies of chiral drugs, becauseoptical isomers can
exhibit different pharmacokinetics (PK) and pharmacodynamics(PD)
(59)Active
or receptor-mediated transport, protein binding, and metabolismmay exhibit
stereo-selectivity, which can result in altered PK of enantiomer drugs.Food and
Drug Administration (FDA) requires the submission of BE studiesof individual
enantiomers when all of the following criteria (chiralassay criteria) are met: (i) the
enantiomers exhibit different pharmacodynamic characteristics;(ii) the enantiomers
exhibit different pharmacokinetic characteristics; (iii) primaryefficacy/safety
activity resides with the minor enantiomer; and (iv) nonlinearabsorption is present
(as expressed by a change in the enantiomer concentration ratio withchanges in the
input rate of the drug) for at least one of the enantiomers
(4)When BE of two
formulations of an enantiomer drug, such as verapamil HC1, is investigated,the
change of enantiomeric ratio over the time course could bean important
consideration
(3, 10)
A stereo-specific assay may be essential for chiral drugs if thereare
substantial differences in the enantiomeric ratios with different inputrates. A212
simulation study was performed as part of an ongoing evaluation of regulatory
criteria in the current policy on assessing BE studies of chiral drug products.Model
METHODS
The PK model used for simulations is shown in Figure 4.1.First-order
213
dissolution and absorption, and nonlinear stereo-specific pre-systemicand systemic
(affinity of S>R) metabolism are assumed. The model consists ofa drug depot for
drug release from the dosage form (i.e., sustained-release dosageform), the
gut/liver, and the plasma compartment.
The following equations are used in the simulations.
dDR
= . DR .relF (1) dt
dDs
= . Ds . reiF (2) dt
dApresyR VmaxR Kdlss. Di. reiF kaR . ApresyR . ApresyR (3)
dt KmR + Apresy R
dApresys. s Vmax s = Kdss . Ds . relFkas . A.presysS . A.presyS (4) dt Kms + Apresys,S
dAp,R VmaxR = kaR .Apresys,R . Ap, R
dt KmR+A,R (5)
dAp,s Vmaxs = kas . Apresys,s . Ap,s (6)
dt Kms+Ap,sDR+S
DissolutioniKdiss
R(DR)
t
Vm ax
ApresysR +KmR
Gut/Liver
(ApresysR)
At
Vmax
APR+KmR
Ka Plasma
(AR)
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Vmax Vmax
Apresys +KmA3+Km
Figure4.1.Pharmacokinetic model representing first-order dissolution and
absorption, and nonlinear stereo-specific pre-systemic and systemic metabolism.
[DRand D (amount of dose for R and S in a dosage formulation, mg), KdI(the first-order
dissolution rate constant), ApreysRand (the amounts of R- and S-enantiomer absorbed in the
gut and/or liver, mg), KaR and Kas (the absorption rate constants of R- and S-enantiomer), Vmax
(the maximum rate of metabolism,ig/h), KmR andKm5(the affinities of each enantiomer,jg/L) and
CP,R and Cp,s (the plasma concentrations of R- and S-enantiomer, ig/L)}215
Where DR and Ds are the amounts of R and S in a dosage, relF is the bioavailability
of the formulation relative to the reference, is the first-order dissolution rate
constant, Apresys,R and Apresys,s are the amounts of R- and S-enantiomer absorbed in
the gut andlor liver, KaR and Kas are the absorption rate constants of R- and S-
enantiomer, Vmax (VmaxR and Vmaxs) is the maximum rate of metabolism, KmR
and Kms are the affinities of each enantiomer, and ApR and A,s are the amounts of
R- and S-enantiomer in the plasma. Within-subject variability (Wvar) (log-normal)
was set at 15% for all parameters including Ka, Km, Vmax, and Volume of
distribution in the central compartment (V). Between-subject variation (Bvar) (log-
normal) was set at 10 or 20% for KdI and 30% for Ka, Km, Vmax, and V.
Four dissolution rates (fast (FST), medium (MED), slow (SLO), and very
slow (VSLO)) and a case (VSLOF9O) when the relative bioavailability (reiF) of
VSLO was 0.9 compared to SLO (relF=90%) and all combinations of the various
factors (N, DR+S, KdI, Wvar, and Bvar) were considered as shown in Table 4.1.
Table 4.1 Parameters for the scenarios.
[Parameter Value
Km,R (mg) 100
Km,s (mg) 50 or 100
Vmax,R (mg/h) 50
Vmax,s (mg/h) 50 or 100
Ka (1/h) 1
V(L) 50
Kdiss 2(FST), 1(MED), 0.5(SLO), 0.3(VSLO)216
Table 4.1 (Continued)
Bvar (%) 10, 20
Var(%) 30
Wvar(%) 15
Number of subjects 24, 48
Dose (mg) 100, 200
Bvar represents between-subject variability forKd1. Var represents between-subject variability for
parameters other than Kdjs1
Monte-Carlo simulation
The input ratio of R!S is changed by various drug releaserates due to
stereo-selectivity (KmR and Kms) metabolism. Comparison oftwo dissolution
profiles was carried out by calculating the similarity factor,2U U
1ff2values were
lower than 50, the dissolution profiles of reference (R) andtest (T) are considered
to be dissimilar The similarity factor(f2)is described in the following equation
(11)
Similarity factor(f2):
-'-05 1 (7) in ' I f2=50.1og{[l+(Rl_TJ)2 .100k
]
j
[Where n is the sample number, R, and T, are the percent dissolved of the reference andtest products
atithtime point
(II)
The values of that were considered for the simulationswere obtained by
calculatingf2such as 43 (FST/MED), 27.5 (FST/SLO), 41 (MED/SLO), and47.6
(SLO/VSLO) using the equation (7) and for FST was used as the reference for217
each comparison. Plasma concentrations of test andreference formulations at 0,
0.25, 0.5, 0.75, 1, 1.5,2,2.5, 3,4, 5,6, 8, and 12-hourswere simulated.
Simulations were carried out with 1000cross-over BE trials under each scenario,
using NONMEM (Version 5.0, Level 1.1).
Analysis of simulation
Data from simulation studies were used to calculateAUC1f(area under the
curve (0 to infinity)),AUCiast(area under the curve (0 to the last sampling point))
and Cmax (maximum plasma concentration) of RS (racemate) andR- and 5-
enantiomers to investigate the impact of the stereo-selective metabolismand the
rate of drug release from the dosage form. Note that rate of drug release fromthe
dosage form is assumed to be equal to rate of drug input. Datawere log-
transformed and compared under the normality assumption. The nullhypothesis of
bioequivalence (He) and the alternative hypothesis of bioinequivalence(Ha) were
established for the comparison of two formulations. The hypotheses forassessment
of bioequivalence are given as follows
H0:0O1or0O2vs. Ha:01<0<02
Where two known bioequivalence limits, O (0.8) and 02(1.25), and theparameter of
interest, B(l.tT/IIR,whereI-1Tis an average BA of test formulation andpis an average BA of
reference formulation)1218
A two-sided Student t-test at a==0.05 and the 80/125 rulewere applied
(4)
Standard BE criteria were applied to determine the probabilityof false positives
(%-+). The probability of false positive (%-+) is definedas the probability of
success that is supposed to be failure in a test in which the outcomemay result in a
misleading conclusion. Statistical analysiswas performed using SAS (Version
6.12).219
RESULTS AND DISCUSSION
Figures 4.2 and 4.3 present typical dissolution profiles and simulated
population mean plasma concentration-timecurves for each dosage form,
respectively. One hundred percentage of dissolutionwas completed at
approximately 2, 5, 10, 15-hour for FST, MED, SLO and VSLO,respectively, and
90% dissolution was achieved at about 15-hours for VSLOF9O andequation (8)
was used to obtain the profiles.
%dissolved = [1 100 (8)
Pharmacokinetic characteristics of enantiomersare in illustrated in Figure
4.3. Figure 4.3.a displays the profile of enantiomers following thesame nonlinear
pharmacokinetics (the same Vmax and Km for R and S). Figures 4.3.b-dexhibits
different nonlinear PK such as different Vmax with thesame Km (VmaxR<Vmaxs
in Figure 4.3.b), different Km with the same Vmax (KmR>Kms inFigure 4.3.c) and
different Km and Vmax (VmaxR<Vmaxs and KmR<KmS in Figure4.3.d). The
circled areas in Figures 4.3.e and 4.3.f describe thesame and different linear PK for
enantiomers, respectively. The time courses of R and S plasmaconcentrations for
different dissolution at 100 and 200-mg doses were simulatedas shown in Figures
4.4.ae.220
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Figure 4.3. Pharmacokinetic characteristics of enantiomers.
100
.c80
a'
60
40
20
0
1 10 100 1000 10000
Concentration, ugIL
(b) Vmax,R<Vmax,s
P
100
. 80
a)
60
40
a>20
0
10 100 1000 lOC
Concentration, ug/L
(d) Vmax,R<Vmax,s, Km,R>Km,s
t'J(e) Same linear PK constants for R and S
Figure 4.3 (Continued)
)00
I IIU
.c80
60
40
>20
0
-RI
1 10 100 1000
Concentration, ug/L
(f) Different linear PK
100001
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Figure 4.4.a. Simulated population mean plasma concentration-timecurves for FST
vs. SLO.
[Panel A and B show the time course of plasma concentration of R and S. () and(---) represent
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Figure 4.4.b. Simulated population mean plasma concentration-timecurves for FST
vs. MED.
[Panel A and B show the time course of plasma concentration of R andS. () and (---) represent
KdI.for fast and medium. Wvar, Var and Bvar were set at 15%, 30% and20%, respectively]225
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Figure 4.4.c. Simulated population mean plasma concentration-timecurves for
MED vs. SLO.
[Panel A and B show the time course of plasma concentration of R and S.() and (---) represent
KdI,for medium and slow. Wvar, Var and Bvar were set at 15%, 30% and 20%, respectively]250
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Figure 4.4.d Simulated population mean plasma concentration-timecurves for SLO
vs. VSLO.
[Panel A and B show the time course of plasma concentration of R and S.() and (---) represent
for slow and very slow. Wvar, Var and Bvar were set at 15%, 30% and 20%,respectively]227
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Figure 4.4.e. Simulated population mean plasma concentration-timecurves for
VSLOF9O vs. VSLO.
[Panel A and B show the time course of plasma concentration of R and S.() and (---) represent
for slow (relF=90) and very slow. Wvar, Var and Bvarwere set at 15%, 30% and 20%,
respectively]228
From Figure 4.4.a, due to nonlinear first-pass effects, Cmax andAUC1f
were higher forKdI(FST) (495 tgIL and 4259 Lg*WL for R and 293 xg/L and
2148 g*wL for S) thanKdlss(SLO) (262 pgIL and 3752 tg*WL for R and 132
pg/L and 1778 tg*hIL for S) at dose 200 mg. The difference of Cmax between
Fast and Slow for R was less than double, whereas this difference for Swas nearly
triple. This indicated that S was more sensitive to measure the difference in two
formulations. Comparisons of profiles of simulated plasma concentration for other
dissolution rates are provided in Figures 4.4.a through 4.4.d. Bioinequivalence is
expected from assessing BE study of two different formulations (f2<50), however it
is possible to obtain bioequivalency unexpectedly. The probability of false positive
(%-+) refers to the probability of success (that is supposed to be failure) in BE
study in which success results in a false conclusion. In this simulation, the
probability of false positive (%-+) was corresponded to the probability (in
percentage) of success in bioequivalency (%BE). Numerous scenarios were
evaluated for different formulations and the primary discussion will be focusedon
probability of false positive onAUC1f(%-+ AUCf) from the case of fast (FST) vs.
slow (SLO) as a representative case, because the ultimate results from the
simulation study were similar among all the scenarios. An example of simulation
scenarios is shown in Table 4.2.229
Table 4.2. An example of simulation scenario for fastvs. medium.
Scenario: FS (Comparison between fast and slow)
Case Bvar N D
FSv1(2)n24(48)dl(2) 10(20) 24(48) 100(200)
[F:fast absorptionofdrug,S: slowabsorptionofdrug,v:variable, n: numberofsubjects, d: dose in
mg]
From the comparison of two fast release formulations (FSTvs. FST), the
probability (in percentage) of demonstrating bioequivalence (%BE) studywith
AUC1f was 99% to 100% for RS, R and S with 10% of Wvar and in therange of
89% to 92% for RS and Rand 81% to 83% for S with 15% of Wvar.Meanwhile,
the %BE for these same two fast release formulations that have identicaldrug
dissolution using AUC1was simulated to be only 54%-63% for RS and Rand
38%-43% for S, when Wvar was set at 20%. Since %BE is expectedto be close to
100% for comparison of two identical formulations, 20% Wvarwas deemed to be
unrealistic in the simulation. Thus, Wvar was set at 15% for all scenariosin this
simulation. The simulation results are provided in Tables 4.3, 4.4 and 4.5.There
was no substantial effect of Bvar (i.e., 68% vs. 68% on %-+AUC1 for Sat 10%
and 20%, respectively) as shown in Table 4.3 and thus, Bvarwas set at 20% for
other simulations displayed in Tables 4.4 and 4.5. The %-+was similar for RS and
R, but lower for S in all cases.
In BE study, FDA allows 20% of variation
(4),and therefore higher than
80% of probability of success in BE study is considered to be acceptablerange for230
bioequivalency. In a case comparing two different formulations(FST vs. MED) in
Table 4.3, the %-+ AUC1f was 88% and 86% for RS and R, while it was 68% for
S. These outcomes for RS and R indicated that FST and MEDwere bioequivalent,
although these two products were different. On the other hand, theoutcome for S
demonstrated bioinequivalency between these two differentformulations.
Therefore, assessing BE study for only R or RScan lead a false conclusion. The
%-+AUC1fescalated by increasing number of subject (N). Insome simulations, 48
subjects were chosen instead of 24 to increase thepower and at least 48 subjects are
commonly suggested for BE study of a highly variable drug suchas verapamil HC1.
Increasing number of subjects or sampling points increases statisticalpower of
analysis. From Table 4.3, %-+AUCIf was increased from 52%, 47%and 28% with
24 subjects to 88%, 86% and 68% with 48 subjects for RS, R andS, respectively.
As indicated by the outcomes from analysis of BE study, the majorenantiomer, R,
showed higher effect on the racemate, RS, than the minor enantiomer,S. The
outcomes also indicated that more accurate conclusion would be made from
examining each enantiomer rather than a racemate in BE study.
Table 4.3. Simulation results of%-+AUC1ffrom comparisons of two formulations,
where KmR is greater than Kms with the same Vmax for enantiomers.
Case N Bvar
(%)
Dose
(mg)
%-+ AUC (%)
RS R S
FM 24 10 100 52 46 29231
Table 4.3 (Continued)
FM 24 10 200 52 47 28
FM 24 20 100 52 46 28
FM 24 20 200 46 44 21
FM 48 10 100 88 86 68
FM 48 10 200 81 80 46
FM 48 20 100 88 86 68
FM 48 20 200 81 81 46
FS 24 10 100 45 4] 19
FS 24 10 200 23 26 4
FS 24 20 100 51 44 25
FS 24 20 200 24 26 4
FS 48 10 200 39 53 3
FS 48 20 100 87 84 67
FS 48 20 200 40 52 3
MS 24 10 100 50 43 26
MS 24 10 200 40 36 16
MS 24 20 100 50 42 26
MS 24 20 200 40 36 16
MS 48 10 100 87 83 66
MS 48 10 200 75 75 37
MS 48 20 100 87 83 66
MS 48 20 200 75 73 38
SVS 24 10 100 47 39 28
SVS 24 10 200 40 30 21
SVS 24 20 100 46 37 27
SVS 24 20 200 38 30 20
SVS 48 10 100 86 79 72
SVS 48 10 200 76 67 52
SVS 48 20 100 85 77 72
SVS 48 20 200 75 67 53
[Wvar was set at 15%. %+-AUCf (in percentage) is the probability of false positive in BE study
with respect to AUC1f]232
Table 4.4. Simulation results of%-+AUC1ffrom comparisons of two formulations,
when Vmaxs is greater thanVmaxRwith the same Km for enantiomers.
Case N Dose (mg) %-+ AUC1 (%)
RS R S
FM 24 100 82 73 70
FM 24 200 55 45 29
FM 48 100 91 85 76
FM 48 200 85 82 66
FS 24 100 51 40 28
FS 24 200 33 28 18
FS 48 100 82 76 70
FS 48 200 58 52 40
MS 48 100 89 83 75
MS 48 200 82 75 65
SVS 48 100 86 77 75
SVS 48 200 77 72 65
[Bvar and Wvar were fixed at 20% and 15%, respectively.%+-AUC1f(in percentage) is the
probability of false positive in BE study with respect toAUCflfl233
Table 4.5. Simulation results of%-+AUCffrom comparisons of two formulations,
when Vmaxs is greater than VmaxR and KmR is greater than Kms.
Case N Dose (mg) %-+ AUC (%)
RS R S
FM 24 100 55 44 14
FM 24 200 51 43 10
FM 48 100 92 86 57
FM 48 200 85 81 30
FS 24 100 47 38 12
FS 24 200 30 27 2
FS 48 100 82 78 36
FS 48 200 51 50 4
MS 48 100 78 69 52
MS 48 200 40 35 15
SVS 48 100 87 77 63
SVS 48 200 76 65 55
[Bvar and Wvar were fixed at 20% and 15%, respectively.%+-AUC1f(in percentage) is the
probability of false positive in BE study with respect to AUC1J
The CV (coefficient of variation, %) for AUC and Cmax from BE studies
were approximately 50% as shown in Appendix 1. One example of statistical
outputs and codes for the simulation was provided in Appendix 1 and 2,
respectively. Increasing the dose decreased the %-+ ofAUC1ffor all moieties. For
example, in the case of FM from Table V.3, the %-+ AUC1fof 88%, 86% and 68%
at dose 100mg was decreased to 80%, 81% and 46% at dose 200mg for RS, R and
S, respectively, which could be explained by nonlinearity. However, the distinction
between RS (or R) and S was consistently present, regardless of varying factors.234
Similar results were obtained from all the scenarios for different formulationsthat
were tested. A sensitivity analysis was carried out to verify the criteria in the
guidance. The criteria (ii) and (iv) in the FDA guidance
(4)were tested. First,
pharmacokinetics of R and S were the same and nonlinear by having thesame Km
and Vmax as shown in the case (a) in Figure 4.3. Second, both enantiomers (R and
5) were following linear absorption process but different pharmacokinetics (case (f)
in Figure 4.3). In this case, there was no first pass stereo-selective metabolism and
so, the differential equations for the model were modified to have a linear
elimination process with different clearance for R and S as shown in equations
below.
dDR
DR. relF
dt (7)
dDs= Kdss .Ds .relF (8) dt
dApresys,R
- Kdlss . DR . reiFka, R . Apresys,R (9)
dt
dApresys, s
KdIss .Ds. reiFka,s. Apresys, s (10)
dt
dAp,R CLR
ka,R . Apresys,R Ap, (11)
dt V
dA,s CLs
kas . Apresys ,s . Ap,s (12)
di' V
Finally, the same and linear pharmacokinetics of R and S were assumedas
provided in the case (e) in Figure 4.3, and the same clearance for enantiomers and
model described with equations (7) through (12) were applied. Table 4.6235
summarizes the result of sensitivity analysis. The predicted the percentage of
success in BE study (% BE) demonstrated that there was no significant difference
in assessing BE studies with either each enaritiomer or a racemate, unless all the
criteria were satisfied and therefore, the analysis verified the reasonableness of the
criteria.
Table 4.6. Simulation results of sensitivity analysis with respect to %BE basedon
AUC1f.
N D (mg) %BE(%)
RS R S
Same PlC!
Nonlinear
48 100 93 86 86
Linear/DifferentPK_______
48 100 100 100 100
Same PKI Linear 48 100 100 100 100
[%BE is the probability of success in BE study based onAUCfin the unit of percentage236
CONCLUSIONS
Simulation showed that the consequence of conductinga BE study for a
racemate was different from that for individual enantiomers. The probability of
false positives (%-+) for R and RS is higher than that for S, whichmeans that the
likelihood to mislead the conclusion on bioequivalency can be high, if BE study is
carried out only for a racemate or a major enantiomer. In Figure 4.4.a, Cmax (Fast)
was less than double to Cmax (Slow) for R, while the difference of Cmax was
almost triple for S. This observation demonstrates S is more sensitive tomeasure
the difference in two formulations as well as assess BE studies. Besides, the %-+
for RS was primarily driven by R, and assessing BE based on S (higher affinity
enantiomer) offered a more sensitive method of discussing two different
formulations. Even when the chiral assay criteria (i) and (iii) are not satisfied, it is
possible to mislabel two different formulations as being bioequivalent, if onlya
racemate is measured according to the current simulation study. This simulation
study confirms that measuring the individual enantiomers in assessing BE study of
a chiral drug is essential as directed in the FDA guidance when the four criteria (i)
the enantiomers exhibit different pharmacodynamic characteristics; (ii) the
enantiomers exhibit different pharmacokinetic characteristics; (iii) primary
efficacy/safety activity resides with the minor enantiomer; and (iv) nonlinear
absorption is present (as expressed by a change in the enantiomer concentration237
ratio with changes in the input rate of the drug) for at least one of the enantiomers
(4)are met.238
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Using xanthan gum and locust bean gum as main excipients, a gastric
retention device was developed. A rectangular shape with dimension of75* 1 .51
cm was applied to formulation of a gastric retention device. Amount of0.75g
xanthan gum and0.5g locust bean gum was used initially for an original gastric
retention device, and amount of0.75g xanthan gum and0.75g locust bean gum
was applied for a modified gastric retention device. Adding more amount of locust
bean gum in formulation of a modified gastric retention device led to increased
rigidity. A foam solution composed of Carbopol 936 and sodium lauryl sulfatewas
combined with a gum solution, and this resulted in increasing hydration rate and
flexibility. Hydrochlorothiazide was chosen to be a model drug to evaluatea
gastric retention device. Hydrochiorothiazide was formulated into sustained-
release beads using a spray coating technique. These sustained release drug beads
were incorporated into a gastric retention device for in vitro dissolution study and
in vivo bioavailability/bioequivalency study.
Using in vitro dissolution profile and a pharmacokinetic model, in vivo
plasma concentration vs. time profile was predicted prior to
bioavailability/bioequivalency study. In simulated in vivo profile, a higher
bioavailability of hydrochiorothiazide from a gastric retention devicewas predicted
compared to an immediate release formulation based on continuous and slow
uniform drug input from a gastric retention device.241
In the preliminary bioavailability/bioequivalency study withan original
gastric retention device, the device failed to stay on an empty stomach resulting in
incompletion of drug release and lower bioavailability thanan immediate release
formulation. This result indicated that an original gastric retention devicewas not
rigid enough to withstand "housekeeping waves" and passed the drug absorption
sites before completing drug release. In the presence of food,an original gastric
retention device was successfully retained to complete the slow drug release and
achieved higher bioavailability than an immediate release formulation.
After modification of an original gastric retention device to bemore rigid,
the full bioavailabilitylbioequivalency study was carried out witha modified gastric
retention device. A modified device achieved bioequivalency to an immediate
release formulation with lower drug peak concentration and prolonged drug effect.
From an absorption profile, the drug input was continued for about 17 hours fora
modified device and for about 3.5 hours for an immediate release tablet,
respectively. This result demonstrated that a modified gastric retention devicewas
rigid enough to stay on an empty stomach until the slow drug release was
completed. Slow drug input triggered fewer homeostatic reaction, which resulted
in higher cumulative drug effect. In spite of development of tolerance to
hydrochiorothiazide on urine production, the total pharmacological effect was
higher for a gastric retention device compared to an immediate release formulation.
Slow input rate of hydrochlorothiazide achieved Reducing drug peak concentration
and prolonging drug effect, which is desirable for patient care.242
In vivo/in vitro correlation was established for an immediate release
formulation and a gastric retention device, and this correlation can be used to
predict in vivo profile prior to bioavailability/bioequivalency study.
Pharmacokinetic/pharmacodynamic relationship of nicotine was studied to
improve the current nicotine replacement therapy in smoking cessation. Plasma
nicotine concentrations, heart rate elevation and the intensity of cravingwere
correlated using Porchet tolerance model and a linear correlation of plasma nicotine
concentration and the intensity of craving. A dosing regimen with a combination
of rapid input every 3- to 4-hour and constant slow input for 16 hours was proposed
to be effective on craving reduction.
A simulation study of assessing bioequivalency study for enantiomeric
drugs validated an importance of pharmacokinetics of each enantiomer. In this
simulation study, measuring a minor enantiomer that has higher affinity and major
efficacy was turned out to be critical on assessing bioequivalency study, in terms of
higher sensitivity of a minor enantiomer in detecting differences of
pharmacokinetics of formulations. Therefore, the current FDA policy requiringan
individual bioequivalency study for each enantiomer is reasonable.243
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Appendix I. An example of statistical output including coding from the simulation.
Bioequivalent study of two formulations (Fast (reference) vs. Medium (test)).
R (test)
Variablelabel N Mean STD
Minimum Maximum
Tmax Time to Cmax 48000 3.18 0.97
0.75 8
Cmax Maximum
concentration
48000 380 320.48
36.7 3026.5
AUClast AUC(0-last) 48000 3742.7 2445.74
93.91 24585.18
AUCinf AUC(0-infinity) 48000 4025.86 2891.39
96.31 34684.58
R (reference)
Variablelabel N Mean STD
Minimum Maximum
Tmax Time to Cmax 48000 2.07 0.58
0.75 6
Cmax Maximum
concentration
48000 495 424.76
69.08 3836.2
AUClast AUC(0-last) 48000 4025.86 2761.51
127.97 27907.14
AUCinf AUC(0-infinity) 48000 4259.7 3160.90
129.41 35274.59
S (test)
Variable label N Mean STD
Minimum Maximum
Tmax Time to Cmax 48000 2.4 0.72
0.75 6
Cmax Maximum
concentration
48000 198 68.46
17.53 2239.4
AUClast AUC(0-iast) 48000 1729.65 1419.01
36.15 16418.35
AUCinf AUC(0-infinity) 48000 1777.89 1528.85
39.11 19430.06267
Appendix 1 (Continued)
S (reference)
Variablelabel N Mean STD
Minimum Maximum
Tmax Time to Cmax 48000 1.65 0.5
0.5 4
Cmax Maximum
concentration
48000 293 124.76
29.97 3262.5
AUClast AUC(0-last) 48000 2125.9 1657.14
33.04 16060.72
AUCinf AUC(0-infinity) 48000 2148.96 1707.04
34.03 19594.4
RS (test)
Variablelabel N Mean STD
Minimum Maximum
Tmax Time to Cmax 48000 2.86 0.77
0.75 8
Cmax Maximum
concentration
48000 596 224.55
57.41 5161.9
AUClast AUC(0-last) 48000 5474.93 3559.97
173.35 40289.31
AUCinf AUC(0-infinity) 48000 5882.41 4181.49
175.15 51817.55
RS (reference)
Variablelabel N Mean STD
Minimum Maximum
Tmax Time to Cmax 48000 1.86 0.48
0.75 5
Cmax Maximum
concentration
48000 806 404.67
131.29 70014
AUClast AUC(0-last) 48000 6389.92 4118.06
230.86 43032.78
AUCinf AUC(0-infinity) 48000 6624.55 4542.2
232.15 60858.52268
Appendix I (Continued)
Parameter TypeAvg difference SD difference N %-+
Ln(Cmax) RS 0.6 0.03 10000.0
Ln(Cmax) R 0.64 0.03 10000.2
Ln(Cmax) S 0.53 0.03 10000.0
Ln(AUClast) RS 0.85 0.05 100025.6
Ln(AUCiast) R 0.88 0.06 100037.1
Ln(AUClast) S 0.79 0.06 10002.8
Ln(AUCinf) RS 0.88 0.06 100039.7
Ln(AUCinf) R 0.9 0.06 1000 52
Ln(AUCinf) S 0.8 0.06 10003.4
Ln(Trnax) RS 1.01 0.10 1000 0
Ln(Tmax) R 1.11 0.13 1000 0
Ln(Tmax) S 0.76 0.10 1000 0Appendix 2. An example of codes for the simulation.
$PROB-MODEL 1 FOR RPTIO CHANGE
$INPUT ID TIME AMT DV CMT FORM EVID
;FORM=0 Ref; =1 test;
;CMT=1,2; Dosing R,S
;CMT=5,6; Sampling R,S
$DATA simdata.prn
$SUBROUTINES ADVA]
$ MODEL
COMP= (DISSR)
COMP=(DISSS)
COMP= (LIVERR)
COMP= (LIVERS)
COMP (PLASMAR)
COMP (PLASMAS)
IGNORE=C
9 TOL=3
;5
;6
$SIM (123456 NEW)(3345857 UNIFORM) ONLYSIM SUBPROBLEMS=1000
$THETA(0,2) ;Dissref*
$THETA(0,1) ;Ka
$THETA(0,100) ;KM_R
$THETA(0,50) ;KM_S
$THETA(0,50) ;VMAX
$THETA(0,50) ;V
$THETA(0 FIX) ;FTst/Ref*
;Tst/Ref Difference
;0.0 0
0.1 10%
0.5 50%
1.0 100%
2.0 200%
$THETA(0,0.5) ;Disstst*
$OMEGA (0.04,FIXED)
$OMEGA (0.04,FIXED)
$OMEGA (0.09,FIXED)
$OMEGA (0.09,FIXED)
$OMEGA (0.09,FIXED)
$OMEGA (0.09,FIXED)
$OMEGA (0.09,FIXED)
;bsDissRef
;bsDisstst
;bska
bs kmr
bskms
bsvmax
bsvol
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$OMEGA BLOCK(l) 0.0225 FIX;wska
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) 0.0225 FIX;wskmr
$OMEGA BLOCK(l) SANE
$OMEGA BLOCK(l) 0.0225 FIX;wskms
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) 0.0225 FIX;wsvmax
$OMEGA BLOCK(1) SAME
$OMEGA BLOCK(1) 0.0225 FIX;wsvol
$OMEGA BLOCK(1) SAME
$OMEGA (0.0,FIXED) ;FTRvar
$SIGMA (0.01,FIXED)
$SIGMA (0,FIXED)
$SIGMA (0.01,FIXED)
$SIGMA (0,FIXED)2
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Appendix 2 (Continued)
LNMU=LOG(THETA(3))
DLTA=3.27*O.3 ;MUST BE 3.27*SQRT(SCVWT)
LO=EXP (LNMU-DLTA)
HI=EXP (LNMU+DLTA)
NDO=O
DOWHILE (KMR.LT.LO .OR. KMR.GT.HI)
NDO=NDO+ 1
IF (NDO.GT.MAXDO) EXIT 14 CALL SIMETA(ETA)
KMR= THETA(3)*EXP(ETA(4) + ETA(10)*FORM + ETA(11)*(1_FORM))
END DO
LNMU=LOG(THETA(4))
DLTA=3.27*O.3
;MUST BE 3.27*SQRT(SCVWT)
LO=EXP (LNMU-DLTA)
HI=EXP (LNMU+DLTA)
NDO=O
DOWHILE (KNS.LT.LO .OR. KMS.GT.HI)
NDO=NDO+1
IF (NDO.GT.MAXDO) EXIT 15 CALL SIMETA(ETA)
KMS= THETA(4)*EXP(ETA(5) + ETA(12)*FORM + ETA(13)*(1_FORM))
END DO
LNMU=LOG(THETA(5))
DLTA=3.27*O.3
;MUST BE 3.27*SQRT(SCVWT)
LO=EXP (LNMU-DLTA)
HI=EXP (LNMU+DLTA)
NDO=O
DOWHILE (VMAX.LT.LO .OR. VMAX.GT.HI)
NDO=NDO+ 1
IF (NDO.GT.MAXDO) EXIT 16 CALL SIMETA(ETA)
VMAX= TI-IETA(5) *EXP (ETA(6) + ETA(14) * FORM + ETA(15)(1-FORM))
EN D DO
LNMU=LOG(THETA(6))
DLTA=3.27*O.3 ;MUST BE 3.27*SQRT(SCVWT)
LO=EXP (LNMU-DLTA)
HI=EXP (LNMU+DLTA)
NDO=O
DONHILE (V.LT.LO .OR. V.GT.HI)
NDO=NDO+ 1
IF (NDO.GT.MAXDO) EXIT 17 CALL SIMETA(ETA)
V=THETA(6)*EXP(ETA(7) + ETA(16)*FORM+ ETA(17)*(1_FORM))
END DO273
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ENDIF
KAS = KAR
S5 V /1000
S6 = V /1000
REP = IREP
$ DES
FPASR= VMAX/(KMR+A(3))
FPASS= VMAX/(KMs+A(4))
CLR = VMAX/(KNR+A(5))
CLS = VMAX/(KMS+A(6))
DADT(1)=DISS*A(1)
DADT(2)= _DISS*A(2)
DADT(3)= DISS*A(1) - KAR*A(3) - FPASR*A(3)
DADT(4)= DISS*A(2) - KAS*A(4)- FPASS*A(4)
DADT(5)= KAR*A(3) - CLR*A(5)
DADT(6)=5*A(4) - CLS*A(6)
$ ERROR
NDO= 0
MAXDO= 100
CPR = A(5)/S5
CPS = A(6)/S6
IF(CPR.LT.0) CPR = 0
IF(CPS.LT.0) CPS = 0
ISCMT5 = 0
IF (CMT.EQ.5) ISCMT5 = 1
ISCMT6 = 0
IF (CMT.EQ.6) ISCMT6 = 1
YR = CPR*(1+ERR(1))+ERR(2)
YS = CPS*(1+ERR(3))+ERR(4)
TY = YR*ISCNT5 + YS*ISCMT6
IF (ICALL.EQ.4) THEN
DOWHILE (TY.LT.0)
NDO=NDO+ 1
IF (NDO.GT.MAXDO) EXIT 1 10 CALL SIMEPS(EPS)
TY = YR*ISCMT5 + YS*ISCMT6
EN D DO
ENDIF
Y = TY
sTABLE REP ID TIME DV CMT FORM NOAPPEND NOPRINT NOHEADER